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OPTIMIZING COLORECTAL CANCER SCREENING: NEW 
STRATEGIES AND INSIGHTS
1. Fecal immunochemical tests are superior to guaiac fecal occult blood tests in detecting 
colorectal cancer in average-risk individuals. (This thesis)
2. The variety of cut-off concentrations and strategies used for fecal immunochemical test 
screening, illustrates that a one-size-FITs-all approach does not exist. (This thesis)
3. Although the detection rates of advanced neoplasia by fecal immunochemical testing 
differ substantially among age groups, age partitioned cut-off concentrations are not 
recommended. (This thesis)
4. Fecal hemoglobin concentration below the cut-off is an independent predictor of incident 
advanced neoplasia. (This thesis)
5. Repeated two-sample fecal immunochemical test screening does not increase the yield 
of advanced neoplasia compared to one-sample screening. (This thesis)
6. In today’s world “just Google it” is considered to be the answer to everything, but for 
health related questions or translations this should be treated with caution. (This thesis, 
and Patil et al. BMJ 2014)
7. A positive screening result does not increase participants’ level of anxiety or depression, 
nor decrease participants’ level of health-related quality of life. (Kirkøen et al. British 
Journal of Cancer 2016) 
8. Nederlandse huisartsen moeten meer weet hebben van de testeigenschappen van fecaal 
occult bloedtesten en zich bewust zijn van de juiste indicatiestelling. (Klein-Puite et al. 
Huisarts Wet 2015)
9. Het beoordelingsproces van nieuwe geneesmiddelen zoals momenteel geaccepteerd 
door registratie autoriteiten staat in scherp contrast met de huidige standaarden voor 
systematische reviews en meta-analyses. (Geneesmiddelenbulletin 2016; 50: 65)
10. To make yourself feel happier, you should help others. (Borgonovi et al. Soc Sci Med. 2008)
11. “Pas als je de moed toont je eigen weg te gaan, toont de weg zich aan jou”. (Paulo 
Coelho)
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General introduction
1.1Colorectal cancer (CRC) is the third leading cause of cancer-related mortality.
1 
The general aim of screening is to filter an average-risk population to detect 
and treat those at an asymptomatic and early stage in order to reduce disease 
burden. CRC is an ideal target for population screening. Besides aiming to improve 
outcomes through earlier diagnosis, detection and treatment of “pre-cancers” 
can prevent the development of CRC. Various test methods and strategies are 
available for CRC screening. Because a screening program focuses on an in 
principle healthy population, it necessitates quality assurance for every aspect 
of the program. 
This thesis is divided into four parts. Part I introduces the main topics of the 
thesis. These chapters are followed by the aims and outline of the thesis. Part 
II and III encompass the main body of the thesis. The last part (IV) summarizes 
and discusses the main findings of the thesis and provides directions for future 
research.
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CHAPTER 1.1
General introduction
SUMMARY
Colorectal cancer (CRC) ranks third among the most commonly 
diagnosed cancers worldwide, with wide geographical variation in 
incidence and mortality across the world. Despite proof that screening 
can decrease CRC incidence and mortality, CRC screening is only 
offered to a small proportion of the target population worldwide. 
Throughout the world there are widespread differences in CRC 
screening implementation status and strategy. Differences can be 
attributed to geographical variation in CRC incidence, economic 
resources, health care structure, and infrastructure to support 
screening such as the ability to identify the target population at risk and 
cancer registry availability. This review highlights issues to consider 
when implementing a CRC screening program and gives a worldwide 
overview of CRC burden and the current status of screening programs, 
with focus on international differences.
KEY MESSAGES
• A successful screening program for a major disease like colorectal 
cancer (CRC) requires comprehensive collaboration among 
multiple parties for an optimal effect in terms of gain in life-years, 
quality of life and cost-efficiency.
• Despite well-developed CRC screening guidelines, implementation 
of screening is markedly different among countries and regions in 
the world.
• In addition to CRC incidence, the impact of the disease relative to 
other health problems and the capacity to treat should be taken 
into account when developing a CRC screening strategy.
• The discrepancy between CRC incidence and the offer of organized 
or opportunistic screening remains an ongoing concern.
• Screening measures and quality indicators of screening should be 
reported, allowing national evaluation and international comparison 
to improve CRC screening quality.
15
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BACKGROUND
Worldwide colorectal cancer (CRC) is the third most common cancer in men (746 000 cases, 10.0% of the total) and the second in women (614 
000 cases, 9.2% of the total).2 There is however wide geographical variation in 
CRC incidence and mortality, with very similar patterns in men and women. The 
age-standardized incidence rates (ASRi) vary ten-fold in both sexes worldwide. 
When comparing world regions as classified by the United Nations, the highest 
estimated rates occur in the Australia/New Zealand region (ASRi 44.8 and 32.2 
per 100 000 in men and women respectively), and the lowest in Western Africa 
(4.5 and 3.8 per 100 000). Almost 55% of CRC cases occur in more developed 
regions.2 However, in many developing countries (including some parts of Africa), 
there is the possibility of under-reporting because cancer registries are lacking 
or have incomplete coverage. Large disparities exist between high-income and 
low-income countries in the proportion of their populations covered by cancer 
registries.3
The lifetime risk of developing CRC in many regions is around 5%. Approximately 
45% of persons diagnosed with CRC die as a result of the disease, despite 
treatment.4 Treatment modalities have largely improved over the past decade. 
Treatment has modestly improved disease outcome and extended survival in 
patients with advanced and metastatic disease. But, these advancements have 
been accompanied by markedly increased treatment costs. As a result, modelling 
studies have shown that various screening strategies are cost-saving.5  Most CRCs 
develop from a preclinical precursor, the adenoma. The progression from early 
adenoma to invasive cancer takes years.6 7 The high incidence, long preclinical 
phase, recognizable and treatable precursor, the high cost of treatment, and 
the correlation of mortality with disease stage make CRC highly suitable for 
population screening.8-10 This has been confirmed by randomized controlled trials 
(RCTs) that have formed the basis for international guidelines recommending 
CRC screening.11-14 Despite these recommendations, screening is currently only 
offered to a small proportion of the target population. 
The goal of this review is to address various aspects to consider for implementing 
a successful screening program and to give an overview of screening programs 
worldwide, with a focus on international differences. 
16
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METHODS
For this review, national and international guidelines on CRC screening were 
evaluated. We collected information on CRC screening program characteristics 
from guidelines, through national governmental websites and international 
contact persons including public health researchers, those responsible for 
the development and implementation of screening programs, and participants 
of the Colorectal Cancer Screening Committee of the World Endoscopy 
Organization.15 A literature search in PUBMED and The Cochrane Central Register 
of Controlled Trials was performed using the following keywords: colorectal 
cancer (CRC) screening, guidelines, Europe, America, Canada, Asia, Australia, 
New Zealand, RCTs, colonoscopy, guaiac fecal occult blood test (gFOBT), 
fecal immunochemical test for hemoglobin (FIT), flexible sigmoidoscopy (FS), 
CT colonography (CTC), DNA-marker and video capsule endoscopy. To 
evaluate and compare screening programs, we used the universally applicable 
CRC screening indicators established by the International Colorectal Cancer 
Screening Network (ICRCSN) based on the criteria of the International Agency 
for Research on Cancer (IARC).16 17 To report screening indicators regarding FIT 
screening, the Fecal Immunochemical TesTs for hemoglobin Evaluation Reporting 
(FITTER) guidelines were followed.18 We used the recommended reporting units 
of microgram hemoglobin per gram feces (µg Hb/g) rather than nanogram 
hemoglobin per milliliter buffer (ng Hb/ml) to ensure comparability of results.19 
The term ‘average risk population’ used in this review refers to an asymptomatic 
population who is at average risk for CRC. The age range of this population is 
influenced by national guidelines and varies per study but is mainly over age 50 
and constantly over age 40 years. For the overview of current status of screening 
programs, at least the top 10 countries with highest age-standardized incidence 
rates (ASRi) for each world continent were included.
SCREENING METHODS 
Detection and removal of cancer precursors can reduce CRC incidence and 
mortality. Early detection of CRC allows less invasive treatment, with lower 
morbidity, mortality, and treatment cost. The implementation of a CRC screening 
program requires that strategic decisions be addressed. One is the selection of a 
screening modality, which can be a non-invasive or an invasive test. 
17
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Non-invasive stool tests
Non-invasive stool tests include guaiac fecal occult blood tests (gFOBT) and 
fecal immunochemical test for hemoglobin (FIT). These inexpensive tests detect 
microscopic amounts of blood by targeting either heme (gFOBTs) or human 
globin (FITs). A meta-analysis of four RCTs concluded that annual or biennial 
gFOBT screening had no effect on CRC incidence (in 3 out of the 4 studies 
included in the analysis) but led to an average 16% reduction in CRC-related 
mortality.20 The impact of the gFOBT is limited by the poor to moderate sensitivity 
for advanced adenomas and cancer (Table 1.2.1).21 For this reason, gFOBTs are 
typically used on multiple bowel movements per screening, and are implemented 
in repeated screening rounds. In contrast, FITs have a higher sensitivity for both 
adenoma and cancer even with a single sample per screening round (Table 
1.2.1). Moreover, unlike gFOBTs, FITs are specific for human globin and do not 
require dietary restriction. Thus, FIT screening is generally associated with higher 
participation and higher detection rates of both adenomas and CRCs compared 
to gFOBT screening.22 23 Furthermore, quantitative FITs offer the opportunity to 
provide tailored screening by adjusting the positivity cut-off level. This can be 
used to adjust screening to available resources and colonoscopy capacity.5 24 
A low cut-off increases the detection of advanced neoplasia, but lowers the 
positive predictive value and specificity thus demanding more colonoscopy 
resources.25 No RCT has reported the impact of FIT screening on CRC incidence 
and mortality. A recent ecological study compared regions in Italy with and 
without population FIT screening. CRC-specific mortality was 22% lower in areas 
with a FIT screening program compared to areas without a screening program.26 
The higher uptake and sensitivity of FIT supports the assumption that biennial 
FIT screening at a low cut-off will have a larger impact than gFOBT on CRC 
incidence and mortality. Modelling studies suggest that the impact can approach 
that of colonoscopy if the adherence to multiple rounds is high.27
Invasive imaging techniques
Four RCTs showed that a single round of flexible sigmoidoscopy (FS) screening 
is associated with a reduction in CRC incidence of 18-23% and CRC mortality 
of 22-31%.28-31 Similar RCTs evaluating colonoscopy are underway, namely 
the NordICC (NCT00883792), COLONPREV (NCT00906997), SCREESCO 
(NCT02078804) and the CONFIRM study (NCT01239082).32 33 CRC incidence 
and mortality results from these RCTS are expected between 2025 and 2034. 
Colonoscopy is generally considered the gold standard for the detection of 
colorectal neoplasia. In prospective cohort studies, colonoscopy has been 
associated with long-term (20 to 30 years) reduction in CRC mortality.34 35 As 
18
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such, some screening programs utilize colonoscopy as the primary screening 
tool. Other programs prefer a two-step approach, using colonoscopy only for 
diagnostic clarification in those with a positive first-line less invasive screening 
test. The latter approach has, for some countries, the advantages of higher 
screening uptake and lesser demand on limited colonoscopy resources. 
Precursor lesions and cancer can be visualized by Computed Tomographic 
Colonography (CTC), also called virtual colonoscopy. In an average risk 
population, the per-patient sensitivity of CTC for advanced neoplasia ≥10 mm 
was 88%.36 However, this sensitivity decreases for the detection of polyps <10 
mm.37 38 Compared to stool tests, imaging tests such as CTC are more invasive 
(making them more burdensome) and costlier. 
Colonoscopy is considered the primary diagnostic method to evaluate a positive 
less invasive screening test, whether that test is based on evaluating stool, serum 
(blood), or colorectal imaging. The demand and capacity for colonoscopy must 
be taken into account when a country chooses a screening modality.
New screening modalities
Other screening methods have become available for CRC screening. Newer non-
invasive tests include DNA, RNA and protein biomarker stool and blood tests. 
Detection of circulating methylated SEPT9 DNA in blood yielded a CRC sensitivity 
of 48%, which is at the lower end of the gFOBT range (37–79%).39 40 Sensitivity 
for the detection of advanced adenomas was very low (11%).40 Biomarker stool 
tests are based on the principle that colorectal neoplasms shed surface cells in 
the stool. DNA from these cells can be isolated and tested for the presence of 
mutations and epigenetic changes acquired during carcinogenesis. Stool DNA 
testing has improved over the last decade. A recent study incorporating FIT with 
DNA markers, reported a 92.3% sensitivity for CRC and 42.4% for advanced 
adenomas, which was significantly higher than FIT at a cut-off of 20 µg Hb/g 
feces (100 ng/ml) (sensitivity for cancer 72%, for advanced adenoma 23%).41 
One cautionary note about this study is the difference in positivity rates between 
the DNA test and FIT that were used. Both non-invasive tests are meant to select 
subjects at a higher risk of neoplasia so they can undergo colonoscopy. In other 
words, a non-invasive test aims to enrich the population undergoing colonoscopy 
and relieves those at low risk of neoplasia of the burden and risk of colonoscopy. 
In this particular study, the investigators used a relatively high FIT cut-off and 
a more “liberal” DNA cut-off. As a result, the number of persons referred for 
colonoscopy was more than twice as high after stool DNA testing than after FIT. 
In further comparisons between non-invasive tests, there is a need to set the cut-
off of each test at such a level that both tests yield a similar positivity rate, since 
19
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this determines colonoscopy demand and thus largely influences the burden and 
costs of a screening program. 
Newer imaging tests include colon capsule endoscopy (CCE) and magnetic 
resonance colonography (MRC). CCE is a procedure that uses an ingestible 
capsule with a camera at each end to produce images of the mucosa during 
intestinal transit. The average sensitivity of second generation CCE (CCE-
2) devices for significant findings (≥ 6 mm size, or ≥ 3 polyps irrespective of 
size) is 86 %. When used as a triage test after a positive FIT to determine who 
should proceed to colonoscopy, CCE has the potential to reduce the number of 
colonoscopies performed by 71%. In case of an incomplete colonoscopy, the 
diagnostic yield of CCE has been reported to be superior to that of CTC for 
polyps ≥6 mm as well as ≥10 mm with colonoscopy as the gold standard.42 An 
MRC study performed in 286 asymptomatic individuals reported a sensitivity of 
78.4% for adenomas >6mm.43 The impact of these new screening modalities on 
screening uptake and CRC incidence and mortality requires further study. 
The efficacy of different screening methods in terms of impact on CRC incidence 
and mortality is not known. Table 1.2.1 outlines the performance of different 
screening tests in an average risk population. For the given rates of reduction 
in CRC incidence and mortality results of a single round, as well as multiple 
rounds were included in this table. Advanced neoplasia is defined as an adenoma 
≥10 mm, or ≥25% villous component, or with high-grade dysplasia or CRC. More 
recently, attention has also been drawn to the relevance of larger or dysplastic 
serrated polyps as potential CRC precursors. The accuracy of individual screening 
methods in detecting these lesions is under study. 
20
Worldwide overview of CRC screening Chapter 1.2
ORGANIZED AND OPPORTUNISTIC SCREENING
An organized screening program involves a systematic process of inviting a target 
population to participate in screening and ensuring follow-up of those with a 
positive screen. An organized program should measure and report on the quality 
of each step in the screening process. The IARC outlines the following elements 
for organized screening programs:
• An explicit policy with specified age categories, screening method, and 
screening interval
• A defined target population
• A management team responsible for implementation
• A health-care team for decisions, care and follow-up of patients with positive 
screening tests
• A quality assurance structure for every step in the process
• A process for monitoring, evaluating, and identifying cancer occurrence in 
the population17
In organized screening, substantial information technology infrastructure is 
required to support the program including systems for invitations, recalls, 
reminders, tracking of screening results, ensuring follow-up and tracking of 
clinical outcomes such as cancer incidence, mortality and stage.57 For tracking 
of screening results, a set of universally applicable CRC screening measures and 
Table 1.2.1 Test performance per screening test in asymptomatic, average-risk adults
gFOBT FIT FS CTC Colonoscopy
Sensitivity (%) for 
detecting advanced 
neoplasia
9 to 24 44-49 32 to 53 44 
45 48 50
90 to 92a  51 88 36 to 9744 88 to 98 52
Sensitivity (%) for 
detecting CRC
13 to 50 45-47 79 53 90 to 92a 51 100b 54 92 to 99 51
Reduction in CRC 
incidence (%)  
intention-to-screen
Noc 20 55 unknown 18 55 unknown 69d 56
Reduction in CRC 
mortality (%)  
intention-to-screen
14 to 16 20 22e 26 28 55 unknown 68d 56
a Sensitivity is given for the distal colon; b No CRCs were missed by CTC in six screening trials; 
c No reduction in incidence was found in 3 of 4 RCTs included in meta-analysis; d Meta-analysis 
of observational studies, more results expected; e ecological study
21
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indicators has been established.16 A cancer registry is critical and can be linked to 
all other relevant databases including laboratories and endoscopic centres.57 In 
contrast, opportunistic screening is delivered outside of an organized screening 
program on an ad hoc basis usually through fee-for-service reimbursement of 
physicians. Since organized screening focuses on quality assurance, it provides 
greater protection against the possible harms of screening including over- and 
under-screening, poor quality, inappropriate use of resources, complications 
arising from screening, and poor follow-up of those with a positive screen.58
The approach to screening in the United States is largely opportunistic. The 
contributions and quality initiatives from many national bodies has been crucial, 
including the United States Preventive Services Task Force (USPSTF), an independent 
volunteer panel of national experts in prevention and evidence-based medicine 
that reviews evidence and makes recommendations to guide the choice of CRC 
screening tests.59 In addition, multiple professional associations have emphasized 
the importance of colonoscopy quality in the context of CRC screening.12 60. Equity 
of access to screening in the USA remains uncertain, however.61
Quality assurance 
In 2010, the IARC published the European Guidelines for Quality Assurance in 
Colorectal Cancer Screening and Diagnosis.13 These guidelines outline targets 
for key performance indicators for CRC screening including participation, 
follow-up, and cancer detection rates. For example, the guidelines recommend 
that invitation coverage in the target population should be high (95%) and that 
programs should aim for participation rates of at least 65%.62 
Given that at least 10 years are required to plan, pilot and implement a screening 
program, the full impact of a nationwide screening program on indicators such as 
CRC mortality rates requires long follow-up.63 Therefore, an intermediate measure 
may be used to evaluate program performance, expressed as the number of 
persons with advanced neoplasia detected per 1000 invited individuals during the 
screening interval. This measure takes multiple factors into consideration namely 
participation rate, positivity rate and the positive predictive value (PPV) for the 
detection of advanced neoplasia. It is thus a balanced assessment of the overall 
performance of a screening program. Table 1.2.2 outlines the number of people 
with advanced neoplasia identified per 1000 invited individuals in those programs 
that have published their results. There is marked variation across screening tests 
and within a screening test type for all indicators. Wide ranges for the gFOBT/
FIT-based results may be due to the use of more sensitive tests or more stringent 
criteria for defining test positivity.
22
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Cost-effectiveness
Cost-effectiveness studies for CRC screening have concluded that screening is 
cost-effective compared to no screening.81-83 Micro-simulation models can help 
to identify the most appropriate screening strategy given the available resources 
and budget constraints. The efficiency frontier will identify strategies that are the 
most effective in terms of life-years gained relative to the cost of the screening 
strategy. 
Cost-effectiveness studies have shown that screening can also be cost-effective in 
countries with limited financial resources.84 However, access to and improvement 
in CRC treatment may be a higher priority than screening in these settings. Using 
resources to implement population-based screening in a region with no or very 
limited access to treatment would not be a cost-effective measure.85 86 
Table 1.2.2 Performance of a first round screening program per screening test, based on screening 
indicators 
gFOBT FIT FSa CTC Colonoscopy
Participation rate 
(%)
16 – 47 17 – 77 30 – 84 18 – 34 16 - 93
Positivity rateb (%) 2.4 – 6.8 1.1 - 13 5.3 – 23 8.6-9.0 4.9 – 11
Advanced neoplasia 
detection ratec (%) 
29 – 50 16 - 43 20 –100 54-71 100 
Detected advanced 
neoplasia per 1000 
invited individualsd
2.1 – 6.3 1.1 – 21 23 – 39 8.8 – 21 14 – 73
References 22 23 64 65 22 23 33 65-73 22 69 74-76 77 78 33 69 77-80
a Relative detected advanced neoplasia per 1000 invited individuals is only for the area of the 
colon examined by FS.
b Those with a positive screen were recommended colonoscopy (except when colonoscopy was 
used as the primary screening test), which enabled the determination of the positive predictive 
value of the primary screen (the proportion of subjects that during colonoscopy were diagnosed 
with advanced neoplasia). The uptake of the test was multiplied by the positivity rate and positive 
predictive value to determine the number of true positives identified with advanced neoplasia per 
1000 invited. 
c Proportion of subjects with a positive primary screening test that were found to have advanced 
colorectal neoplasia on secondary screening by colonoscopy. 
d Detection rate per screening round
23
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CRC SCREENING PROGRAMS WORLDWIDE
Over the past two decades, the range of CRC screening modalities has expanded, 
and many population-based programs have been implemented. Nevertheless, 
large geographic variations remain with respect to implementation of CRC 
screening (Figures 1.2a-c). As expected screening programs have been more 
frequently implemented in Western countries with higher CRC incidence and 
more available resources. Table 1.2.3 shows an overview of screening methods 
used worldwide grouped into the six WHO regions. 
European region
Within Europe, the ASRi rates show a fivefold variation, with lowest rates for men 
and women in the Balkan countries of Bosnia Herzegovina (30 and 19 per 100 000 
respectively) and Albania (13 and 11 per 100 000 respectively). Highest incidence 
rates in men are found in Slovakia, Hungary and Czech Republic, while highest 
incidence rates in women are found in Norway, Denmark and The Netherlands.2 
Although CRC mortality rates follow a similar geographic pattern to incidence 
rates, CRC mortality is also high in some countries with relatively low incidence 
rates (Moldova, Russia, Montenegro, Poland and Lithuania).87 A low CRC 
incidence accompanied by a high CRC mortality can imply limited access to 
healthcare, and/or suboptimal CRC treatment. It is estimated that in 2015 around 
490 000 Europeans will be diagnosed with CRC and 240 000 will die from the 
disease.2
There are large variations among national CRC screening practices in Europe 
especially since European guidelines for CRC first appeared in 2010.13 Various 
screening programs (pilot, opportunistic, or organized) were already in place at that 
time. There are also considerable differences with respect to financial resources 
available for screening. The same pertains to colonoscopy capacity, with a more 
than threefold variation in endoscopy resources across European countries. Taken 
together, these factors have led to widespread variation. For details by country, 
see Table 1.2.3.
Most countries in Europe have implemented an organized screening program. 
Nine countries have an opportunistic program in place, and 16 countries either 
have or are beginning to implement organized screening (Table 1.2.3). In 2015, 
24 out of 28 European Union countries had established or were preparing a 
nationwide organized or opportunistic CRC screening program. 
For instance Finland, France, Slovenia and the United Kingdom (UK) have 
completed rollout of their organized programs. In Belgium, The Netherlands, 
24
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Denmark, Ireland, Italy, Malta, Poland and Spain, rollout is ongoing. Norway, 
Portugal and Sweden are in the pilot phase.
Some countries have yet to implement a screening program. For instance, the 
Greek Hellenic Society of Gastroenterology released guidelines for CRC screening 
in 2013. Despite previous low uptake and restricted resources, it recommended 
colonoscopy as the method of choice for CRC screening. Implementation of an 
organized program is in a planning phase. 
Slovakia has the highest CRC rates in Europe (world standardized ASRi is 43 
per 100 000 and ASR mortality 18).2 However, the country does not have a CRC 
screening program, despite the Ministry of Health publishing a list of departments 
performing screening colonoscopy.88 Further work is needed to move forward 
with a national screening program. No population-based CRC screening program 
is in place in Bulgaria, Albania, Bosnia and Herzegovina, Kosovo, Macedonia, 
Montenegro, Romania, Serbia or Russia.89 90 
Most European countries with an organized program screen by means of a non-
invasive stool test, in which previously implemented gFOBT based programs 
are switching to FIT, such as the UK since 2014 and France since 2015. Flexible 
sigmoidoscopy is gradually being introduced in England. As of March 2015, about 
two thirds of screening centers were beginning to offer this one-time-only test 
to 55 year olds. Countries with an opportunistic program are sometimes faced 
with low screening uptake. Such is the case in Austria and the Czech Republic, 
which has achieved coverage of approximately 25% of the target population.91 
92 Organized programs may also face uptake issues, such as in France and 
Croatia. In France participation rates were initially 34.3% in the first two years, 
with nearly three million people being screened.93 Active participation by general 
practitioners increased the participation up to 50% in some parts of the country.94 
The participation rate in Croatia after three years of invitations of about 1 million 
people was only 19.9%.95
To match the number of FIT-positives with the available colonoscopy capacity, 
the FIT cut-off had to be raised in the Netherlands, Scotland and the Republic 
of Ireland.96 97 Compliance to colonoscopy following a positive non-invasive 
screening test can also be an issue. In Lithuania only 52.4% of the FIT-positives 
undergo colonoscopy; resulting in a very low combined adenoma and CRC 
detection rate of 1.2% cumulatively over 3 years.98
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Figure 1.2.1 Overview of screening programs 
Regional differences within one country are, except for North-America, not taken into account in 
these figures. (A) Overview of screening programs in European region. (B) Overview of screening 
programs in region of the Americas. (C) Overview of screening programs in Western Pacific, 
South-East Asia and Eastern Mediterranean region. 
FIT, fecal immunochemical test for hemoglobin; gFOBT, guaiac fecal occult blood test.
A
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Region of the Americas
North-America
The ASRi for North America is 26.1 per 100 000 (23 and 30 for women and men 
respectively).2 An approximate 136 830 persons have been diagnosed with CRC 
and 50 310 persons died of the disease in the United States in 2014.99 An additional 
estimated 24 400 new cases of CRC were diagnosed in Canada in the same year.100 
Reimbursement for colonoscopy in these Western countries has facilitated the early 
adoption of opportunistic screening. For example, previous work in Ontario, Canada 
Figure 1.2.1 Continued
B
27
Worldwide overview of CRC screening 
1.2
demonstrated an increase in colonoscopy use prior to the launch of an organized 
CRC screening program in the province in 2008.101 
To date, all 10 Canadian provinces have announced, are planning or have 
implemented organized CRC screening programs.102 No organized screening 
programs have been announced in any of the three territories. Special challenges 
faced by the territories include a lack of resources/facilities and a low population 
density across vast areas of land. Most provinces are currently using FIT to 
screen persons aged 50 to 74 years of age at average risk for CRC (Figure 
1.2.1B).102 Ontario’s ColonCancerCheck, Canada’s first organized CRC screening 
program, launched province-wide in 2008.103 Participation in the gFOBT aspect of 
the program was 29.8% in 2010 to 2011.103 In Ontario in 2013, 58% of the target 
pxopulation were up-to-date with CRC screening, taking all screening modalities 
into account. Early aggregate results from the first round of screening (January 
2009 to December 2011) of five other provincial programs (British Columbia, 
Saskatchewan, Manitoba, Nova Scotia, and Prince Edward Island) showed a 
much lower participation rate (16%).104 Opportunistic screening colonoscopy is 
available to a variable extent in most Canadian provinces.
Colorectal cancer screening in the United States is recommended by the USPSTF 
for persons at average risk (50 to 75 years old) with annual gFOBT, periodic 
FS, or colonoscopy.59 Data from the annual Behavioral Risk Factor Surveillance 
System (BRFSS) survey revealed that approximately 65% of U.S. adults were up-
to-date with CRC screening in 2012, with colonoscopy being the most widely 
used test.105 The American Cancer Society (ACS) recently reported that CRC 
incidence and mortality rates significantly decreased over the past decade.106 
This is in particular attributed to CRC screening.107 Enablers for the success of 
opportunistic screening seen in the U.S. include the quality initiative supported 
by the national gastrointestinal societies including the USPSTF, ACS, American 
Gastroenterological Association (AGA), American Society for Gastrointestinal 
Endoscopy (ASGE), and National Colorectal Cancer Roundtable (NCCRT) 
among others. This has played a significant role in the high uptake of screening 
in the country. On the other hand, organized screening programs in various 
regions of the country have also been established. Two prime examples include 
the Kaiser Permanente Northern California (KPNC) Program and the Veterans 
Health Administration (VHA) program. KPNC participation rates have doubled 
since 2004 and were 69% in 2010 108 while screening rates in the VHA among 
veterans aged 52 or older were already as high as 68% as early as 2001.109 
Mexico has also launched a CRC awareness campaign focusing on gFOBT 
screening but without much uptake. 
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Central and South America
Although numerous Central and South American countries have national 
guidelines in place for CRC screening, very few national screening programs have 
been implemented.110 111 The current infrastructure in many countries is lacking 
to support a full organized screening program. In addition, very little is done to 
raise awareness in most regions including Venezuela, Bolivia, Peru, Columbia, 
and Costa Rica. As a result, many of those diagnosed with CRC in these regions 
are identified after the disease has metastasized.110 
For example, in Brazil, screening colonoscopies for those aged 50 and older have 
been approved by the Ministry of Health, but uptake remains low.110 Numerous 
CRC pilot programs have begun in various municipalities. One example is the 
program by the Brazilian Association for Colorectal Cancer Prevention, developed 
in Sao Paulo.112 Starting in 2006, those 40 years and older at average risk were 
screened with FIT. Of the 4 567 kits that were distributed between August 
2006 and March 2007, 79.7% were returned and analyzed. Positivity rates were 
approximately 10.7%.113 
Some success was seen with Argentina’s CRC screening program in urban areas 
of the country.114The program will next be piloted in rural regions of the country.110 
In Uruguay, a CRC pilot program was launched in 1996 for those at average 
risk. Persons aged 50 or older were screened with FIT and followed up with 
colonoscopy.73 Between June 1997 and July 2004, 90.1% of the 11 734 persons 
enrolled in the CRC screening program completed a FIT. Of these, 11.1% had a 
positive test.
Caribbean
Organized screening for CRC is not routinely performed in the Caribbean. 
Opportunistic screening with colonoscopy is available on some islands.111 
However, even with effective screening, many Caribbean countries lack the 
medical facilities to provide appropriate cancer treatment. As such, organized 
CRC screening is not a priority. For example, in Jamaica, screening accounts for 
11% of the performed colonoscopies.115 Similarly, low uptake of CRC screening 
has been reported in other countries such as Puerto Rico and Cuba.116 117 
African region
A mathematical modelling study showed that in the sub-Saharan African region, 
screening for CRC by colonoscopy at age 50 in combination with treatment 
can be considered cost effective.84 However, the need for population-based 
CRC screening in the low income countries of Africa is questioned given the 
overall relatively low burden of disease, the substantial burden of communicable 
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diseases, and the limited resources.86 In addition, means by which to identify 
the target population, availability of colonoscopy and an appropriate number of 
well-trained specialists are lacking in most regions.118
Eastern Mediterranean region 
Predictions specific to the Eastern Mediterranean region indicate that generally 
countries in this part of the world will experience an increase in all cancer mortality 
of approximately 181 % over the next 15 years.119 The current CRC incidence is 
highest in Israel (36 per 100 000), Jordan (26), Kazakhstan (23), Armenia (19), 
Syrian Arab Republic (16), Lebanon (16) and the State of Palestine (15). CRC 
mortality rates are highest in Jordan (16 per 100 000), Kazakhstan (13), Armenia 
(11) and Israel (11). 2 
In Israel, an organized program for individuals aged 50-74 has been put in place by 
the country’s four health care providers with the government establishing national 
oversight of provider activities and quality. Insured persons are approached by 
their general practitioner (GP) for annual FIT screening. In Jordan, the national 
health authorities have not yet adopted a specific strategy or guidelines for CRC 
screening despite the high prevalence of the disease in the country.120 In Middle-
Eastern countries that have adopted a Western lifestyle, some opportunistic 
programs are in place. Physicians in the United Arabic Emirates have called for 
country-wide screening but Abu Dhabi is the only emirate to screen for CRC. 
The Health Authority Abu Dhabi (HAAD) advises colonoscopy for people over 
the age of 40.121 An opportunistic FIT-based pilot study in Qatar showed a low 
colonoscopy follow-up rate among those with a positive FIT of 56%.122
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C
Figure 1.2.1 Continued
Western Pacific and South-East Asia region 
In the Asia Pacific region, CRC incidence varies among regions. The country 
with the highest CRC incidence in the world is Korea (ASRi 45 per 100 000). 
Other countries with high CRC incidence in Asia are Singapore (ASRi 34 per 100 
000), and Japan (ASRi 32 per 100 000).2 There is an alarming rising trend in CRC 
incidence and mortality in Asia, especially in Japan, Korea and China.14 This trend 
has been explained by changes in diet and a Westernized lifestyle.123 In addition, 
the overall prevalence of advanced colorectal neoplasia in asymptomatic Asian 
populations is similar to Western populations.124 The CRC incidence and mortality 
rates in India (6 and 5 per 100 000 respectively) remain low compared with rising 
rates in East Asia.2 125 
Recommendations for CRC screening in the Asia Pacific region have been 
published126 and recently updated.14 The Asia Pacific Colorectal Cancer Working 
Group recommends CRC screening in regions where the incidence is high, defined 
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as greater than 30 per 100 000.14 Recommendations include screening for those 
50 to 75 years at average risk with a quantitative FIT as the preferred screening 
method.14 Those with a positive test result should be referred for colonoscopy. The 
guidelines recommend that a clinical risk index can be employed in regions with 
limited healthcare resources to prioritize screening in those at increased risk. Several 
studies investigated barriers to CRC screening in different cultural and socio-political 
contexts in the Asia Pacific region. These barriers included poor knowledge of 
CRC screening and test characteristics, lack of financial support and lack of health 
insurance.127-129
Several countries in the Asia Pacific region have already developed population-
based screening programs. This includes China, Japan, Taiwan, Korea and 
Singapore. In China, those aged 40 to 74 are screened with gFOBT and followed 
up by a digital rectal exam (DRE) and colonoscopy. However, the program is 
not available to the entire population and the national registry used to track 
clinical outcomes is estimated to capture only 13% of the country’s population, 
making planning for health care services difficult.130 Studies have shown 
that screening uptake in China is low and varies widely.130 131 In Japan, a CRC 
screening program has been in place since 1992 for national health insurance 
beneficiaries.68 Individuals aged 40 to 69 years with national health insurance are 
offered screening with FIT. In 2010, participation rates for those aged 40 to 69 
years were 28.1% for men and 23.9% for women.132 Nationwide CRC screening 
was introduced in the Republic of Korea in 2004. The National Cancer Screening 
Program sends invitation letters to the target population at the beginning of the 
year advising them to get screened with annual FIT, while those with a positive 
test are offered follow-up with colonoscopy or double contrast barium enema 
(DCBE).64 70 Published results from the program show an increase in participation 
rates since launch (10.5% in 2004 to 21.1% in 2008) and a decline in positivity 
rates from 8.0% to 6.8%.64 Opportunistic screening is also available in the region. 
In other regions, such as Hong Kong, community-based screening programs have 
been piloted to evaluate the feasibility of a large population-based organized 
screening program. Similarly in New Zealand, a four-year CRC screening pilot 
began in late 2011 to determine whether a screening program should be rolled 
out nationally. The pilot results will inform the decision regarding implementation 
of a national population-based screening program. In Thailand, an organized pilot 
program based on FIT screening has been implemented in April 2011. It focuses 
on persons aged 50 to 65 years in the Lampang Province.66 Preliminary results 
from the pilot show participation rates of 62.9% among the 127 301 persons in 
the target population.66 
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In Australia, a pilot started in 2002. In 2006, the National Bowel Cancer Screening 
Program (NBCSP) began providing biennial FIT (New Hem Tube) to people turning 
55 and 65 years. The program will continue to expand between 2015 and 2020 to 
fully implement biennial screening for all Australians aged 50 to 74 years.133 In other 
regions, such as in Malaysia, no organized population-based screening program 
exists despite published guidelines for CRC screening.134 
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CONCLUSION
Colorectal cancer incidence and mortality rates vary widely among continents and 
within continents. High-quality incidence and mortality data allow understanding 
of disease and are thus the first essential step for effective cancer control 
planning. In considering whether to move forward with a CRC screening program, 
the local impact of the disease relative to other health problems and the capacity 
to treat the disease adequately should be taken into account. Non-communicable 
diseases as CRC are rapidly becoming the leading health-care problem in middle-
income and low-income countries. This in particular pertains to those countries 
that are transitioning to Western lifestyles and have aging populations. Therefore, 
the need to consider implementing CRC screening beyond the countries in which 
it is currently taking place is likely to increase over time. Most countries with a 
high CRC incidence however, already have some form of screening in place. 
Despite major changes over the past 15 years, there remain many countries 
without population-based CRC screening despite high CRC incidence and 
mortality. This is in most cases explained by limitations in resources including 
colonoscopy capacity, and the organization of structure of health care delivery. 
Some countries without an existing program already have CRC screening on the 
agenda. This will likely result in implementation of CRC screening in the coming 
years. 
Most organized CRC screening programs use non-invasive stool tests (FIT or 
gFOBT), whereas most opportunistic programs are based on endoscopy, in 
particular colonoscopy. For both screening strategies, levels of screening uptake 
vary considerably throughout the world. A screening strategy should be chosen 
carefully to meet the needs of the applicable screening scenario. A comprehensive 
understanding of the full range of screening modalities and strategies available 
for CRC screening is needed for appropriate selection of strategies relative to 
available financial resources and colonoscopy capacity. 
The lack of CRC screening in many countries and the low screening uptake in 
various others provide room for improvement. In countries with a CRC screening 
program with low uptake levels, targeted actions need to be considered to 
improve uptake. This may include adaptations to the invitation and follow-up 
protocol, in particular implementing an active call-recall system. Other measures 
may include a change to or addition of another screening modality. Professional 
gastroenterology associations may actively promote such changes in close 
conjunction with health authorities and screening organizations. 
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Finally, quality assurance and evaluation is of paramount importance to ensure 
optimal impact, minimal burden, and balanced use of resources. Therefore, 
screening measures and quality indicators should be reported, allowing national 
evaluation and international comparison to improve CRC screening quality.
In conclusion, the global challenge is to evaluate the need for CRC screening 
in a given jurisdiction or country, and, if indicated, to develop a tailored CRC 
screening program for which the uptake is high. This is especially necessary for 
low resource countries that face an increase in CRC incidence, as populations 
adopt a more Westernized lifestyle.
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ABSTRACT
Colorectal cancer (CRC) forms an important public health problem, 
especially in developed countries. CRC screening tests can be 
used to identify asymptomatic individuals with CRC pre-cursors and 
(early) cancer. Removal of these lesions reduces CRC incidence and 
prevents CRC related mortality. There are a range of screening tests 
available, each with advantages and disadvantages. Stool screening 
tests can broadly be divided into fecal occult blood tests (FOBTs) 
and molecular biomarker test, such as DNA/RNA marker tests, protein 
markers and fecal microbiome marker tests. Guaiac fecal occult blood 
tests (gFOBT) have been demonstrated in large randomized screening 
trials to reduce CRC mortality. Fecal immunochemical tests (FIT) have 
superior adherence, usability and accuracy as compared to gFOBT. 
Advantage of the use of quantitative FITs in CRC screening programs 
is the cut-off level that can be adjusted. Molecular biomarker DNA tests 
have shown to detect significantly more cancers than FIT. By combining 
biomarker DNA tests with FIT, sensitivity for advanced adenomas can be 
increased significantly. However, it has lower specificity thus demands 
more colonoscopy resources, is more cumbersome and costly. The 
adherence has not been assessed in population screening trials. For 
these reasons, FIT is therefore at present regarded as the preferred 
method of non-invasive CRC screening. This chapter will review the 
current status of fecal test based CRC screening.
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INTRODUCTION
Colorectal cancer (CRC) forms an important public health problem, especially in developed countries.1 It ranks third among the most commonly diagnosed 
cancers worldwide, affecting approximately 1.23 million patients each year.4 In 
developed countries, it is the second cause of cancer-related death in men and the 
third cause in women.135 136 The high incidence and associated mortality, and the 
natural history of CRC with slow progression from a premalignant polyp to cancer, 
makes CRC very suitable for population screening.6 7 The National Polyp Study 
within the United States showed that adenoma removal reduced the incidence 
of CRC by 76–90%. After a median follow-up of nearly 16 years, colonoscopy 
with removal of adenomas resulted in a 53% reduction in CRC mortality (mortality 
ratio 0.47, 95% CI 0.26-0.80) compared to the expected CRC mortality rate in the 
general population.8 34 Further studies showed screening and prevention of CRC is 
cost-effective and dependent on strategy also cost-saving.5
Various CRC screening tests are available, which can basically be divided into non-
invasive stool or blood tests and more invasive imaging or endoscopy procedures. 
There is no single worldwide-agreed optimal CRC screening method. This results 
in different approaches in various countries.137 The choice which screening method 
should be used is mainly dependent on financial and endoscopy resources, and 
secondly on the willingness of the population to undergo the primary screening 
test. As a result of limited resources and population preferences for non-invasive 
screening, many organized screening programs use a two-step approach. This 
includes primary screening with a non-invasive fecal test, followed by bowel 
inspection by means of colonoscopy for individuals that tested positive. For a 
screening test several test characteristics are necessary. Since screening involves 
asymptomatic and mostly healthy people, a test should be safe, meaning that the 
test and screening program should cause no harm. In this light a high test-specificity 
is preferred, reducing the risks of harm from both unnecessary (follow-up) testing 
and overdiagnosis. This is contrary to a diagnostic test in a clinical setting, where 
the high pretest-probability of the disease has often already been established 
and the disease needs to be confirmed or ruled out. Furthermore, a screening 
test should be acceptable to the screenee. Adherence rates of those invited for 
screening are a direct reflection of the acceptance of the test. A screening program 
with low adherence will by definition not impact on CRC incidence and mortality, 
irrespective of the characteristics of the test that is offered. Also, practical use and 
costs of the test need to be taken into account. Fecal tests may differ in positivity 
rate, and thus number of people referred for colonoscopy. They consequently 
have different demands for colonoscopy resources. Recently, the variability of 
fecal tests as CRC screening tool is rapidly increasing and more countries have 
been implementing CRC screening programs. The large variability and expanding 
range of fecal tests may impair knowledge of the available screening options. 
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Therefore, this review aims to give an overview of the recent advances in fecal 
tests and its use in colorectal cancer screening programs.
FECAL OCCULT BLOOD TESTS 
Fecal occult blood tests (FOBTs) detect hemoglobin (Hb) in feces. A range of 
FOBTs is available; they can be divided into two types: guaiac FOBT (gFOBT) 
and fecal immunochemical tests (FIT). 
Guaiac fecal occult blood tests 
Guaiac tests were already available a century ago. They were then used to detect 
gastric blood loss from peptic ulcer and gastric cancer, conditions that affected 
large numbers of patients. Guaiac FOBTs were in the 1970s the first widely 
used FOBT for population-based CRC screening. The gFOBT detects blood by 
the use of guaiac-impregnated paper to which hydro-peroxidase is added. In 
contact with heme, the hydro-peroxidase oxygenizes guaiac leading to a blue 
discoloration. The test-result, i.e. the blue discoloration, is qualitative (positive 
/ negative). The standard gFOBT consists of three paper cards each with two 
panels, requiring sampling from three separate stools. Guaiac FOBTs can be 
analyzed with and without hydration. The former has the advantage of a higher 
sensitivity, however, it also leads to more false-positives.138 The impact of gFOBT 
screening on CRC incidence and mortality has been prospectively assessed in 
several, large randomized trials. These trials demonstrated that repeated annual 
or biennial gFOBT screening reduces CRC-related mortality by approximately 
32-33% and 6-18% respectively.139-142 The Minnesota trial, which used rehydrated 
gFOBT, also demonstrated a reduction in CRC incidence.141 A subsequent meta-
analysis reported a pooled 15% reduction in CRC-related death among the three 
biennial screening trials with gFOBT compared to controls.20 The Minnesota 
trial recently after 30 years follow-up reported an overall 27% reduction in CRC 
mortality.143 
A main disadvantage of gFOBT is that it does not specifically target human heme. 
Hydro-peroxidase also reacts with non-human heme present in red meat. This 
may cause a false-positive test result. Several fresh fruits and vegetables contain 
peroxidase activity, which may also lead to false-positive test results. Vitamin C 
may on the contrary block the peroxidase reaction, resulting in false-negative test 
results.144 As a result of the dietary restrictions and the need for three different 
samples on consecutive days, adherence rates of gFOBT-screening are generally 
poor.57 144 Furthermore, although gFOBT has a high specificity, its sensitivity is 
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limited since it does not detect hemoglobin concentrations below approximately 
600 µg/g feces.138 Consequently, adenomatous polyps, precursors of most 
CRCs, are less likely to be detected as they generally bleed less. The focus on 
early cancers provides a short window of opportunity, which explains the need 
for short screening intervals. For these reasons high sensitivity gFOBTs have been 
designed, with an enhancer to allow detection of lower Hb concentrations.145 
However, these gFOBTs come with a lower specificity making these test less 
suitable for population-based screening. Due to the low sensitivity and adherence 
rates, gFOBT screening is associated with a significant proportion of interval 
cancers.57 In the Scottish population program, the proportion of interval cancers 
increased from 31.2% to 58.9% after the first, respectively third screening 
round.146 This increase can partly be explained by a decrease in screen-detected 
cancers over the screening rounds. 
Fecal immunochemical tests for hemoglobin (FIT)
Fecal immunochemical tests detect human globin by means of an antibody-
based assay. FITs either provide a qualitative result or quantitative result in 
terms of fecal Hb concentration per gram feces. The latter has the advantage 
that the selection of cut-off level in population based screening can be tailored 
to financial and endoscopy resources. There are many different FIT brands 
available on the market. Figure 1.3.1 shows some of the different FITs. These 
tests sample different amounts of fecal material, use different amounts of buffers, 
analytical procedures, and reporting units. They generally present results as Hb 
concentration in nanograms per ml test buffer. As a result of these differences, 
the quantitative results of different tests cannot be compared one-to-one. It has 
therefore been proposed to standardize the reporting units of fecal Hb to µg Hb 
/ gram feces.19 However, even when using these standardized Hb concentrations, 
different brand of FITs perform differently in mass screening.147 These differences 
apply for both qualitative and quantitative results.144 Currently, there is no evidence 
for one FIT to be superior over another.57 
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At present there are no results from large prospective randomized trials 
concerning the impact of repeated FIT screening on CRC incidence and 
mortality. Even so, the current European guidelines recommend FIT screening 
as the preferred method of fecal occult blood testing.148 Screening by means 
of FIT has advantages over gFOBT screening (Table 1.3.1). Firstly, FIT testing 
requires only one stool sample instead of sampling from three bowel movements. 
Furthermore, the sampling probe connected to the inside of the lid of the test 
facilitates test handling (Figure 1.3.1). Together this results in significantly higher 
adherence rates with higher detection rates of CRC and advanced adenomas.25 
Also, FIT is more sensitive in detecting hemoglobin than gFOBT with reported 
sensitivities for advanced neoplasia detection of two to three times higher 
compared to gFOBT.45 This higher sensitivity for advanced neoplasia would allow 
prevention of the development of CRC, and thereby potentially decreasing CRC 
incidence in addition to detecting CRC in an early stage. Lastly, when comparing 
FIT to gFOBT regarding cost-effectiveness, FIT screening is more cost-effective 
at any given cut-off. At the same colonoscopy demand, FIT screening led to lower 
costs and more life years gained than gFOBT.149 
Figure 1.3.1 FIT brands with different sampling probes, collection tubes, and volume of 
preservative buffer
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FIT performance shows variability among different subgroups. Some studies 
reported a higher sensitivity for left-sided adenomas than right-sided lesions.150 
151 Also, FIT sensitivity has shown to be higher for aspirin users compared with 
nonusers.152 At the same cutoff, men have higher FIT positivity rates than women.153 
This is a reflection of the higher prevalence of advanced neoplasia in men, as well 
as their more frequent distal location.154
Currently, most quantitative FITs have been mainly used with a fixed cut-off, thereby 
limiting the FIT to a qualitative result (i.e. either positive or negative). Rationale 
for choosing a specific cut-off greatly depends on the aim of screening and 
available colonoscopy resources.149 Using a higher cut-off is of particular interest 
in situations with limited colonoscopy capacity where screening programs aim for 
maximal diagnostic yield with restricted resources.96 A high cut-off also comes with 
a high positive predictive value. A lower cut-off increases sensitivity for detection 
of subjects with advanced neoplasia but requires larger colonoscopy resources 
due to a lower positive predictive value. There is still much to gain concerning the 
quantitative nature of FIT, as the exact fecal Hb concentration could be of great 
clinical use. There is evidence that fecal Hb concentration is related to the severity 
of advanced neoplasia.155 By adding fecal Hb concentration in predictive models, 
individuals with the highest risk of advanced neoplasia can be identified.156 This 
may also allow for gender-specific approaches. Combining individual fecal Hb 
concentrations with other risk factors for CRC to base colonoscopy indication 
on, and not solely a qualitative test result, could possibly improve FIT-screening 
efficiency. Also FIT could be of clinical importance after the initial positive test 
result, because the fecal Hb concentration is associated with the risk of a second 
colonoscopy within one year after screening colonoscopy.157 Future research in 
FIT screening should therefore explore the possibilities of incorporating individual 
fecal Hb levels in CRC screening programs. 
Table 1.3.1 Differences between gFOBT and FIT screening in average-risk individuals 
gFOBT FIT
repeat sampling from multiple bowel move-
ments
single sampling from one bowel movement
dietary restrictions no dietary restrictions
qualitative result quantitative or qualitative result
semi-automated analysis automated analysis
sensitivity CRC 31-63%* sensitivity CRC 69-100%**
specificity CRC 92-96 %* specificity CRC 92-96%**
*48 49  
**151 158 159
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DNA- AND RNA-BASED MARKER TESTS 
DNA- and RNA-based stool tests aim to detect markers of aberrant DNA or RNA 
from neoplastic cells. They are based on the principle that colorectal neoplasms 
shed surface cells in stool. DNA or RNA from these cells can be isolated and 
tested for the presence of mutations and epigenetic changes acquired during 
carcinogenesis. DNA- and RNA-based testing is relatively new compared to 
FOBTs. DNA analysis techniques are developing rapidly and are very sensitive.160 
DNA markers
A recent study combined FIT with several DNA markers, consisting of molecular 
assays for aberrantly methylated BMP3 and NDRG4 promoter regions, mutant 
KRAS, and β-actin (a reference gene for human DNA quantity).41 This multi-
target stool DNA plus FIT test had a significantly higher sensitivity for advanced 
adenomas (42%) and a somewhat higher sensitivity for CRC (92%) than FIT alone 
(sensitivity for advanced adenoma 23%, for CRC 72%). However, this increase 
in detection came against the background of a considerably higher test positivity 
rate (16% vs 7%). As a consequence, the demand for colonoscopy is more than 
twice as higher after DNA-FIT testing than after FIT alone, and the DNA-FIT test 
had a lower specificity for advanced neoplasia compared to FIT, 87% versus 95% 
respectively. In the light of population based screening and limited colonoscopy 
resources, the higher positivity rate and lower specificity are important pullbacks. 
Since colonoscopy resources are in many regions the limiting factor in population 
screening, it has been advocated to compare non-invasive tests not at a fixed 
test cut-off, but over a range of positivity rates, allowing a direct comparison 
between tests at the same positivity rate.57 Also, the multi-target DNA test 
requires a full stool sample to be sent in a container, which comes with additional 
costs and impracticality to an already expensive testing procedure. Furthermore, 
the multi-target DNA test is recommended once every three years, whereas FIT 
is offered annually in the Unites States. Cumulative sensitivity, specificity and 
costs after three years of annual FIT screening would therefore be the fairest 
comparison before drawing conclusions on superiority of either of the two tests. 
Lastly, adherence to the multi-target stool DNA test has not yet been investigated. 
Since adherence is crucial in screening efficacy, this should be evaluated before 
proceeding to implementation of the test in a screening program. 
The performance of DNA tests may differ per CRC subtype, on the grounds that 
CRC is a heterogeneous disease that can develop via multiple pathways. To 
detect all CRC subtypes with a screening test, different tumor markers have to 
be used.161 162 A recent study showed that different subtypes are associated with 
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marked differences in survival. Subjects with tumor markers reflecting a serrated 
morphology have the highest disease specific mortality (Hazard ratio 2.20).163 This 
was compared to subjects with tumor markers reflecting the traditional adenoma-
carcinoma sequence (the most predominant tumor). However, the biologic basis 
for the observed difference remains an important topic for future research. 
RNA markers
A microRNA (miRNA) is a small non-coding RNA molecule (containing 
approximately 22 nucleotides), which functions in RNA silencing and post-
transcriptional regulation of gene expression. MiRNAs are thought to be cell-
type and disease specific and may be quantified in stool by quantitative real-time 
polymerase chain reaction (qPCR).164 Aberrant expression of a specific miRNA 
may display the effects of a tumor suppressor or oncogene. A large number 
of studies of single or panels of miRNAs for the detection of CRC have been 
published recently.165 A Japanese group showed that the addition of fecal miRNA-
106a to FIT testing improved the sensitivity but decreased the specificity of 
FIT.166 Since most published studies were based on selected populations, further 
research in an asymptomatic population should be conducted. 
PROTEIN MARKERS 
Protein based stool markers focus on either the detection of cancer specific 
proteins or detection of proteins released from inflamed and/or bleeding tissue. 
Fecal tumor M2 pyruvate kinase (M2-PK) has received the most attention as a 
potential cancer specific protein marker. The test is based on the detection of 
proteins in stool derived from neoplastic colonocytes. A recently reported meta-
analysis of studies comparing M2-PK with colonoscopy reported a pooled CRC 
sensitivity and specificity of 79% and 80%, respectively.167 
A non-cancer specific protein marker is calprotectin. Calprotectin is a calcium 
binding protein in granulocytes, macrophages, and epithelial cells. Elevation of 
calprotectin occurs during intestinal inflammation, including inflammation caused 
by inflammatory bowel disease. Elevated fecal calprotectin in CRC is suggested 
to be due to neutrophil shedding from an ulcerated tumor into the intestinal lumen. 
A large Norwegian CRC screening trial evaluated calprotectin and reported a 
lower sensitivity and specificity than FIT.168 
So far, no single protein stool marker has shown to be of adequate accuracy 
to be considered for population-based CRC screening. A Chinese study 
investigated the possibility of combining seven biomarkers in a biochip for the 
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detection of colorectal cancer.169 The most optimal result was the combination 
of two biomarkers (TPO, FGF-23) leading to a sensitivity of 0.8 with a specificity 
of 0.7 for detection of cancer. The use of protein makers in CRC screening, or 
combining protein markers with FIT, requires further research. 
Currently novel molecular tests to analyze stool for a combination of genetic, 
epigenetic, and protein biomarkers are being developed. The largest is the 
Molecular Early Detection of Colorectal Cancer (MEDOCC) project. It is a long-
term collaborative research between the Netherlands and United States. 
HUMAN FECAL MICROBIOME-BASED BIOMARKERS
Recent studies suggest an important role for the gut microbiome in the 
development of CRC. Patients with CRC have a different gut microbiome than 
healthy subjects.170 One of the first bacteria more commonly found in patients 
with CRC was Streptococcus bovis.171 At present, other bacteria have been 
identified that play a role in gastro-intestinal cancers, such as Helicobacter 
pylori, and Fusobacterium nucleatum.170 The latter has been of particular interest 
in colorectal neoplasia, with several studies indicating that F. nucleatum in feces 
is associated with the occurrence of colorectal adenomas and cancer. However, 
its precise role in this process is poorly understood.170 It has been suggested 
that F. nucleatum could be useful in detecting serrated polyps.172 This is relevant 
as FOBT does not seem sensitive to serrated lesions.173 The fecal microbiome in 
CRC screening has largely been unstudied, but measuring the fecal microbiome 
to identify those at risk of CRC seems promising as a novel screening method. 
A major advantage of this method of screening could be that non-bleeding 
lesions are also detected. One study combined the gut microbiome with other 
risk factors and found that by adding the microbiome the pretest to posttest 
probability increased, resulting in better identification of subjects with advanced 
neoplasia.174 The use of the gut microbiome as a CRC screening tool has great 
potential. Hence, studies identifying specific microbiota that are associated with 
CRC are much awaited. 
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CONCLUSION
There is a wide range of fecal tests for colorectal cancer screening available. The 
guaiac FOBT was one of the first fecal tests used in colorectal cancer screening. 
Large trials have shown a significant reduction in CRC-related mortality after 
screening with gFOBT. However, its use has several limitations when compared 
to FIT. These limitations include ease of use, adherence, and sensitivity. Also, 
FIT has the advantage that fecal Hb concentrations can be measured yielding 
a quantitative test result. Nonetheless, at present FIT is mostly analyzed using a 
pre-determined cut-off. Aside from FOBTs, to date, only DNA-based stool tests 
have undergone the full spectrum of development and testing for clinical practice. 
The multi-target stool DNA test was approved by the FDA in the United States 
for CRC screening in 2014. So far, biomarker tests such as the multi-target stool 
DNA test are more expensive than the FOBTs, and come with a relatively low 
specificity. Furthermore, adherence rates have not been evaluated. Therefore, a 
sensitive single biomarker of panel of biomarker (stool) test at affordable cost is 
much awaited. Also, further identification of the gut microbiome could open up 
new possibilities in CRC screening strategies. Expansion of molecular biomarker 
screening tests may become imaginable in the future. At the current stage, 
screening by means of FIT seems the way to go. Requirements in test sensitivity, 
specificity and costs in order for new molecular biomarker technologies to be 
cost-effective compared to the FIT should be investigated. Future focus should 
also be on using FIT quantitatively and incorporating FIT results in risk prediction 
models to maximize screening benefit and efficacy. 
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This thesis provides strategies and insights that may contribute to optimizing colorectal cancer (CRC) screening. PART I starts with an overview of 
the burden of CRC worldwide and global initiatives to reduce this burden by 
screening (Chapter 1.2). The available screening methods are discussed, which 
can mainly be divided into non-invasive fecal tests and more invasive colon 
imaging tests. Chapter 1.3 concentrates on the recent advances in fecal tests 
for CRC screening. 
In PART II, we further focus on fecal occult blood test-based CRC screening. 
The main two fecal occult blood tests are the guaiac-based fecal occult blood 
test (gFOBT) and the more recently developed fecal immunochemical test (FIT). 
Screening by means of gFOBT has been proven to reduce CRC-related mortality, 
although for FIT these data have not yet become available. We compare the 
diagnostic accuracy of FIT and gFOBT in average-risk individuals by performing 
a Cochrane systematic review and meta-analysis (Chapter 2). This chapter 
provides an overview of the test performance characteristics for both types 
of fecal occult blood tests. The general aim of the subsequent chapters is to 
explore various aspects of FIT screening and screening strategies. This aim is 
pursued using important data derived from four rounds of a large prospective 
population-based CRC screening trial called the ‘CORERO’-trial. This study was 
implemented in 2006 and invited 13,205 asymptomatic average-risk individuals 
for quantitative FIT screening. FITs can be either qualitative, providing a positive 
or negative test result, or quantitative, quantifying fecal hemoglobin (Hb) 
concentrations in feces. Quantitative FIT offers the opportunity of selecting a 
specific cut-off concentration used to identify candidates for further evaluation 
by colonoscopy. We aimed to study the effect of various fecal Hb cut-off 
concentrations and screening age on diagnostic yield of advanced neoplasia, 
missed lesions, and colonoscopy demand (Chapter 3). Because adenomas 
can bleed intermittently, neoplasia can be missed with the use of one sample of 
one bowel movement. With the use of two FITs per round, the detection rate of 
advanced neoplasia may therefore be increased. In Chapter 4, we explore the 
best screening strategy to detect advanced neoplasia in terms of number of FIT 
samples offered to screenees. In screening, quantitative FITs are invariably used 
in a dichotomous manner using pre-specified cut-offs. We aim to determine if 
fecal Hb concentrations of participants with a FIT result below the cut-off could 
be used to predict future colorectal advanced neoplasia risk (Chapter 5). 
The aim of PART III of this thesis is to provide more insight in factors that are 
associated with quality in CRC screening, surveillance and colonoscopy. We first 
focus on online information on CRC screening and surveillance. The internet is 
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increasingly used for health information and assessing the availability and quality 
of online information intended for screenees is therefore essential. We evaluated 
the accuracy, quality, and readability of online information on CRC screening 
and surveillance in Chapter 5. Colonoscopy is the most commonly performed 
gastrointestinal endoscopic procedure and considered the ‘gold standard’ 
investigation of the colon. Aside from primary colonoscopy screening, all CRC 
screening tests are generally followed by colonoscopy in case of a positive test 
result. Measuring and optimizing quality of colonoscopy contribute to a higher 
preventive effect of CRC screening and surveillance. The quality of colonoscopy 
can be measured by comparing performance parameters i.e. quality indicators of 
an individual endoscopist or group of endoscopists with predetermined targets. 
Reduction in variation of quality has also emerged as an important priority for 
colonoscopy practice. We therefore assessed whether plenary feedback on 
quality indicators can stimulate improvement of colonoscopy and thereby reduce 
inter-hospital differences (Chapter 7). In Chapter 8, we expand our knowledge on 
quality assurance of surveillance colonoscopies after the removal of adenomas.
In PART IV, the main findings of this thesis are summarized and discussed. In 
addition, the implications for CRC screening and directions for further research 
are highlighted (Chapter 9).
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CHAPTER 1.1
General introduction
ABSTRACT 
Background
Worldwide, many countries have adopted colorectal cancer (CRC) 
screening programmes, often based on faecal occult blood tests 
(FOBTs). These FOBTs fall into two categories based on technique and 
detected blood component: qualitative guaiac-based FOBTs (gFOBT) 
and the more recently developed faecal immunochemical tests (FIT) that 
can be both qualitative and quantitative. Screening by means of gFOBT 
has been proven to reduce CRC-related mortality. The effectiveness 
of FIT screening in decreasing CRC-related mortality has not yet been 
studied in large long-term prospective randomised controlled trials. 
Objectives
The primary objective of this review was to compare diagnostic 
accuracy of gFOBT and FIT screening for detecting advanced colorectal 
neoplasia in average-risk individuals.
Search methods
We searched MEDLINE, EMBASE, Cochrane Library, BIOSIS Citation 
Index, and Science Citation Index Expanded until March 21st 2016. We 
also searched references lists and PubMed-related articles of included 
studies to identify additional studies. We did not restrict studies based 
on language, date, or whether data had been collected prospectively 
or retrospectively.
Selection criteria
Only studies that provided the number of true positives, false positives, 
false negatives, and true negatives for gFOBT and/or FIT with 
colonoscopy as the reference standard were included. Two types of 
studies were included; those in which all participants underwent both 
the index test and the reference standard (type I); and those in which 
only participants with a positive index test underwent the reference 
standard while the negatives were followed for at least one year for 
development of interval carcinomas (type II). The target population 
were asymptomatic, average-risk individuals undergoing colorectal 
cancer screening were included. 
Data collection and analysis
Two authors independently selected studies for inclusion and collected 
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the data from each study. In case of doubt a third author made the final 
decision. We used a bivariate and HSROC statistical model to obtain 
summary estimates of sensitivity and specificity and summary ROC 
curves. 
Main results
A total of twenty-three type I studies involving 85,403 participants were 
included, reporting on a total of thirty-two faecal occult blood tests. 
Six studies evaluated gFOBT, thirteen studies evaluated FIT, and four 
studies included both gFOBT and FIT. Twenty-one studies reported 
advanced neoplasia as outcome, and nineteen studies reported on 
colorectal cancer. The cut-off for positivity of FIT varied between 2.4 
to 50 µg Hb/g faeces. The summary curve estimated by the HSROC 
model showed that FIT had a higher discriminative ability than gFOBT 
for advanced neoplasia (p=0.002), and colorectal cancer (p=0.025).
We included nineteen type II studies reporting a total of twenty-three 
tests involving 1,495,344 participants. Overall six gFOBT studies, ten 
FIT studies, and three studies combining both gFOBT and FIT were 
included. The cut-off for positivity of FIT varied between 2.4 to 10 µg 
Hb/g faeces. The summary curve estimated by the HSROC model 
showed that FIT had a higher discriminative ability than gFOBT for 
colorectal cancer (p<0.001).
Authors’ conclusions
FIT is superior to gFOBT in detecting advanced neoplasia and colorectal 
cancer in average-risk individuals. The specificity of both tests is similar. 
These results strongly support current guidelines for implementing FIT-
based CRC screening programs and the switch from gFOBT to FIT 
testing for existing programs.
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BACKGROUND
Based on the Wilson & Jungner criteria published in 1968 and updated by the World Health Organization in 2008,1 2 screening is justified when (1) a disease 
is common and associated with significant morbidity or mortality; (2) screening 
tests are sufficiently accurate in detecting early stage disease, are acceptable 
to invitees, and are feasible in general clinical practice; (3) treatment after early 
detection by screening improves prognosis relative to treatment after usual 
diagnosis; and (4) the potential benefits outweigh the potential harms and costs 
of screening. Colorectal cancer (CRC) screening fulfils all of these criteria. 
There are various methods for CRC screening. These vary in level of supporting 
evidence, effectiveness, test-related burden, costs and willingness of target 
subjects to undergo screening. The screening modalities for CRC broadly fall 
into two categories; (a) faecal tests (i.e., faecal occult blood tests and faecal 
DNA testing), and (b) partial or full structural exams (i.e., flexible sigmoidoscopy, 
colonoscopy and computed tomography-colonography (CTC)). Colonoscopy 
can be used as the reference standard for those with a positive screening test or 
as a primary CRC screening tool.
Stool blood tests are conventionally known as faecal occult blood tests (FOBTs), 
which are used as a two-step testing approach in CRC screening (i.e., positive 
test result requires further examination with visualization of the colon, predominantly 
by means of colonoscopy). FOBT screening is based on the principle that a large 
proportion of colorectal neoplasia bleed microscopically before any clinical signs 
or symptoms become noticeable. Bleeding tends to be intermittent, and blood is 
distributed unevenly in the stool. The concept of detecting CRC by testing for blood 
in the stool is based on the observation that cancers bleed because of disruption of 
the normal mucosa. The amount of blood increases with the size of the polyp and/
or the stage of the cancer.3-6 In general, the amount of faecal haemoglobin tends 
to be absent or low in those without neoplasia, higher for those with advanced 
adenomas, and highest for those with CRC.7 Faecal occult blood testing detects 
a higher proportion of CRCs and a lower proportion of advanced adenomas, 
since CRCs tend to have a more constant bleeding pattern and give rise to higher 
amounts of blood in stools than advanced adenomas, which are believed to bleed 
more intermittently. In this way FOBT screening identifies those individuals who 
are most likely to have advanced neoplasia. Therefore, it should be followed by 
visualization of the colon and rectum. Colonoscopy is considered the gold standard 
for detection of advanced neoplasia with high sensitivity and specificity (both 
above 90%) and has the advantage that (adenomatous) polyps and early CRCs 
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can be removed during the same procedure. A meta-analysis of the accuracy of 
colonoscopy (performed for various indications), reported that the pooled miss rate 
for adenomas ≥10mm was 2%, for ≥5-10mm 13%, and for 1-5mm 26%.8
FOBTs fall into two categories based on the detected component of blood: guaiac-
based FOBTs (gFOBT) and the more recently developed faecal immunochemical 
tests (FIT) for haemoglobin.
Guaiac-based faecal occult blood test
Guaiac-based FOBTs enable detection of occult blood in stool through the 
pseudo-peroxidase activity of haem. However, peroxidase also reacts with 
non-human haem present in red meat. Also, several fresh fruits and vegetables 
contain peroxidase activity, which may lead to false-positive test results. Vitamin 
C may block the peroxidase reaction, resulting in false-negative test results. 
Guaiac FOBTs may detect bleeding from any site in the gastro-intestinal (GI) 
tract, including the stomach, as haem remains relatively stable during transport 
through the GI-tract.9 The usual gFOBT protocol consists of three test cards, 
each containing two panels. The screenee is instructed to collect two faecal 
samples from three consecutive bowel movements yielding a total of six stool 
panels. Applying a hydrogen peroxide reagent to the faeces on the guaiac 
material in the panel leads to oxygenation of guaiac, which in turn leads to a 
blue colour change when haem is present. A panel is considered positive if such 
coloration appears.10 The number of positive panels for referral to colonoscopy 
varies between screening programs. In most programs, a single positive panel is 
sufficient for referral, however in others the number of positive panels is set at five 
out of six. In this case, less positive panels imply renewed gFOBT testing. Prior to 
faecal sampling, individuals are asked to restrict their diet and medication as this 
might affect the number of false-positive and false-negative test results. 
The sensitivity and specificity of gFOBT screening varies widely due to the variation 
in type of test (brand), instructions for stool collection, number of stool samples 
per screening round, the use of non-hydrated or rehydrated stool samples, double 
reading of the test, the number of positive panels used to refer a screened person for 
colonoscopy, and the interval between successive screening rounds. In some trials, 
rehydrated gFOBT has been studied; rehydration reduces the false negative rate 
(improves sensitivity) while increasing the false positive rate (reduces specificity).11 12 
Guaiac FOBTs are the only stool tests for which there is evidence of efficacy 
from four prospective, randomised controlled trials (RCTs). These trials from 
the USA, United Kingdom, Denmark and Sweden demonstrated that multiple 
rounds of annual or biennial gFOBT screening can reduce CRC-related mortality by 
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approximately 13-33%.11 13-15 The American trial, which used rehydrated gFOBT, also 
demonstrated a reduction in the incidence of CRC.11 A subsequent meta-analysis 
reported a pooled 15% reduction in CRC-related mortality among the three biennial 
screening trials with gFOBT compared to controls.16 The American trial recently 
reported an overall reduction in CRC mortality of 27% after 30 years of follow-up.17 
The efficacy of gFOBT screening in reducing CRC-related mortality is limited due to 
a limited sensitivity for detecting CRC and low sensitivity for detection of advanced 
adenomas.18 Furthermore, the process of analysing gFOBTs is time consuming and 
is faulted by the possibility of inaccurate processing and evaluation.19
Faecal immunochemical test
FITs have several technological advantages compared to guaiac based screening. 
FIT specifically targets human globin, a protein that along with haem constitutes 
the haemoglobin molecule. Therefore, FITs only detect human blood, in contrast to 
the gFOBT which can falsely detect other substances. For this reason, FITs are less 
subject to interference by dietary factors and medication. Studies have suggested 
that NSAID or aspirin use increased the sensitivity of FIT without a decrease in 
specificity.20 21 In addition, FITs are more specific for lower GI-tract bleeding since 
globin is degraded by digestive enzymes in the upper GI-tract. This improves their 
specificity for neoplasia in the colon and rectum. The sample collection for most FIT 
variants is less demanding than for gFOBT-sampling, both in terms of requiring a single 
sample and less direct handling of stools (smear cards for gFOBTs vs brush/spatula 
for FIT testing). Furthermore, FIT screening does not require dietary restrictions. Both 
qualitative and quantitative FITs have been developed and are described below. 
Qualitative FITs
Qualitative tests require a manual interpretation of test results as positive or negative. 
There is a range of such tests on the market. They often use immunochromatographic 
technology, and allow for simple, office-based analysis. Since qualitative FITs 
provide dichotomous test results and thresholds for a positive test differ between 
brands, test performances differ.22 23 However, like gFOBT, inter-observer variations 
in interpretation of test results may influence performance. 
Quantitative FITs
Quantitative FITs on the contrary can be analysed automatically, quantifying the 
amount of haemoglobin found in the stool sample. One advantage of quantitative 
FITs in CRC screening programs is that the cut-off level (i.e. the amount of 
haemoglobin above which the test is considered positive and individuals are 
referred for follow-up examination) can be adjusted. This allows the number of 
FIT-positives to be matched with the available resources for further investigation, 
in particular colonoscopy capacity.24 Quantitative FITs have further important 
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advantages over qualitative FITs due to the use of automated analysis. This 
automation removes inter-observer variation in interpretation of test results, 
improves reproducibility, and allows for high-throughput testing. Nevertheless, 
studies suggest variable performance of different brands of quantitative FITs, 
even when the standardized same cut-off is used.22 
To date, there are no long-term prospective randomized data that demonstrate 
that FIT is superior to gFOBT in terms of reducing CRC-related mortality. 
However, a recent ecological study compared regions in Italy with and without 
population FIT screening. CRC-specific mortality was 22% lower in areas with a 
FIT screening program compared with areas without a screening program.25 With 
this review, we aim to compare the diagnostic test accuracy measures of gFOBT 
and FIT screening in order to answer the question “Can gFOBT be replaced by 
FIT for primary CRC screening?”. In order to answer this question, an overview 
of the test performance characteristics for both types of FOBT will be provided.
Target condition being diagnosed
FOBT screening primarily aims at early detection of bleeding colorectal neoplasia, 
since only bleeding lesions can be detected by stool blood tests. CRC screening 
in general aims at lowering CRC mortality by early detection of CRC and lowering 
CRC incidence by removal his pre-malignant lesion i.e., adenomatous polyps.
Index test(s)
The tests under evaluation are two FOBTs: gFOBT and FIT. More detailed 
information about the tests and the methods of execution have been previously 
described. FIT can be both quantitative as well as qualitative, the latter does not 
report individual faecal Hb concentrations. 
Alternative test(s)
There are several alternative tests that can be used for CRC screening purposes. 
These tests vary in the level of supporting evidence, attendance, effectiveness, 
and test-related burden, costs. Alternative screening modalities usually considered 
as effective CRC screening tools include flexible sigmoidoscopy, colonoscopy, 
computed tomography-colonography and, more recently, capsule endoscopy, 
faecal DNA testing and serum molecular markers.26 27
Rationale
In the Western world, many countries have adopted a CRC screening program, 
often based on FOBT.28 Screening by means of gFOBT has been proven to 
reduce CRC-related mortality. The results on effectiveness of FIT screening in 
decreasing CRC-related mortality are not yet available. The main explanation for 
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this is that many countries have already implemented a CRC screening program. 
In addition, decisions on the optimal screening test have to be based on data 
about the sensitivity and specificity, existing RCT results, and modelling.29
OBJECTIVES
The primary objective of this review is to compare the diagnostic test accuracy 
of gFOBT and FIT screening for detecting advanced colorectal neoplasia in 
average-risk individuals.
Investigation of sources of heterogeneity
We aimed to investigate the following sources of heterogeneity. 
A.  Heterogeneity related to characteristics of the study population (i.e. sex, age 
limits, ethnicity, selection of invitees (identified from general practitioner records 
or population registers), cancer stage, distribution and cancer location. 
B.  Heterogeneity related to the number of FOBTs performed per screening round 
C.  Heterogeneity related to the cut-off value used for FIT or the number of 
positive panels used to refer a gFOBT-screened person for colonoscopy. 
Due to reasons described later in this review, analysis for heterogeneity could not 
be performed for all of these factors.
METHODS
Criteria for considering studies for this review
Types of studies: Two different types of studies were included and categorized 
in this review: 
Type I studies: All (randomised, comparative) accuracy studies in which all 
participants underwent both the index test and the reference standard. Diagnostic 
case-control studies were considered inappropriate for this review because such 
studies are likely to overestimate diagnostic performance.30 Moreover, literature 
suggests that measures of accuracy may vary with the prevalence and stage-
distribution of the target condition.31 For instance, the sensitivity of a test will often 
vary according to the severity of the detected disease (e.g. advanced CRCs are 
more easily detected with FOBTs than early stage tumours). For these reasons, we 
did not include case-control studies in this review.
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Type II studies: All (randomised, comparative) accuracy studies in which all 
participants with a positive index test were referred for the reference standard 
and all participants with a negative index test were followed for at least one year 
to identify development of interval carcinomas. Only data from the first screening 
round were included for analysis.
Participants
Asymptomatic average-risk individuals aged 40 years and above were considered 
as representative for a CRC screening program. Study participants included 
subjects volunteering for a medical health check-up (including CRC screening), 
as well as individuals identified from population registers, and general practitioner 
or managed care organisation records. 
Index tests 
The index test was either gFOBT or FIT (both qualitative and quantitative) as 
described previously in the Background section.
Comparator tests
Studies were included regardless of whether they made comparisons with other 
CRC screening modalities.
Target conditions 
The primary target condition was CRC, which was defined as the invasion of 
malignant cells beyond the lamina muscularis mucosa. Patients with an intra-
mucosal carcinoma or carcinoma in situ were classified as having high-grade 
dysplasia.32 The secondary target condition was advanced neoplasia, which 
included CRC and advanced adenomas. An advanced adenoma was defined as 
an adenoma with a greatest dimension of at least 10 mm, or an adenoma with ≥ 
25% villous component, and/or high-grade dysplasia.32 For each included study, 
we assessed whether these definitions were applied. If another definition was 
adopted in a study, we stated this in the characteristics of included studies table.
Reference standards
Studies were included for this review if colonoscopy was used as the primary 
reference standard. Only in case of an incomplete colonoscopy, CTC or double 
contrast barium enema (DCBE) was accepted as reference. Furthermore, in 
type II studies participants with a negative index test result had to be followed 
for at least one year to assess the development of interval carcinomas. Interval 
carcinomas were defined as CRC diagnosed in an FOBT negative screenee in 
the period between two successive FOBT screening rounds.33 If a study did not 
use this definition, we stated this in the characteristics of included studies table.
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Exclusion criteria
We excluded studies where more than 5% of the population consisted of high-
risk individuals. High-risk individuals were defined as patients with a history of 
CRC; subjects with a personal history of adenoma(s); individuals scheduled for 
diagnostic colonoscopy because of hereditary CRC syndromes or a positive family 
history of CRC; symptomatic subjects with complaints suspicious for CRC such 
as rectal blood loss, changed bowel habits, or weight loss; and all patients with a 
history of inflammatory bowel disease. We also excluded studies in which a positive 
gFOBT test result needed to be confirmed by a positive FIT test result or vice versa. 
We excluded studies in which less than 75% of the participants with a positive FOBT 
underwent colonoscopy or in case of an incomplete colonoscopy, CTC or DCBE.
Search methods for identification of studies
Electronic searches
To identify appropriate studies, the Trial Search Coordinator of the Cochrane 
Colorectal Cancer Group in collaboration with the Medical School Library of the 
Erasmus MC conducted a literature search by using the electronic databases 
Medline, Embase, the Cochrane Library, BIOSIS, SCI-expanded, Pubmed 
publisher and Google scholar.34  The Embase, Medline and Biosis searches were 
run in OVID. There were no restrictions on date or language of the articles being 
reviewed. Native speakers related to our departments and personal acquaintances 
translated articles written in languages other than English. The searches were 
developed using the Boolean term ‘AND’ between the topics colorectal cancer 
and faecal occult blood test. To cover the topic of colorectal cancer, the searches 
were developed by searching MeSH and/or EmTree terms colorectal neoplasms, 
colorectal cancer and large intestine tumour, and the text words: colorectal, 
rectal, rectum, colon*, cancer*, carcinoma*, adenocarcinom*, neoplas*, tumor*, 
tumour*, polyp* and adenom*. To cover the topic of faecal occult blood testing, 
the search was developed by searching MeSH and/or EmTree terms occult blood, 
immunochemistry and feces analysis, and the text words; faecal, fecal, feces, faeces, 
stool*, occult blood, occult blood test*, FOBT*, gFOBT*, FIT*, immunochem*, 
immunological*, guaiac*, fecal immunochem*, faecal immunochem* and test*. In 
exploratory searches, we identified articles that used gFOBT brand names without 
explicitly mentioning either gFOBT or FOBT in the title, abstract or MeSH terms. 
We have therefore incorporated most of the gFOBT brand names in our literature 
search. This brand name issue was not present when searching for articles related 
to the FIT. Differing from the previous published search strategy in our protocol, 
we did not include the brand name “colorectal” as this yielded too many irrelevant 
results. Initial searches were conducted on January 31st, 2015. We performed a 
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further search on March 21st, 2016. Those results have been incorporated in the 
review. Five studies were added to ‘Studies awaiting classification’ and will be 
incorporated into the review at the next update.
Searching other resources
The references of all included relevant studies were hand-searched for additional 
trials. In addition, we searched for articles citing the relevant studies included 
in the review. We defined relevant included articles as any included article that 
was published within the 5 years preceding our search. Furthermore, we searched 
PubMed for Related Articles of the most relevant included articles. We examined 
the first 20 results from ‘PubMed Related Articles’ after sorting by publication date 
from newest to oldest. We also contacted principal investigators of the included 
articles to clarify aspects of methods and results, and ask for any unpublished 
data in the area of FOBT characteristics, where necessary.
Data collection and analysis
Selection of studies 
Two reviewers (EJG and EHS) independently assessed whether the titles and 
abstracts were eligible for further reading. After this initial retrieval, all selected 
articles were read entirely. Disagreements about including a study for this review 
were resolved through discussion with a third reviewer (AvR). All studies that 
did not meet the inclusion criteria, as ascertained in reading the full article, were 
listed in a separate table with reasons for exclusion. The reference management 
software EndNote X7 was used for the selection process.
Data extraction and management 
Data were extracted from those trials that fulfilled the inclusion criteria. The data 
that were extracted for both advanced neoplasia and CRC were: 
• Positivity rate (PR), i.e. the proportion of participants having a positive index test result.
• True positives (TP), i.e. participants having a positive index test result, followed 
by detection of advanced neoplasia by means of the reference standard. 
• False positives (FP), i.e. participants having a positive index test result, but no 
advanced neoplasia when assessed with the reference standard. 
• True negatives (TN), i.e. participants having a negative index test result, and 
no advanced neoplasia during colonoscopy for Type I studies and no interval 
CRC identified during follow up for Type II studies. 
• False negatives (FN), i.e. participants having a negative index test result, and 
advanced neoplasia during colonoscopy for Type I studies and interval CRC 
identified during follow up for Type II studies.
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The analyses only include the main outcome measures sensitivity and specificity 
(which were derived from TP, FP, TN, FN). For CRC we included data from both 
type I and II studies, and for advanced neoplasia we included data from type I 
studies only. For both study types, the extracted data were merged into separate 
2 x 2 tables (containing TP, FP, FN, TN). We excluded non-interpretable test results 
and FOBT-positives who refused to undergo the reference standard from the 2x2 
table and in consequence from the meta-analysis. If data were lacking in a specific 
article we contacted the principal investigators to ask for the original data and/or 
tried to reconstruct the aforementioned cell frequencies from the information that 
was published. If this was not successful, we excluded the study. The numbers 
of participants analyzed in our review is stated in the characteristics of included 
studies table. The data presented in the 2 x 2 table were used to conduct meta-
analysis on sensitivity and specificity. For type II studies, only data regarding CRCs 
were generally available during follow-up. Therefore, for type I studies we were 
able to extract data for both advanced adenomas and CRC, but for type II studies 
we extracted data for CRC only. We extracted data for all possible cut-offs. Since 
the concentration used for cut-off [ng Hb/ml buffer in the device] is unique to 
the device or system and cannot be compared with other devices, cut-offs were 
transformed to the internationally accepted unit of µg Hb/g faeces.35 All data were 
extracted independently by two reviewers (EJG and EHS).
Assessment of methodological quality
Two authors (EJG and EHS) independently assessed the quality of each individual 
study using the Quality Assessment of Diagnostic Accuracy Studies (QUADAS-2) 
tool.36 We excluded some of the questions from the QUADAS-2 tool in case they 
were not applicable. Details of each study are described in the Characteristics of 
Included studies table. If data was not specified in the article, this was mentioned. 
When authors did not respond also manufacturers were contacted to retrieve 
additional details about the test used if needed. 
Statistical analysis and data synthesis
Descriptive analysis 
The descriptive analysis provides an overview of all available studies. Tables 
were split by gFOBT or FIT, and by type I or type II studies. For all study types, 
the following test characteristics were extracted into 2x2 tables: TP, FP, TN, and 
FN. The extracted data were entered into Review Manager 5. Study-specific 
estimates and exact 95% confidence intervals (CI) of sensitivity and specificity 
were obtained and displayed in forest plots per test type. Different symbols were 
used per test type, in order to create a clear overview of between-test variability. 
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Inferential statistics
In secondary analyses, we compared the performance of the gFOBTs and versus 
the FITs. We complied with the methods and techniques introduced and explained 
in chapter 10 of the Cochrane Handbook for Systematic Reviews of Diagnostic Test 
Accuracy.37 We started with an exploration of the study-specific sensitivities and 
specificities that were extracted from the included studies using RevMan software. 
Based on the available reported sensitivities and specificities, we used the bivariate 
model, and the Rutter and Gatsonis Hierarchical summary receiver-operator curves 
(HSROC) model38 to explore differences between tests and identify potential 
sources of heterogeneity. When at least three studies were found in which both 
gFOBT and FIT were compared with the reference standard we analysed these as 
a separate group from studies in which only one of the two tests was compared. 
When less of these studies were found, we allowed that these contributed an 
observation to both series of tests. These studies were then included twice in the 
data set. We also calculated initial summary estimates of sensitivity and specificity 
when it turned out that more than three studies using common cut-off points for 
test positivity were available. If enough studies appeared per test brand with the 
same outcome parameters, we performed meta-analyses. 
The HSROC model was used to analyse sensitivities and specificities for type I 
and type II studies separately, including all studies. For the quantitative FIT where 
2x2 tables for multiple cut-offs were available, we used the cut-off as advised by 
the manufacturers for this analyses. 
We investigated the effect of cut-off by carrying out subgroup meta-analyses for 
cut-offs where sufficient data were available. As some studies reported 2 x 2 data 
for more than one cut-off, this analysis allowed us to include all of the available 
data. To analyse the sensitivities and specificities from the various studies and 
test types that used the same cut-off, we used the bivariate model as introduced 
by van Houwelingen et al., extended by Reitsma et. al., and explained in the 
Cochrane Manual Chapter 10. 37 39 40 The bivariate model was fitted using proc 
nlmixed from SAS version 9.2 conforming to the examples of SAS syntax given in 
chapter 10 of the Manual. We primarily compared the accuracy of gFOBT and FIT 
tests, employing a model that had the same between study variance/covariance 
matrix in these two test types. In order to include studies that had zero counts 
in any of the four cells we added 0.5 to cells containing no observations. Model 
output provided confidence and prediction region parameters and summary 
estimates of test accuracy measures per test type (gFOBT or FIT).
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Investigations of heterogeneity
The I2 statistic41 was not calculated as it doesn’t account for heterogeneity 
explained by phenomena such as positivity threshold effects, it is therefore 
not routinely used in Cochrane DTA reviews. The magnitude of observed 
heterogeneity was depicted graphically by the prediction ellipse. We planned to 
address heterogeneity by adding covariates of interest to the HSROC model. The 
factors that we aimed to include in our heterogeneity analyses are described in 
our objectives. However, there are several caveats to keep in mind: 
A. Heterogeneity related to gender was assessed as percentage of male 
participants; investigation of heterogeneities within other population 
characteristics was not feasible due to lack of information provided in 
individual studies. Nevertheless, only (studies with) average-risk individuals, 
as defined in our protocol, were included. The well-defined criteria resulted 
in homogenous studies according to prediction ellipses. Investigation of 
heterogeneities within cancer stage, distribution and cancer location was not 
feasible due to lack of information provided in individual studies. 
B.  Heterogeneity related to the number of tests  and/or the number of stools per 
screening round was assessed.
C.  Summary estimates of sensitivity and specificity for the two most common 
cut-off levels to refer screenees for further evaluation by the reference 
standard (i.e. cut-off value for FIT in µg/ml or the number of positive panels 
for gFOBT) were performed. Heterogeneity related to the quantitative or 
qualitative nature of FIT was assessed.
Sensitivity analyses 
Sensitivity analyses were performed in which the QUADAS-items were used to 
identify studies that scored differently on certain quality items to determine the 
effect of poor study quality on the overall results. The impact of each study was 
tested by removing each one from the analysis separately and recalculating the 
summary estimates.
Assessment of reporting bias 
Investigation of publication bias in diagnostic test accuracy studies has proven 
to be problematic, because many studies are done without ethical approval or 
study registration.42-44 Therefore, identification of studies from registration until 
final publication of the results is not possible.42 Furthermore, funnel plot-based 
tests that are commonly used to detect publication bias in reviews of randomised 
controlled trials, have been shown to be misleading for diagnostic test accuracy 
reviews such as ours. Therefore we did not assess reporting bias.
87
gFOBT versus FIT for CRC screening – meta-analysis
2
RESULTS
Results of the search
The search identified 6,005 titles, of which 3,148 remained after removal of 
duplicates. Of these, 2,666 were excluded on the basis of title and abstract. 
Manual removal of duplicates for the remaining articles resulted in 38 additional 
duplicate articles. From 40 articles, the PDF could not be retrieved, even after 
trying to contact the authors. Full articles were retrieved for 404 titles. After hand-
searching the references of all included articles and PubMed related articles of 
included studies, nine additional articles were identified and fully assessed. 
An updated search in March 2016 identified 391 additional records. From this 
updated search, a total of 355 records were excluded based on title and/or 
abstract. Full-texts were assessed for 36 articles of which 31 have been excluded 
with reasons and 5 study reports were added to ‘Studies awaiting classification’ 
(Figure 2.1). 
In total, 413 full-text articles were assessed for eligibility, of which 367 articles 
were excluded because they met one of the exclusion criteria or were otherwise 
assessed as ineligible for the following reasons: 
• In 180 studies, only FOBT-positive subjects had undergone the reference 
standard without follow-up of FOBT-negatives; 
• Forty-eight studies did not focus on average-risk subjects; 
• Forty studies had not used colonoscopy as the first choice of reference 
standard; 
• Sixteen studies only provided data on cumulative mortality over multiple 
screening rounds making it impossible to determine absolute numbers of 
advanced neoplasia detected per screening round; 
• In 13 studies the full-text was a letter or editorial, and 13 were reviews; 
• Seventeen articles encompassed the same cohort as an already included 
article; 
• Nine articles summarized the results of multiple screening rounds and 
separate data-extraction of the first round was not possible; 
• Four articles focussed on digital FOBT where a stool sample was obtained by 
digital rectal examination; 
• Twenty-seven articles were excluded for various other reasons (Figure 2.1). 
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A total of 41 studies were included. One additional study (Faivre 2004) was 
included after contacting the author to obtain data on another article to be 
included.45 We combined two articles (Brenner 2013, Haug 2011) for gFOBT and 
FIT results.46 47 Both studies analysed the same population of 3,077 patients. For 
the Haug’s study the authors provided results for different FIT cut-offs to allow 
direct comparison with other studies using the same cut-off. The 15 excluded 
cases in the original article for the analysis about left/right sided lesions were 
included in our analysis after contacting the principal investigators.
Records identied through database 
searching March 21st 2016 
(n=6,005)
Records screened after duplicates removed 
(n=3,148)
Full-text articles retrieved
(n=404)
Full-text articles assessed for eligibility
(n=413)
Studies included in qualitative synthesis
type I (n=23)
type II (n=18)
Additional includes
identied through 
other sources
(n=1)
Studies included in quantitative synthesis
(meta-analysis)
type I (n=23)
type II (n=19)
Excluded full-texts
(n=367)
  180 type II without follow up
  48  not average risk
  40 notcompared to colonoscopy
  16 cumulative mortality
  13 editorial or letter
  13 (systematic) review
  17 same cohort as included article
   9 cumulative screening rounds
   4 case control study
  27  other
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of related articles
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Figure 2.1 Flowchart of search and included studies.
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A total of 23 type I studies were included: five were performed in the United 
States, five in Germany, four in Taiwan, two in the Netherlands, two in Japan, and 
the remaining studies were performed in France, Spain, South-Korea, China and 
Hong Kong. Seven studies compared more than one test and of those there were 
six studies in which participants had undergone more than one index test; resulting 
in 91,971 test evaluations with a total of 32 separate tests in 85,403 participants. 
Overall, six gFOBT studies, thirteen FIT studies, and four studies combining both 
gFOBT and FIT screening were included for this review. The earliest study was 
published in 2000 (Nakama 2000), with the majority being published between 
2008 and 2013. For all but one study (Nakama 2000) advanced neoplasia was 
the main outcome. Twenty papers separately described the numbers of detected 
CRC and advanced adenoma. In two studies, no CRC was detected. For eleven 
studies, data for a cut-off of 10 µg Hb/g faeces could be retrieved, and for eight 
studies a cut-off of 20 µg Hb/g faeces was used. For all included gFOBT studies 
a positivity criterion of at least one positive panel was used. All but two studies 
used a single stool sample for FIT-testing and for all but two gFOBT-studies three 
consecutive stools were used (Table 2.1). 
A total of nineteen type II studies were included: four were performed in France, 
three in Italy, two in Japan, two in the Netherlands, and the remaining studies 
were performed in Taiwan, Denmark, Israel, Ireland, Scotland, Finland, Spain 
(Tenerife), and Germany. Four studies compared more than one index test with 
each participant undergoing one FOBT. In total they reported on a total of 23 
tests in 1,495,344 participants. Overall, six gFOBT, ten FIT, and three combination 
studies were included. Out of the studies combining gFOBT and FIT, two studies 
randomized participants and one study performed both tests in all participants. 
The earliest study was published in 1987 (Kronborg 1987), with the majority being 
published in 2002 to 2014. All studies had at least one year of follow-up, with 
a maximum of four years of follow-up. Eleven of nineteen included studies had 
exact two years of follow-up. For four studies, data with a cut-off of 10 µg Hb/g 
faeces could be retrieved, and for four studies (five FITs) data with a cut-off of 20 
µg Hb/g faeces. All but one study used a single stool sample for FIT-testing and 
for all gFOBT-tests, three consecutive stools were used (Table 2.2).
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Methodological quality of included studies
All characteristics of included studies can be found in Table 2.1 and 2.2.
Type I studies
The overall quality of type I studies is summarized in Figures 2.2A and 2.2B using 
QUADAS-II. Nineteen (83%) studies clearly included a representative spectrum 
of average-risk participants, which reflects population-based screening. For 
three studies this spectrum was unclear because the studies it were either 
retrospective or did not describe exclusion criteria clearly. However, all these 
studies were performed in an average-risk CRC screening setting and therefore 
included for analysis. One study (Cruz-Correa 2007) had a high risk of bias 
regarding the spectrum as it included patients referred for colonoscopy outside 
of a screening setting. However, only asymptomatic patients over the age of 
55 years were included, for these reasons we choose to include this article 
for analysis. Eighteen (78%) of the studies had a low risk of bias concerning 
the index test; four were unclear because either the method of collection was 
not clearly described or the positivity threshold was not described. One study 
(4%) had a high risk of bias since the study conducted the index test differently 
than as advised by the manufacturer. Unanalyzable tests were only reported 
in five studies (22%). Twenty-two studies (96%) had low concerns regarding 
applicability of the index test; with one study rated as unclear because this 
study did not describe whether the threshold was pre-specified. All studies had 
a low risk concerning the reference standard with over 80% of the participants 
undergoing colonoscopy as the reference standard. However, many studies 
had missing values and FOBT-positivity rates were often lacking. The majority 
(87%) of studies had clear definitions of advanced adenomas; mainly defined as 
adenomas ≥10 mm, adenomas with at least 25% villous component, and /or high 
grade dysplasia.
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2
Figure 2.2A Risk of bias and applicability concerns graph type I studies: review authors’ 
judgements about each domain presented as percentages across included studies
Figure 2.2B Risk of bias and applicability concerns summary type I studies: review authors’ 
judgements about each domain for each included study
96
Chapter 2 gFOBT versus FIT for CRC screening – meta-analysis
Figure 2.3A Risk of bias and applicability concerns graph type II studies: review authors’ 
judgements about each domain presented as percentages across included studies
Figure 2.3B Risk of bias and applicability concerns summary type II studies: review authors’ 
judgements about each domain for each included study
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Type II studies 
The overall quality of type II studies is summarized in Figures 2.3A and 2.3B. 
Fourteen studies (74 %) clearly included a representative spectrum of participants 
with an average-risk of developing advanced neoplasia. Two studies had a high 
risk of bias with regard to selection of patients; in one study (Itoh 1996) Japanese 
workers in a FIT-based screening program could have experienced gFOBT 
screening during earlier years. In another study (Sieg 2002), the article stated that 
subjects below the age of 44 could also participate if they heard of the study, but 
when contacted the authors stated this was not the case. Risk of bias concerning 
the index test was potentially present if the paper did not specify how the authors 
had handled non-interpretable or borderline test results. Around 84% specified 
their reference standard as being colonoscopy. Three studies were marked as 
unclear because while they used colonoscopy as a reference standard, they did 
not describe how many people underwent CT-colonography or DBCE in case of 
a failed colonoscopy. With regard to flow and timing, 47% of the studies had a 
low risk of bias. This was due to multiple reasons. All studies had at least 1 year 
of follow up, five studies had a follow-up of three years, and one study had a 
follow-up of four years.
Findings 
Type I studies - diagnostic test accuracy of gFOBT and FIT for advanced 
neoplasia 
Twenty-one type I studies reported on advanced neoplasia (AN) as outcome; 
their median sample size was 1,046 (range 126 to 18,296). Figure 2.4 shows the 
Forrest plot of all included studies reporting on advanced neoplasia. 
98
Chapter 2 gFOBT versus FIT for CRC screening – meta-analysis
Sensitivities for detecting AN ranged from 0% to 33% for gFOBT and from 5% 
to 67% for FIT screening. Specificities ranged from 79% to 98% and from 86% 
to 99%, respectively. The cut-off for positivity of FIT varied between 2.4 to 50 µg 
Hb/g faeces. The summary curve estimated by the HSROC model for all Type 
I studies for AN can be found in Figure 2.5. FIT showed a higher discriminative 
ability for AN than gFOBT (p=0.002).
Figure 2.4 Forrest plot of all gFOBT and FIT (Type I) for advanced neoplasia 
For all FIT’s a cut-off of 10 mcg Hb/ g faeces was used, unless this cut-off was unavailable. 
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In addition, sensitivities and specificities were calculated solely for those studies 
reporting on FIT screening with a cut-off value of 10 µg Hb/g faeces and 20 
µg Hb/g. Analyses for cut-off 10 µg Hb/g faeces contained both qualitative as 
quantitative FITs. The sensitivity of FIT screening for detection of AN ranged 
between 5% and 67% with a cut-off of 10 µg Hb/g, and from 13 to 44% with 
a cut-off of 20 µg Hb/g. The sensitivity for AN was lower for gFOBT screening 
with a summary sensitivity of 16% (95% CI 12-21%) compared to 31% 995% CI 
25-39% for FIT with a cut-off of 10 µg Hb/g and 27% (95% CI 21-34%) with a 
cut-off of 20 µg Hb/g Specificities of FIT screening for detecting AN ranged from 
87% to 97% for a cut-off of 10 µg Hb/g, and from 89% to 100% for a cut-off of 
20 µg Hb/g. No significant differences in summary specificity for AN were found 
between gFOBT (94%; 95% CI 92-96%), FIT with a cut-off of 10 µg Hb/g (95%; 
95% CI 92-97%) and with a cut-off of 20 µg Hb/g (97%; 95% CI 94-98%). 
Figure 2.5 Summary curve using the HSROC model for gFOBT and FIT for multiple cut-offs for 
advanced neoplasia (Type I) Scale of individual study points is based on sample size.
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Type I studies - diagnostic test accuracy of gFOBT and FIT for colorectal cancer 
Nineteen type I studies reported on colorectal cancer (CRC) as separate outcome 
measure; their median sample size was 2,235 (range 285 to 18,269). Figure 2.6 
shows the Forrest plot of all included studies reporting on colorectal cancer. 
Sensitivities ranged from 13% to 100% for gFOBT, and from 0% to 100% for FIT. 
Specificities ranged from 80% to 98% for gFOBT and from 85% to 96% for FIT. 
The cut-off for positivity of FIT varied between 2.4 to 50 µg Hb/g faeces. The 
summary curve estimated by the HSROC model for AN can be found in Figure 
2.7. FIT showed a higher discriminative ability for AN than gFOBT (p=0.025).
Figure 2.6 Forrest plot of all gFOBT and FIT (Type I) for colorectal cancer For all FIT’s a cut-off 
of 10 µg Hb/ g faeces was used, unless this cut-off was unavailable.
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In addition, sensitivities and specificities were calculated solely for those studies 
reporting on a cut-off of 10 µg Hb/g faeces and 20 µg Hb/g for FIT. Sensitivities 
for CRC ranged from 13% to 100% for gFOBT, from 0% to 100% for a FIT cut-off 
of 10 µg Hb/g, and from 50% to 100% for a cut-off of 20 µg Hb/g. Sensitivity for 
CRC was lower for gFOBT with a summary sensitivity of 41% (95% CI 29-54%), 
compared to 81% (95% CI 71-89%) for a FIT cut-off of 10 µg Hb/g, and 76% 
(95% CI 61-86%) for a FIT cut-off of 20 µg Hb/g. Specificities for FIT ranged 
from 87% to 99% when using a cut-off of 10 µg Hb/g, and from 88% to 96% 
with a cut-off of 20 µg Hb/g. No significant differences in summary specificity for 
colorectal cancer were found between gFOBT (94%; 95% CI 91-95%), FIT with 
a cut-off of 10 µg Hb/g (93%; 95% CI 91-95%), and with a cut-off of 20 µg Hb/g 
(93%; 95% CI 90-95%). 
Figure 2.7 Summary curve type I CRC. Summary curve using the HSROC model for gFOBT and 
FIT (Type I) for multiple cut-offs for colorectal cancer. Scale of individual study points is based 
on sample size.
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Type I studies – linked ROC
Four studies (Brenner 2010, Brenner 2013 & Haug 2011 combined, Graser, 2009, 
Hoepffner 2006, Park 2010) compared FIT and gFOBT in the same population. 
The cut-off for positivity of FIT varied between 2.4 to 10 µg Hb/g feces. The 
summary curve estimated by the HSROC model for linked Type I studies for AN, 
can be found in Figure 2.8. FIT showed a higher discriminative ability for AN than 
gFOBT (p=0.073).
Type I studies heterogeneity analyses
There was a significant difference in sensitivity or specificity, or both, for males 
versus females for FIT, both for outcome AN as CRC (p<0.001). For gFOBT, 
difference in accuracy for males versus females was significant for outcome AN 
but not for CRC (p=0.002 and p=0.638, respectively). There was no evidence 
(all p-values >0.01) to suggest a difference in sensitivity or specificity, or both, 
between studies using one, two or three stools per screening round. There was 
Figure 2.8 Linked-HSROC curve of studies (Type I) with outcome advanced neoplasia 
(including: Brenner 2012, Graser 2009, Brenner 2013 and Haug 2011 combined, Park 2010, 
Hoepffner 2006). Scale of individual study points is based on sample size.
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no significant difference in sensitivity or specificity, or both, between studies 
using a quantitative or a qualitative FIT at a cut-off of 10 µg Hb/g for the outcome 
AN as well as CRC (p = 0.645 and p = 0.216, respectively). 
Type I studies sensitivity analyses
For the analyses including all cut-offs, a sensitivity analysis was undertaken by 
excluding the studies  that yielded an high risk of bias following the QUADAS 
assessment (Alhquist 2008, Brenner 2013, Cruz-Correa 2007, Hoepffner 2006, 
Omata 2011, Sung 2013). Even when excluding these studies, FIT remained 
significantly superior to gFOBT in the HSROC model.
Type II studies - diagnostic test accuracy of gFOBT and FIT for colorectal cancer 
There were nineteen type II studies that reported on CRC as separate 
outcome; their median sample size was 7,355 (range 1,179 to 747,076). 
Figure 2.9 shows the Forrest plot of all included studies reporting on CRC. 
Figure 2.9 Forrest plot of all gFOBT and FIT (Type II) for colorectal cancer. For all FIT’s a cut-
off of 10 mcg Hb/g faeces was used, unless this cut-off was unavailable.
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23649
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20448
2173
36673
1621
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0.60 [0.54, 0.66]
0,67 [0.35, 0.90]
0.67 [0.54, 0.78]
0.57 [0.51, 0.62]
0.61 [0.39, 0.80]
0.62 [0.32, 0.86]
0.65 [0.55, 0.75]
0.57 [0.29, 0.82]
0.67 [0.63, 0.71]
0.98 [0.98, 0.98]
0.98 [0.97, 0.98]
0.98 [0.98, 0.99]
0.98 [0.98, 0.98]
0.99 [0.99, 0.99]
0.98 [0.97, 0.98]
0.98 [0.98, 0.98]
0.98 [0.97, 0.99]
0.98 [0.98, 0.98]
0 0.2 10.80.60.40 0.2 10.80.60.4
0 0.2 10.80.60.40 0.2 10.80.60.4
Castiglione 2007
Chiang 2014
Chiang 2014
Crotta 2012
Denters 2012
Itoh 1996
Launoy 2005
Levi 2011
McNamara 2014
Nakama 1996
Parente 2013
Parra-Blanco 2010
Sieg 2002
van Roon 2013
65
1197
284
5
12
77
22
6
16
10
95
14
23
22
894
21539
6639
62
174
1130
344
102
402
147
1957
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206
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16
381
101
3
4
12
4
0
1
4
8
0
6
2
26390
723959
201905
1585
2634
26358
6985
1071
4549
3204
36293
1573
5053
4141
0.80 [0.70, 0.88]
0.76 [0.74, 0.78]
0.74 [0.69, 0.78]
0.63 [0.24, 0.91]
0.75 [0.48, 0.93]
0.87 [0.78, 0.93]
0.85 [0.65, 0.96]
1.00 [0.54, 1.00]
0.94 [0.71, 1.00]
0.71 [0.42, 0.92]
0.92 [0.85, 0.97]
1.00 [0.77, 1.00]
0.79 [0.60, 0.92]
0.92 [0.73, 0.99]
0.97 [0.97, 0.97]
0.97 [0.97, 0.97]
0.97 [0.97, 0.97]
0.96 [0.95, 0.97]
0.94 [0.93, 0.95]
0.96 [0.96, 0.96]
0.95 [0.95, 0.96]
0.91 [0.90, 0.93]
0.92 [0.91, 0.93]
0.96 [0.95, 0.96]
0.95 [0.95, 0.95]
0.92 [0.91, 0.94]
0.96 [0.96, 0.97]
0.92 [0.92, 0.93]
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Sensitivities for detection of CRC ranged from 57% to 67% for gFOBT, and from 
63% to 100% for FIT. Specificities ranged from 98% to 99% for gFOBT and from 
91% to 97% for FIT. The cut-off for positivity of FIT varied between 5 to 250 µg 
Hb/g faeces. The summary curve estimated by the HSROC model, for all Type II 
studies for CRC, can be found in Figure 2.10. FIT showed a higher discriminative 
ability for FIT than gFOBT (p<0.001)
In addition, sensitivities and specificities were calculated separately for those 
studies reporting on a FIT cut-off of 10 µg Hb/g faeces, and those with a cut-off 
of 20 µg Hb/g for CRC. Sensitivities for detection of CRC ranged from 75% to 
100% when using a cut-off of 10 µg Hb/g , and from 63% to 94% with a cut-off of 
20 µg Hb/g. Sensitivity for CRC was lower for gFOBT with a summary sensitivity 
of 63% (95% CI 58-67%), compared to 87% (95% CI 80-92%) for a cut-off of 
10 µg Hb/g, and 88% (95% CI 74-94%) for a cut-off of 20 µg Hb/g. Specificities 
for FIT ranged between studies from 92% to 96% when using a cut-off of 10 µg 
Figure 2.10 Summary curve type II studies. Summary curve using the HSROC model for gFOBT 
and FIT (Type II) for multiple cut-offs for colorectal cancer. Scale of individual study points is 
based on sample size.
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Hb/g, and from 92% to 97% for a cut-off of 20 µg Hb/g. Specificity for CRC was 
higher for gFOBT with a summary specificity for colorectal cancer of 98% (95% 
CI 98-99%) for gFOBT, compared to 92% (95% CI 92-95%) for FIT with a cut-off 
of 10 µg Hb/g, and 95% (95% CI 93-97%) at a cut-off of 20 µg Hb/g. 
Type II studies heterogeneity analyses
There was a significant difference in sensitivity or specificity, or both, for males 
versus females for gFOBT, for the outcome CRC (p<0.001). There was no 
significant difference in sensitivity or specificity, or both, between studies using a 
quantitative or a qualitative FIT at a cut-off of 10 µg Hb/g for the outcome CRC (p 
= 0.684). Heterogeneity related to the number of stools per screening round was 
not performed for gFOBT since all studies used three stools. For the following 
covariates analyses were not possible due to convergence difficulties; gender for 
FIT, number of stools for FIT.
Type II studies sensitivity analyses
For the analyses including all cut-offs, a sensitivity analysis was undertaken by 
excluding the studies  that yielded an high risk of bias following the QUADAS 
assessment (Giai 2014, Itoh 1996 Nakama 1996, Parra-Blanco 2010, Sieg 2002).72 
73 78 81 82 Even when excluding these studies, FIT remained significantly superior 
to gFOBT in the HSROC model. The effect of removing studies, in which the 
percentage of participants with a positive FOBT that underwent the reference 
standard was unknown, was herein evaluated (Nakama 1996, Giai 2014).72 78
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Summary of Findings 
Diagnostic accuracy of gFOBT compared to FIT
Patients/  
population
Asymptomatic, average-risk individuals over the age of 40 years undergoing 
colorectal cancer screening
Prior testing Only the results of the first screening round were included in this analysis
Settings Population- based colorectal cancer screening
Index test Guaiac faecal occult blood test or faecal immunochemical test
Importance Many screening programmes worldwide are currently changing from gFOBT 
to FIT-based screening
Reference  
standard
Colonoscopy is the gold standard for the diagnosis of colorectal cancer 
which was used as the reference standard. Only in case a colonoscopy was 
not complete a CT-colonography (or double contrast barium enema) was 
used as a surrogate. 
Studies Prospective and retrospective studies including average-risk individuals 
invited for colorectal cancer screening
Type I: all screenees underwent both the index test and colonoscopy (n=23).
Type II: only screenees with a positive index test underwent colonoscopy and 
all screen negatives were followed for at least one year (n=19).
Quality  
concerns 
Due to strict inclusion criteria most studies were of high quality. Few studies 
had unclear risk of bias due to poor reporting of a pre-specified cut-off value. 
Only three studies had a high risk of bias regarding the selection of study 
population. Regarding these studies, sensitivity analyses showed significant 
differences in outcome when excluding these studies from analyses. 
Test /subgroup*
studies  
(participants)
gFOBT/FIT
summary 
sensitivity
gFOBT 
(%, 95% CI)
summary 
specificity
gFOBT
(%, 95% CI)
summary 
sensitivity
FIT*
(%, 95% CI)
summary 
specificity
FIT*
(%, 95% CI)
Type I
advanced  
neoplasia
10 (15.741) / 
16 (55.881)
15 (12-19) 94 (91-96) 31 (25-39) 95 (92-97)
colorectal  
cancer
8 (15.465) / 
-15 (69.998)
41 (29-54) 94 (91-96) 82 (71-89) 93 (90-95)
Type II
colorectal  
cancer
9 (413.191) / 
14 (1.082.153)
63 (58-67) 98 (98-99) 87 (80-92) 92 (92-95) 
Conclusions The results of this systematic review concludes that FIT is the preferred 
tool for FOBT-based population CRC screening due to the higher 
sensitivity and comparable similar specificity as compared to gFOBT.
CAUTION: The results on this table should not be interpreted in isolation from the results of 
the individual included studies contributing to each summary test accuracy measure. These are 
reported in the main body of the text of the review. 
* results for FIT cut-off 10 µg Hb/g faeces are shown
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DISCUSSION
Summary of main results 
The main results are presented in the Summary of Findings. For this review 
we chose to include two types of studies and report the results separately as 
they differ in type of study and yield comparable but not similar results. We 
included twenty-three type I studies and nineteen type II studies. Four type I 
studies evaluated the diagnostic accuracy of gFOBT, thirteen studies evaluated 
FIT and four studies assessed both gFOBT and FIT tests. Twenty-one studies 
evaluated the diagnostic accuracy for advanced neoplasia and nineteen studies 
evaluated the diagnostic accuracy for colorectal cancer.  FIT showed a higher 
discriminative ability than gFOBT as assessed by the HSROC curve for both 
advanced neoplasia (p=0.002) and CRC (p=0.025). As type I studies allowed the 
use of multiple FIT cut-offs within one study population, the two most commonly 
used cut-offs worldwide (10 and 20 µg Hb/g faeces) were analysed separately 
and these results were in line with the overall analyses. Nineteen type II studies 
were included, with six studies evaluating the diagnostic accuracy of gFOBT, 
ten studies evaluating FIT, and three studies combining both. In type II studies 
FIT also showed a higher discriminative ability than gFOBT as assessed by the 
HSROC curve for CRC (p<0.001). 
The results of this systematic review demonstrate that FIT is the preferred 
tool for FOBT-based population screening due to the superior sensitivity and 
similar specificity compared as to gFOBT screening. Furthermore, beside some 
qualitative tests, many FITs are quantitative tests which allows use of different 
cut-offs to tailor for screening resources and colonoscopy capacity. Finally, 
various studies have consistently shown that FIT screening is associated with 
higher uptake than gFOBT screening which is an important finding to reach a high 
coverage of the target population (i.e. cumulative uptake). 
Strengths
The results of this review are based on strict and thorough searching without any 
language or date restrictions. The use of diagnostic test accuracy, or randomised 
controlled trial filters may lead to the loss of some studies, for this reason we 
have not used any filters.85 Two independent reviewers identified and extracted 
data from the studies, thus decreasing inaccuracies related to single-person 
data extraction.86 All included studies reported the results for average-risk, 
asymptomatic individuals after the age of 40 years, making our results reflective 
of a screening population. Also, data for different cut-offs were retrieved, in cases 
where this had not already been reported in the original publication, contacting 
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the author provided additional data for most studies allowing sub-analyses with 
the two most commonly used cut-offs. These cut-offs were converted to the 
internationally used measuring standard of µg Hb/g faeces.35 To avoid potential 
bias caused by the use of an inappropriate reference standard, e.g. barium-
enema or sigmoidoscopy, we restricted the studies to those with colonoscopy 
as the reference standard. As mentioned above, two types of studies were 
included for this review and analysed separately. The inclusion of type I studies 
allowed evaluating both advanced neoplasia and colorectal cancer as outcome 
of FOBT-based screening. Advanced neoplasia is of special importance because 
by removing adenomas development of colorectal cancer and CRC deaths might 
be prevented.29 87 In type II studies sensitivities and specificities were calculated 
with the use of interval carcinomas identified through adequate follow-up as a 
surrogate for the gold standard; colonoscopy. This different character of type 
I and type II studies may explain the observed differences in sensitivity and 
specificity. The use of interval carcinomas as endpoint in type II studies may 
underestimate the true proportion of false negatives, as by definition only those 
cancers were reported that had become clinically evident during the observation 
period. On the other hand, Type II studies are more reflective of a FOBT based 
screening programme in a general population. In these studies willingness to 
undergo FOBT as a primary screening tool was assessed whereas in type I 
studies participants had to be willing to undergo a full colonoscopy irrespective 
of the FOBT-result. For this reason type II studies are also often performed in 
larger populations. Combining both types of studies provides insight on both 
settings, and results in a broad evaluation of FOBT diagnostic test accuracy in 
colorectal cancer screening. Type I studies give insight in test sensitivity, whereas 
type II studies give insight in program sensitivity. The overall quality of included 
studies was high, supporting the validity of the results of our analyses. 
Weaknesses
This systematic review was designed to evaluate the diagnostic test accuracy 
of two types of FOBTs commonly used for colorectal cancer screening. Even 
though diagnostic test accuracy is of major importance in screening, usability of 
the test and participation, e.g. willingness to undergo the screening test, is also 
very relevant. One major limitation of this review is that these latter points have 
not been taken into account for this review as they do not involve diagnostic test 
accuracy. Yet, these factors are also of importance when estimating screening 
efficacy on population level (programme sensitivity and specificity). The ultimate 
purpose of screening programmes is a decrease in colorectal cancer-related 
mortality. However, diagnostic test accuracy can only be used as a surrogate 
in estimating mortality decrease after screening. In past years, results of large 
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prospective gFOBT-based screening trials have been published that unfortunately 
could not be included in this review as their main outcome was mortality. Mortality 
rates could not be converted into contingency tables to calculate sensitivity and 
specificity. We excluded non-interpretable test results and FOBT-positives who 
refused to undergo the reference standard from the 2x2 table and in consequence 
from the meta-analysis. Missing FOBT results are likely to be completely random 
(incidental missing data) and will not lead to biased estimates of test accuracy. 
Because only the participants who received the reference standard were included 
in the type I studies analysis (complete case analysis) and positive participants 
who did not receive the reference standard in the type II studies were excluded 
from analysis, estimates of the accuracy of the diagnostic tests could be biased.88 
The percentage of participants that did not undergo colonoscopy is reported in 
the characteristics of included studies table. Because of the large size of the 
studies, we believe that excluding these participants for whom the reference 
standard result is missing is mostly at random and will not bias the results but 
will only decrease precision. We attempted to conduct a comprehensive search 
for studies, but the fact that the studies awaiting classification have not yet been 
incorporated may be a source of potential bias.
Another limitation is the inability to explore the sources of heterogeneity 
concerning age, gender, ethnicity, adenoma type, tumour localization and stage 
distribution, because of limited information in the included studies. This problem 
was more prominent in type II studies, which often described large populations 
without prospective registration of study outcomes, but rather national databases 
of hospitals or cancer registries. The chosen random effect model accounts 
to a certain level for heterogeneity across studies by considering both within 
and between-study variation. This leads to a greater precision of the pooled 
estimates, but larger confidence.89 For only for a limited amount of studies was 
a direct comparison possible, as most studies did not perform both tests in the 
same patients. This could be a limitation, as results from non-comparative studies 
may differ from comparative studies.90 However, in this review results from the 
comparative studies are in line with the overall results. Many test brands are 
available, and sub analyses of these brands was not possible due to limited data 
and the use of different sub-types of the same brand. 
A previously published meta-analysis evaluated the test accuracy of FIT for 
colorectal cancer but not advanced neoplasia and did not compare these results 
to the performance of gFOBT.91 To the best of our knowledge there is only one 
other systematic review comparing the diagnostic test accuracy of gFOBT and 
FIT.75 The highest summary sensitivity of this study for FIT (OC-sensor) was 87% 
110
Chapter 2 gFOBT versus FIT for CRC screening – meta-analysis
and specificity was 93%, and for gFOBT (Hemoccult,) the summary sensitivity 
was 47% and summary specificity was 95%. They did not distinguish between 
type I, type II, and case-control studies, possibly leading to underestimation 
(type II studies) or overestimation (case-control) studies of test accuracy.30 Even 
though this large variation in type of studies included, their search strategy was 
very limited yielding only 761 hits and 22 inclusions. Finally, only three brands of 
FOBTs were included in their meta-analysis. In general this is the first review to 
adequately and systematically present an evaluation of gFOBT and FIT screening 
in an average-risk population. 
Applicability of findings to the review question
All participants included in this review were asymptomatic, average-risk individuals 
over the age of 40 years old, and invited for colorectal cancer screening, making 
the findings of this review extremely relevant for colorectal cancer screening 
programmes. Two types of studies were included. Type I studies are more 
homogenous than type II studies, yet may be less representative of a FOBT-
based screening population. This is due to the fact that all screenees had to be 
willing to undergo colonoscopy. For type II studies false negatives were identified 
through interval carcinomas that were identified during follow-up. This might give 
an underestimation of test sensitivity, yet is appropriately representative of FOBT 
population-based screening programmes. 
Implications for practice 
Faecal immunochemical testing has a superior sensitivity compared to guaiac 
faecal occult blood testing and is the preferred method of occult blood screening 
in terms of diagnostic test accuracy. Test usability and participation were not 
evaluated for the purpose of this review. The summary of findings table should be 
interpreted with acknowledgement of this. However, FIT’s quantitative nature allows 
the use of different cut-offs tailoring to screening resources and colonoscopy 
capacity24. Furthermore, it should be noted that several studies consistently 
reported higher rates of participation for FIT than for gFOBT screening.92 93 Both 
gFOBT and FIT have lower sensitivity for colorectal cancer than colonoscopy 
as gold standard. However, when combining test accuracy with participation 
FIT-based screening in many populations results in a higher diagnostic yield of 
advanced neoplasia compared to other CRC screening methods.10 28
Implications for research 
Future studies should be conducted in a prospective manner mimicking population-
based colorectal cancer screening and targeting average-risk populations. We 
encourage authors to systematically report data on participation, positivity rate 
and colonoscopy adherence. Also, future studies should report a clear definition 
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of advanced neoplasia and interval carcinomas. In the included studies definitions 
of interval carcinomas were often vague or completely missing. The ultimate 
purpose of colorectal cancer screening is decreasing mortality, so future studies 
should be conducted to compare long-term follow up on mortality between 
gFOBT- and FIT-based colorectal cancer screening programmes. 
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CHAPTER 1.1
General introduction
ABSTRACT 
Background & Aims
Several countries have implemented programs to screen for colorectal 
cancer (CRC) using the fecal immunochemical test (FIT). These 
programs vary considerably in age of the population screened and 
the cut-off concentration of fecal hemoglobin (Hb) used to identify 
candidates for further evaluation; these variations are usually based a 
country’s colonoscopy resources. We calculated how increasing the 
Hb cut-off concentration and screening age affects colonoscopy yield, 
missed lesions, and demand.
Methods
We collected data from 10,008 average-risk individuals in The 
Netherlands, 50–74 years old, who were invited for a FIT in the first round 
of a population-based CRC screening program from November 2006 
through December 2008. Fecal samples were collected and levels of 
Hb were measured using the OC-sensor Micro analyzer; concentrations 
≥10 µg Hb/g feces were considered positive. Subjects with a positive FIT 
were scheduled for colonoscopy within 4 weeks. Logistic regression 
analysis was performed to evaluate the association between age and 
detection of advanced neoplasia.
Results
In total, 5986 individuals (62%) participated in the study; 503 had a 
positive test result (8.4%). Attendance, positive test results, detection 
advanced neoplasia, and the FIT’s positive predictive value (PPV) 
all increased significantly with age (P<.001). Detection of advanced 
neoplasia ranged from 1.3% in the youngest age group to 6.2% in the 
oldest group; the PPV value of the FIT was 26% in the youngest group 
and 47% in the oldest group. Increasing the starting age of invitees from 
50–74 years to 55–74 years reduced the proportion of subjects who 
underwent colonoscopy evaluation by 14% and resulted in 9% more 
subjects with advanced neoplasia being missed. Increasing the cut-off 
concentration from 10 to 15 µg Hb/g feces reduced the proportion of 
subjects who underwent colonoscopy evaluation by 11% and resulted in 
6% of advanced neoplasia being missed. 
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Conclusion
In an analysis of an average-risk screening population in The Netherlands, we 
found that detection of advanced neoplasia by FIT increases significantly with 
age and fecal Hb cut-off concentration. Increasing the cut-off concentration 
or screening age reduces the numbers of patients who undergo colonoscopy 
evaluation in FIT-based CRC screening programs. Our findings provide 
insight in these effects per age category and cut-off concentration, and the 
consequences, in terms of missed lesions.
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INTRODUCTION
Colorectal cancer (CRC) is the second most common cause of cancer-related mortality in the Western world.1 Screening with guaiac-based fecal 
occult blood tests (gFOBT) can reduce CRC-related mortality.2 The gFOBT 
is now gradually replaced by fecal immunochemical test (FIT) for hemoglobin 
because of its superior adherence and accuracy.3 Quantitative FIT furthermore 
offers the opportunity of selecting a specific cut-off fecal Hb concentration 
used to identify candidates for further evaluation; that provides an optimal match 
between screening population and available financial and endoscopy resources. 
In recent years, several countries have implemented a FIT-based nationwide CRC 
screening program.4 Cut-off concentration and age of the population screened 
vary between countries, often tailored to available financial resources and 
colonoscopy capacity.5 6 For example, organized FIT screening is offered to 55-
75 year-olds in the Netherlands, using a positivity cut-off of 47 µg Hb/g feces, 
whereas in the United Kingdom 60-74 year-olds are invited for FIT screening 
and a cut-off concentration of 20 µg Hb/g feces is used. A high cut-off and 
narrow screening age range result in a low positivity rate and consequently 
low colonoscopy demand.7 However, this comes at the cost of a decrease in 
detection rate of advanced neoplasia (AN).7
Previous studies showed that the prevalence of AN, defined as colorectal 
cancer and advanced adenomas, increases with age in individuals undergoing 
a screening colonoscopy.8 9 Also, fecal Hb concentrations determined by FIT 
tend to increase with age, and higher positivity rates and detection rates are 
found in elder screenees compared to younger screenees.10-12 Therefore, age 
partitioned cut-offs for fecal Hb concentration may be warranted if AN detection 
rate increases relatively slower than positivity rate. 
The aim of this study was to assess positivity rates and detection rates of FIT in 
different age categories and to assess how this relates to the positive predictive 
value (PPV) in a population-based CRC screening program. Our secondary aim was 
to estimate the effect of increasing the cut-off concentration and screening age on 
the numbers of patients who undergo colonoscopy and AN detection and miss rate.
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METHODS
Study population
This study compromises the first round of a population-based organized CRC 
screening program (CORERO-I) by means of FIT, of which the methods and primary 
results have been described elsewhere.13-15 In short, 10,008 CRC screening-naïve 
individuals aged 50-74 years living in region Rotterdam-Rijnmond in the South-
West of the Netherlands were randomly selected and invited. We excluded 
individuals who met one of the exclusion criteria (a history of inflammatory bowel 
disease or CRC; colonoscopy, sigmoidoscopy, or barium contrast enema within 
the previous three years; inability to give informed consent) or who died or moved 
away. Recruitment took place between November 2006 and December 2008. 
For the purpose of this study, we assessed rates of attendance, test positivity, 
detection of AN, and PPV in the following five age categories; 50-54, 55-59, 60-64, 
65-69 and 70-74 years. In these age groups, we also calculated differences in the 
diagnostic yield of FIT, number needed to screen and number needed to scope 
to detect one case with AN. We further assessed if the PPV differed with age, 
when corrected for the confounders gender, socioeconomic status and fecal Hb 
concentration. We calculated the effect of offering CRC screening to later ages 
with steps of 5 years on the numbers of patients who undergo colonoscopy and 
number of detected and missed AN. We also assessed the effect of increasing 
cut-off concentrations on these parameters. Finally, the effect of these screening 
strategies was converted into a risk ratio with 95% CI, i.e. the percentage reduction 
of those who undergo colonoscopy was divided by the percentage of missed 
advanced neoplasia. This ratio explains the relative decrease in colonoscopy 
demand per percentage lesion missed advanced neoplasia. 
Intervention and follow-up evaluation
One FIT (OC-sensor, Eiken Chemical, Tokyo, Japan) was sent by mail to 
collect a single sample of one bowel movement. Participants returned the 
FIT and an informed consent form at ambient temperature by freepost to the 
Gastroenterology & Hepatology laboratory of the Erasmus Medical Centre, 
Rotterdam, the Netherlands. The test was analyzed on the OC-sensor Micro 
system (Eiken, Japan) and considered positive at a fecal Hb concentration of 
≥10 µg Hb/g feces (≥ 50 ng Hb/mL). 
Subjects with a positive FIT were scheduled for colonoscopy within four weeks 
and subjects with a negative FIT were referred back to the screening program. All 
colonoscopies were done by experienced gastroenterologists. Removed polyps 
were evaluated by expert gastrointestinal pathologists. Patients with a positive 
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colonoscopy entered a surveillance program, whereas subjects with a negative 
colonoscopy were considered not to require FIT screening for 10 years.16
Definitions 
Attendance rate was calculated by dividing the number of eligible participants 
by all eligible subjects (all invitees minus the excluded clients). Positivity rate 
was defined as the proportion of positive tests in participants with an analyzable 
test-result. Detection rate was defined as those with AN or CRC relative to all 
participants with an analyzable test. Advanced neoplasia included CRC and 
advanced adenomas. An advanced adenoma was defined as an adenoma ≥ 10 
mm, with ≥ 25% villous component and/or high-grade dysplasia. When multiple 
lesions were present in one person, the screenee was classified according to 
the most advanced lesion. The PPV compromised all screenees diagnosed with 
AN or CRC proportionally to screenees with a positive FIT who underwent a 
colonoscopy. The diagnostic yield of FIT per 10,000 eligible invitees was defined 
as screenees with AN relative to all eligible invitees. Number needed to scope 
was calculated as the number of colonoscopies needed to find one screenee with 
AN. Number needed to screen describes the number of complete FITs needed to 
find one case with AN. 
Statistical analyses
Comparisons of continuous variables were performed using the Mann–Whitney 
U-test. Categorical variables with two categories were compared using the χ2 
test and those with multiple categories with binary logistic regression analyses. 
Equality of fecal Hb concentration distributions between age categories was 
tested with the Kruskal-Wallis test. Attendance rate, positivity rate, detection rate 
and PPV were described as proportions with 95% confidence intervals (CI). 
To estimate significant differences in PPV for all ages, a multivariate binary 
regression analysis was performed, with age included as continuous variable. 
First, univariate binary logistic regression analyses were performed to determine 
the independent association of multiple variables (sex, age, social economic 
status, fecal Hb concentration) with the PPV of AN. In these analyses the PPV 
was used as outcome variable by selecting all participants with an analyzable 
FIT. In addition, detection of AN was selected as the dependent variable. 
Subsequently, all univariate significant variables and variables chosen by the 
clinician’s rationale (i.e. gender) were included in a multivariate logistic regression 
analysis. Interactions were tested between all variables that were included in the 
multivariate model. Interactions were included in the final model when significant 
(P<0.01). Hosmer and Lemeshow chi-square statistics were used as goodness 
of fit statistic. The outcome of the final multivariate logistic regression model 
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resulted in a predicted probability of having AN per screenee who had a positive 
FIT and subsequent colonoscopy. These predicted probabilities of having AN per 
screenee were depicted in a figure with age as a continuous variable. 
The analyses were performed using SPSS V.21 statistical package (SPSS Inc, 
Chicago, Illinois, USA). All p-values were two-sided and considered significant if 
P<0.05, except for interactions which were considered significant if P<0.01. 
Ethical approval
All participants signed informed consent. The study was approved by the Dutch 
Ministry of Health (2006/02WBO). The invitation letters and information brochures 
were approved by the Institutional Review Board of the Erasmus MC (MEC-2005-
264). All authors had access to the study data and reviewed and approved the 
final manuscript. 
RESULTS
Participant characteristics 
The trial profile is summarized in Figure 3.1. Of the 10,008 individuals invited, 
385 subjects were excluded from analyses, due to various reasons as described 
previously.13-15 In total, 5,986 (62%) attended screening, of which 5,982 had an 
analyzable screening test. A total of 503 (8.4%) screenees had a positive test 
at a cut-off concentration of ≥10 µg Hb/g feces of which 481 (96%) underwent 
colonoscopy. 
Test characteristics per age 
Test results per age category are given in Table 3.1. Screening participants had a 
median age of 61 years and 48% of the participants was male. Attendance rate 
and positivity rate increased significantly with age (P<.001). Detection rates of 
AN and CRC increased significantly with age as continuous variable (P<.001), 
and ranged from 1.3% for AN in the youngest age category of 50 to 54 years 
old, to 6.2% in the eldest age category of 70 to 74 years. The PPV for AN per age 
category ranged from 26% to 47%. The number needed to screen and number 
needed to scope to detect one case with AN ranged from 138 to 26 and 3.9 to 
2.1, respectively. The diagnostic yield of AN per 10,000 eligible invitees ranged 
from 73 in the 50 to 54 year-old to 392 in the 70 to 74 year-old. 
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Figure 3.1 Trial profile.
CRC: Colorectal cancer
Test characteristics per cut-off 
Fecal Hb concentration ranged from 0 to 921 µg Hb/g feces in participants with 
an analyzable screening test. Fecal Hb concentration increased significantly with 
age as a continuous variable (p<.001) and was significantly higher in men than in 
women (p<.001). Positivity rate decreased from 8,4% to 6,2%, 4,4% and 3,8% 
when the cut-off was increased from ≥10 µg Hb/g feces to sequentially ≥20 µg 
Hb/g feces, ≥30 µg Hb/g feces, and ≥40 µg Hb/g feces. 
Regression model
Univariate logistic regression analyses showed that an increase in age (P=.003) 
and increase in fecal Hb concentration (P<.001) were both associated with a 
higher PPV (Table 3.2). Age remained significantly related to PPV in the multivariate 
logistic regression analysis, with an odds ratio (OR) of 1.53 per 10 years (95% CI 
1.13-2.07), when corrected for fecal Hb concentration and gender. There were no 
significant interactions in this model and no significant differences in frequencies 
10,008 invited
9,623 eligible 
5,986 participated (62.2%)
385 
no fulfillment of 
inclusion criteria
503 positive test
481 successful colonoscopy
164 advanced adenoma 
29 CRC
3,637 
 no participation
4 
incomplete test
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Figure 3.2 The predicted probability of having advanced neoplasia displayed for screenees with 
a positive FIT per age and different fecal hemoglobin concentrations (corrected for gender). 
*microgram hemoglobin per gram feces, FIT: fecal immunochemical test.
between the observed values and the predicted values (Goodness-of-Fit; 
P=.276).  The predicted probability of having AN for participants with a positive 
FIT per age, corrected for gender and fecal Hb concentration, was depicted in 
Figure 3.2 for different fecal Hb concentration subgroups.
Table 3.2 Univariate and multivariate logistic regression analyses of factors associated with the 
detection of advanced neoplasia in a FIT based CRC screening program. 
Univariate Multivariate
Odds ratio (95% CI) p-value Odds ratio (95% CI) p-value
Sex male 1.24 (0.85-1.81) .27 1.12 (0.74-1.68) .60
Age (per ten years  
increase)
1.53 (1.15-2.03) .003 1.53 (1.13-2.07) .005
Socio-economic status 
(SES)
.43
   Low Reference
   Middle 0.90 (0.54-1.48)
   High 0.76 (0.51-1.15)
Fecal Hb concentration  
(per 10 µg Hb/g feces 
increase)
1.07 (1.05-1.09) <.001 1.07 (1.05-1.09) <.001
FIT: fecal immunochemical test; CRC: colorectal cancer. 
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Increasing the screening starting age and cut-off
Colonoscopy demand and detection rate of AN per age category and cut-off 
concentration are shown in Figure 3.3a and Figure 3.3b. Increasing the starting 
age from 50 to 55 years resulted in a total decrease in colonoscopy demand of 
14%, however at the expense of missing 9% of AN (Table 3.3). If solely the cut-
off was increased from 10 to 12,5 µg Hb/g feces, this resulted in a decreased 
colonoscopy demand of 11%, at the expense of missing 7% AN. Thus in both 
strategies, for every 1.6% decrease in subjectss who undergo colonoscopies, 
1% of screenees with AN were missed, resulting in a 1.6 ratio.
Figure 3.3  A. Colonoscopy demand and B. detection rate of advanced neoplasia (AN) per age 
category and cut-off concentration in µg Hb/gram feces. 
A
B
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Table 3.3 Effects of FIT-based CRC screening strategies on the numbers of patients who 
undergo colonoscopy and missed lesions in a screening population of 10,000 eligible invitees. 
  
Number 
strategy 
Screening 
strategies
Total 
Colonoscopies 
needed
per 10,000  
eligible invitees
Detected lesions
per 10,000 eligible 
invitees
Ratio of percentage
decrease in
colonoscopies 
needed
per percentage AN 
missed (95% CI)
Age range, 
cut-off **
N (%*) AN (%*) CRC (%*)
50-74, 10 
(reference)
500 201 30
1 55-74, 10 431 (-14) 183 (-9) 29 (-3) 1.6 (0.94 – 2.52)
2 60-74, 10 328 (-34) 141 (-30) 21 (-30) 1.2 (0.90 – 1.47)
3 65-74, 10 211 (-58) 98 (-51) 15 (-50) 1.1 (0.97 – 1.32)
4 70-74, 10 99 (-80) 48 (-76) 9 (-70) 1.1 (0.96 – 1.15)
5 50-74, 12.5 447 (-11) 188 (-7) 28 (-7) 1.6 (0.91 – 2.93)
6 50-74, 15 374 (-25) 175 (-13) 28 (-7) 1.9 (1.32 – 2.88)
7 50-74, 20 316 (-37) 160 (-20) 28 (-7) 1.9 (1.34 – 2.43)
8 50-74, 50 202 (-60) 119 (-41) 21 (-30) 1.5 (1.21 – 1.75)
9 50-74, 100 134 (-73) 93 (-54) 16 (-47) 1.4 (1.19 – 1.57)
10 50-54, 30;
55-59, 25;
60-64, 20;
65-69, 15;
70-74, 10
347 (-31) 166 (-18) 29 (-3) 1.8 (1.23 – 2.44)
11 50-54, 10;
55-59, 15;
60-64, 20;
65-69, 25;
70-74, 30
334 (-33) 160 (-21) 27 (-10) 1.6 (1.21 – 2.20)
*Percentage decrease
** (µg Hb/g feces)
Total colonoscopies needed and detected lesions are shown, compared to the reference 
screening strategy (first round, screen age 50-74 years, cutoff 10 µg Hb/g feces). Screening 
strategies are altered by 1. increasing the starting age and 2. increasing cut-offs and 3. 
Combinations of age and cut-off alterations
FIT: fecal immunochemical test; Hb: Hemoglobin; AN: Advanced Neoplasia; CRC: colorectal 
cancer; µg: microgram; g: gram; PPV: positive predictive value.
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Screening strategies with age-specific cut-off concentrations were also assessed 
on these outcomes (Table 3.3). The highest benefit of the reduction of numbers 
of patients who undergo colonoscopy relative to the loss in AN detection was 
achieved by strategy 6 and, while strategy one and five resulted in the lowest 
decrease of AN detection rate.  
DISCUSSION
In this study we showed that there were substantial differences in diagnostic 
yield of FIT between age groups. In this population-based CRC screening 
cohort, FIT positivity rates, detection rates and the PPV all significantly increased 
with age. Both increasing the screening starting age and increasing the cut-off 
concentration resulted in a substantial reduction in colonoscopy demand. 
Currently, cut-off concentrations and age of the population screened varies 
between countries with a FIT-based screening program.4 FIT-based screening with 
more tailored approaches based on sex, age or risk factors have been suggested 
in several studies.11 12 We calculated the effect of increasing the screening starting 
age and cut-off concentration on colonoscopy demand and number of detected 
and missed AN. We showed that both actions result in a substantial reduction 
in colonoscopy demand. However, also AN and CRC are missed subsequently. 
Increasing the screening starting age and increasing the cut-off concentration 
had different effects on the absolute numbers of screenees who undergo 
colonoscopy and missed lesions. An interesting finding was however that in 
relative ratios equal effects were found. For every missed AN in one screenee, 
both increasing the cut-off concentration and increasing the starting age, resulted 
in a similar decrease in screenees who undergo colonoscopy. 
In our cohort, the PPV for AN increased significantly with age, even when 
corrected for confounders. This is in line with a recent Spanish study.17 A likely 
explanation for the increasing PPV of FIT with age is that a greater proportion of 
AN occurs in elder persons.8 9 Lower detection rates compared to elder individuals 
are generally accepted as younger persons have more life-years to gain.18 
In addition to age, we showed that incremental increase of fecal Hb concentration 
detected by FIT is associated with an increase in PPV for AN, suggesting (pre)
malignant lesions bleed more compared to other lesions. This mechanism is also 
suggested in previous literature.17 Differences in detection rates between age 
groups, sex and fecal Hb concentrations determined by FIT have been described 
before in FIT-based CRC screening populations.19-21 In our cohort, sex was not 
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associated with the PPV for AN. This is most likely due to the small absolute 
numbers of screenees with AN in our study. Literature has shown that FIT detects 
AN more often in males than females.11 22
The relation between fecal hemoglobin concentrations and age on the predicted 
probability of having AN was linearly shaped for the lower concentrations and 
parabolically shaped for the higher concentrations. This parabolic shape is possibly 
a result of the low numbers of subjects with high fecal Hb concentrations for the 
youngest and oldest ages. In addition, a prozone effect might have occurred at 
very high fecal Hb concentrations (>200 µg Hb/g feces). A prozone effect can 
appear if the fecal Hb concentration exceeds the limit of antigen agglutination.23 
As a result, the actual sample concentration can be higher than the measured Hb 
values for values >200 µg Hb/g feces. It should be of note that it is hypothesized 
that FIT is relatively insensitive for the detection of serrated neoplasia.24 Serrated 
lesions are thought to bleed less often compared with adenomas.25-27 
An optimal cut-off concentration or screening age range could not be established 
in this study. Evidence has been published that in a Western population the 
optimal cut-off concentration is low (10 µg Hb/g feces) and screening age range 
is wide (45-80 years).18 However, such screening programs require the availability 
of unlimited colonoscopy resources. In our study we showed that alterations in 
cut-off concentrations and age of the population screened are both good options 
when facing colonoscopy capacity limitations, dependent on available resources.
The main limitation of our study is the size of the cohort. Since CRC was detected in 
only few persons, changes in the cut-off concentration or screening starting age had 
a substantial effect in percentage of missed CRC. Therefore, the effect of increasing 
the screening starting age and cut-off concentration on the missed CRCs should be 
carefully interpreted. However, our study size was acceptable to calculate effects of 
screening alterations on detected and missed AN. Information on age differences 
in missed lesions in population based FIT screening has been limited until now. This 
study provides insight into this matter. It should however be taken into account that 
in our cohort only those subjects with a cut-off ≥ 10 µg Hb/g feces were offered 
colonoscopy. Missed lesions below this cut-off could therefore not be evaluated.
In conclusion, increased age is associated with an increase in positivity rates, detec-
tion rates and PPV in a FIT-based CRC screening cohort. Our findings give insight 
in the effect of increasing the screening starting age and cut-off concentration on 
colonoscopy demand and missed lesions in absolute numbers. When facing colonos-
copy capacity problems, these effects can be taken into account. Further research to 
evaluate the impact of age-tailored cut-offs in multiple screening rounds is needed.
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CHAPTER 1.1
General introduction
ABSTRACT 
Background
Many countries implement fecal immunochemical test (FIT) based 
colorectal cancer (CRC) screening. Because of suboptimal sensitivity 
of a single FIT, successive rounds are required to achieve an optimal 
preventive effect. It is unknown whether 2-sample FIT (2-FIT) increases 
program sensitivity over multiple screening rounds. Therefore we 
compared CRC screening by repeated 2-FIT to one sample FIT (1-FIT) 
on participation, positive predictive value (PPV), diagnostic yield and 
interval CRC.
Methods
A random selection of 13,205 average-risk individuals in The Netherlands, 
aged 50–74 years, were between 2006 and 2015 invited for four rounds 
of biennial 1-FIT or 2-FIT screening. Per round, persons received one 
or two identical FITs to sample on one versus two consecutive bowel 
movements. Screenees with a hemoglobin (Hb) concentration of 
≥10 µg Hb/g feces in at least one test were referred for colonoscopy. 
Persons with a positive FIT in previous rounds were not re-invited for FIT 
screening.
Results
In total, 9,787 1-FIT and 3,131 2-FIT invitees were eligible at least 
once during the screening period. In the 1-FIT screening cohort, 75% 
participated at least once versus 73% in the 2-FIT cohort (p=0.01). Of 
persons attending at least once, the cumulative positivity rate was 19% 
for 1-FIT and 29% for 2-FIT screening (p<0.001). Cumulative PPV for 
advanced neoplasia was significantly lower for 2-FIT screening, 24% 
compared to 33% for 1-FIT screening (p<0.001). The cumulative yield 
for advanced neoplasia after 4 rounds was 4.4% for 1-FIT and 4.7% for 
2-FIT screening (p=0.46). The interval CRC rates for 1-FIT and 2-FIT 
screening were 0.08% and 0.06% respectively.
Conclusions
Repeated 1-FIT and 2-FIT screening result in the same yield of 
advanced neoplasia. The lower PPV for 2-FIT screening results in a 
higher colonoscopy demand. Therefore, the use of 1-FIT screening is 
recommended for FIT-based CRC screening programs.
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BACKGROUND
Colorectal cancer (CRC) ranks third among all cancers worldwide, affecting approximately 1.36 million patients each year.1 The high burden of disease and 
long preclinical stage make CRC suitable for population screening .2 3 Long-term 
randomized prospective trials using guaiac fecal occult blood testing (gFOBT) 
have proven to decrease CRC-related mortality.4 5 Currently many countries are 
implementing fecal immunochemical test (FIT) based CRC screening.6 These 
programs are routinely based on one sample from one bowel movement, whereas 
gFOBT uses 6 samples from three consecutive bowel movements. Advanced 
neoplasia can bleed intermittently and may thus be missed with single stool 
sampling. Screening by means of 2-sample FIT (2-FIT) can reduce the risk of 
missing advanced lesions, and increase test sensitivity.7
We and others demonstrated that, in a single screening round, 2-FIT screening 
at a low cut-off detects significantly more advanced neoplasia than 1-sample 
FIT (1-FIT).8-10 However, FIT screening requires successive rounds for an optimal 
effect. Results after repeated 1-FIT screening have been published.11-13 There are 
however currently no data on multiple rounds of 2- FIT screening, nor comparisons 
of both strategies.
Interval cancers, i.e. cancers occurring after a negative screening test and 
before the next screening test is due, are worldwide considered an important 
indicator of the quality and effectiveness of CRC screening.14 When evaluating 
multiple rounds of screening, assessment of interval cancer rates is of paramount 
importance. Although large number of screening studies were performed over the 
last two decades, few studies reported on interval CRC rates.15-17
We therefore conducted a population-based CRC screening trial to determine 
participation, positive predictive value (PPV) diagnostic yield and interval cancer 
rate of 2-FIT versus 1-FIT screening over four successive rounds. 
METHODS
Population and design
The screening cohort have been described elsewhere.8 11 18 In short, 13,205 
average-risk individuals were invited for CRC screening by means of either 1-FIT 
or 2-FIT screening. Demographic data of all individuals between 50 and 74 years 
living in the Rotterdam-Rijnmond region in the Netherlands were obtained from 
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municipal population registers. Random samples of the selected population 
were taken based on different postal codes by a computer-generated algorithm 
(Tenalea, Amsterdam, The Netherlands). Allocation to 1-FIT or 2-FIT screening 
occurred prior to invitation. As there was no CRC screening program at the time 
of the trial, the cohort was screening-naive when first approached. The screening 
cohort was invited by postal mail and invitations were coordinated by and sent 
from the Regional Organization for Population Screening in the South-West of the 
Netherlands. 
Per round, persons were excluded if they had a history of CRC or inflammatory 
bowel disease, had undergone colon imaging ≤ 3 years, had an estimated life 
expectancy <5 years, were unable to give informed consent, had been positive in 
previous rounds, had become older than 74 years, had moved out of the region, 
or when they had died.
1-FIT screening cohort
The 1-FIT screening cohort (n=10,008) was invited from 2006 to 2014 for 
four rounds of biennial 1-FIT screening. After the first round, this cohort was 
randomized over three groups to repeat screening at different intervals in the 
second round (i.e., one, two, and three years, respectively).17 No significant 
difference in participation, detection rate or positive predictive value (PPV) was 
found between groups.17 Therefore, a two year interval was applied to all groups 
in the third and fourth screening round. With each screening round, one FIT (OC-
sensor Micro, Eiken Chemical, Tokyo, Japan) was sent to collect a single sample 
of one bowel movement. At the fourth round, this cohort was randomized to 
receive either an OC-sensor or an FOB-Gold (Sentinel, Italy) at the same fecal 
Hb cut-off concentration (trial registration no. NTR5385).19 The OC-Sensor and 
FOB-Gold perform equally over the relevant concentration range.20
2-FIT screening cohort
The 2-FIT screening cohort (n=3,197) was invited from 2008 to 2015 for four 
rounds of biennial 2-FIT screening (trial registration no. NTR5740). Each round, 
participants received two identical FITs (OC-sensor Micro, Eiken Chemical, 
Tokyo, Japan) to sample from two consecutive bowel movements.
FIT analysis and follow-up
For both cohorts, the test result was considered positive if the hemoglobin 
concentration in the FIT sample was ≥ 10 µg Hb / g feces in at least one FIT. 
The Fecal Immunochemical TesTs for Hemoglobin Evaluation Reporting (FITTER) 
check list was used to adequately report handling of the FIT (Supplementary file 
4.1).21 Screenees with a positive FIT were referred to colonoscopy. Experienced 
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endoscopists performed all colonoscopies. The maximum reach of the 
endoscope, adequacy of bowel preparation, and the characteristics and location 
of any polyps were recorded. Location was considered right-sided when proximal 
to the splenic flexure. Colonoscopy results were classified according to the 
most advanced lesion found. All removed polyps were evaluated by experienced 
gastrointestinal pathologists. Advanced neoplasia included CRC and advanced 
adenomas. An advanced adenoma was defined as an adenoma >10mm, or 
>25% villous component and/or high-grade dysplasia. Patients with a positive 
colonoscopy entered a surveillance program, whereas persons with a negative 
colonoscopy were excluded from FIT screening for 10 years.22 
In the Netherlands all cancers are registered by the Dutch Comprehensive Cancer 
Centre (www.iknl.nl). For our study all recruited participants were linked with the 
Dutch Comprehensive Cancer Centre. 
Definitions
The participation rate was defined as the number of eligible participants relative 
to all eligible invitees (eligible defined as all invitees minus the excluded invitees). 
The positivity rate was defined as the proportion of positive tests in eligible 
participants with an analyzable test-result. Detection rate was defined as persons 
with advanced neoplasia or CRC relative to all participants. Diagnostic yield was 
defined as those with advanced neoplasia or CRC relative to all invitees. The PPV 
compromised all diagnosed with advanced neoplasia or CRC proportionally to 
positive screenees who underwent colonoscopy. The number needed to scope 
was calculated as the number of colonoscopies needed to find one screenee 
with advanced neoplasia. Number needed to screen describes the number of 
complete FITs needed to find one case with advanced neoplasia. 
Screen-detected CRC was defined as CRC diagnosed at colonoscopy 
performed after a positive FIT. Interval cancers were defined as CRC detected 
after a negative FIT and before the next invitation.14 A CRC after a positive FIT 
and subsequent colonoscopy but before the next colonoscopy is due, was 
considered a post-colonoscopy interval CRC (within a FIT screening program).14 
Statistical analysis
Differences in proportions were calculated using a Chi-squared test and 
expressed with corresponding 95% confidence intervals (CI). Differences in 
means were analyzed using Student’s T test. To test differences in participation 
between rounds, a generalized estimating equation was used to account for 
clustering at the level of the invitee. The cumulative screening results after four 
rounds of 1-FIT and 2-FIT screening were calculated. Cumulative participation 
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was calculated as the total number of persons participating at least once, relative 
to all persons who had been eligible at least once over four screening rounds. 
This approach most closely mimics a population-based screening program. 
Cumulative yield reflected the total number of persons with advanced neoplasia 
or CRC in all persons who had been eligible at least once. The program sensitivity, 
expressed as a percentage, was calculated by dividing the number of screenees 
with screen-detected CRC, by the total number of screenees diagnosed with 
both interval CRC and screen-detected CRC. For all tests, a two-sided-p-value 
of <0.05 was considered significant. SPSS package version 22.0 was used for 
the calculations.
The Dutch National Health Council and the Institutional Review Board of the 
Erasmus MC University Medical Centre approved the study. All participating 
screenees gave written informed consent.
RESULTS
Four rounds of 1-FIT and 2-FIT screening
Over four rounds, a total of 10,008 persons were invited for 1-FIT screening 
and 3,197 persons were invited for 2-FIT screening (Figure 4.1). The results per 
round are shown in Table 4.1, showing high and stable participation rates in both 
screening cohorts. In the first round, 8.4% of test results were positive in the 1-FIT 
cohort and 12.7% in the 2-FIT cohort (p<0.001). Positivity rates of both cohorts 
decreased over subsequent rounds (Table 4.1). The positivity rate of the 2-FIT 
cohort rose between the third and fourth round from 9.6% to 10.8%, although 
this was not significantly different (p=0.367). In all rounds, the PPV of FIT for 
advanced neoplasia was significantly lower for 2-FIT screening compared to 
1-FIT screening (Table 4.1). Differences in diagnostic yield among eligible invitees 
between 1-FIT and 2-FIT screening are shown in Figure 4.2. In the first round, 
the number needed to screen to detect one subject with advanced neoplasia 
was lower for the 2-FIT cohort; 40 versus 50 for the 1-FIT cohort. In subsequent 
rounds, this was reversed (Table 4.1).
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Figure 4.1  Flow chart
CRC: colorectal cancer, FIT; fecal immunochemical test
Total invited 2-FIT
n = 3,197
Invitees eligible at 
least once 
n=3,131
71% had at least 
one negative FIT
n=1,622
29% had a positive 
FIT
n=647
1.1%  of participants 
had a CRC
n=26
5.3% of participants 
had advanced 
adenoma
n=121
Random sample from population 
register
Random sample from population 
register
0.09% of 
participants had a 
FIT interval CRC
n=2
Total invited 1-FIT
n = 10,008
Invitees eligible at 
least once 
n=9,787
75 % participated 
at least once
n=7,310
81% had at least 
one negative FIT
n=5,903
19% had a positive 
FIT
n=1,407
5.2% of participants 
had advanced 
adenoma
n=379
0.7% of participants 
had a CRC
n=53
0.11% of 
participants had a 
FIT interval CRC
n=8
93% undewent 
colonoscopy
n=1308
94% undewent 
colonoscopy
n=607
73 % participated 
at least once
n=2,269
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Cumulative results after four rounds of 1-FIT and 2-FIT screening
Over four rounds, 9,878 screenees from the 1-FIT cohort and 3,131 screenees 
from the 2-FIT cohort were eligible at least once. In total, 75% of these eligible 
persons in the 1-FIT screening cohort participated at least once, versus 73% in 
the 2-FIT cohort (p=0.01). Among those attending at least once, the cumulative 
positivity rate of 1-FIT and 2-FIT screening was 19% (95%CI; 18 – 20) and 
29% (95%CI; 27 – 30) respectively (P<0.001). The cumulative detection rate of 
advanced neoplasia among participants was 6.0% (95%CI; 5.5 – 6.6) for 1-FIT 
and 6.6% (95%CI; 5.6 – 7.7) for 2-FIT screening (p=0.32). The cumulative PPV for 
advanced neoplasia was significantly lower for 2-FIT screening, 24% compared to 
33% for 1-FIT screening (p<0.001). The cumulative yield of CRC among invitees 
was 0.7% (95%CI; 0.6 – 1.0) for 1-FIT and 1.2% (95%CI; 0.8 – 1.7) for 2-FIT 
screening (p=0.06). 
Screen detected and interval carcinomas
In the 1-FIT screening cohort, a total of 89 (1.2%) CRCs were detected among 
participants within the study period. Of these, 53 were screen-detected at 
colonoscopy after a positive FIT. Among screenees that underwent colonoscopy 
because of a positive 1-FIT, seven post-colonoscopy interval CRCs were found 
(0.5%). Classification of other detected CRCs are shown in Table 4.2. Eight 
Figure 4.2  Diagnostic yield advanced neoplasia (upper lines) and CRC (lower lines) among 
eligible invitees
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persons (0.08% of screenees that were eligible at least once during the study 
period) were diagnosed with an interval carcinoma after a negative FIT. 
In the 2-FIT screening cohort, a total of 35 CRCs (1.5% of participants) were 
detected of which 26 were screen detected. Two FIT interval CRCs were found 
compromising 0.06% of screenees that were eligible at least once during the 
study period (p=1.00 compared to 1-FIT). Among screenees that underwent 
colonoscopy because of a positive 2-FIT, one post-colonoscopy interval CRC 
was found (0.3%).
Among screenees participating at least once, screen-detected CRC rate was 
0.7% for 1-FIT and 1.1% for 2-FIT screening (p=0.06). Screen-detected CRCs 
were more often left-sided in both cohorts, 74% of 1-FIT and 85% of 2-FIT 
(P=0.27). FIT interval CRC rate among screenees participating at least once 
was 0.11% for 1-FIT and 0.09% for 2-FIT screening (p=1.00). FIT interval CRCs 
were equally left and right sided in both cohorts (both 50%). Among screenees 
participating at least once in the 1-FIT cohort, program sensitivity for CRC was 
60% (95%CI 49 – 69). The program sensitivity for CRC in the 2-FIT participants 
was 74% (95%CI 58 – 86).
Table 4.2  Characteristics of CRCs detected among invitees eligible at least once
1-sample
N=9,787
2-sample
N=3,131
n (%) n (%)
Screen detected 53 (0.54) 26 (0.83)
FIT interval carcinoma 8 (0.08) 2 (0.06)
Positive FIT but refused colonoscopy 1 (0.01) 1 (0.03)
Post-colonoscopy interval carcinoma 7 (0.07) 1 (0.03)
Surveillance detected 3 (0.03) 2 (0.06)
Not eligible* 17 (0.17) 3 (0.09)
 Total 89 35
* Includes CRC detected before first invitation, and in screenees older than screening age 
range.
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DISCUSSION
Currently many countries are implementing FIT based CRC screening programs. 
To optimize FIT based CRC screening programs, to meet financial and 
colonoscopy resources, different strategies can be followed. The suboptimal 
sensitivity of FIT for detection of advanced neoplasia asks for repeated screening 
at 2-year interval. This is the first study to compare 1-FIT versus 2-FIT screening 
over multiple rounds. Participation in repeated rounds of FIT screening was high 
for both 1-FIT and 2-FIT screening. After four rounds, 1-FIT and 2-FIT screening 
result in the same yield of advanced neoplasia. The FIT interval cancer rates were 
0.08% for 1-FIT and 0.06% for 2-FIT screening. 
In our population based screening cohorts, stable and high participation rates 
over multiple rounds were found. Cumulative participation for 1-FIT and 2-FIT 
screening was 75% and 73% respectively (p=0.01). An American study, using 
1-FIT, reported a total participation of 63.8% over 4 rounds.13 
The FIT positivity and detection of advanced neoplasia were highest in the first 
round. This pattern is consistent with detecting more prevalent cases of advanced 
neoplasia in the initial round of screening-naïve persons and more incident cases 
in subsequent rounds. Similar trends have been reported in previous FIT and 
gFOBT screening trials.11 13 23 24 An increase in positivity rate in the fourth round 
Figure 4.3  Distribution of CRC by stage for 1-FIT and 2-FIT screening
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was also seen in other FIT screening trials.12 13 Possible explanations for this rise 
are increasing age, improvement in FIT buffer, and the fact that for this analyses 
a closed cohort (i.e., which was not replenished with screening naïve persons) 
was used. 
Effective population based FIT screening requires follow-up colonoscopy 
after a positive FIT result. In total, 93% to 94% of positive screenees received 
colonoscopy after a positive result. This is above the internationally accepted 
quality indicator of more than 90% adherence to colonoscopy after a positive 
FIT.25 While our results show high adherence rates, low colonoscopy follow-up 
rates have also been reported in literature.26 27 Low colonoscopy follow-up rates 
should be assessed to increase CRC screening effectiveness since positive 
screenees are at high risk of having advanced neoplasia.11 
Although numbers are small, the relative high percentage of stage one CRCs 
aligns with the expectation of ongoing detection of newly developing cancers 
during aging (Figure 4.3). Nevertheless, interval cancers after a negative FIT also 
occurred, yet to a lesser extent with 2-FIT versus 1- FIT screening, although not 
statistically significant.. Theoretically, 2-FIT screening may detect tumors that 
bleed intermittently more easily because fecal samples from bowel movements 
of different days are used. Interval cancers after a negative FIT remain an on-
going concern and also suggest different biology compared to screen detected 
CRC. The so-called serrated pathway has been proposed as an alternative to the 
adenoma-carcinoma sequence, and is thought to contribute to the risk of interval 
CRC, especially in the proximal colon.28 29 
In the first round, detection rates for advanced neoplasia and CRC, as well 
as number needed to screen and scope to detect one subject with advanced 
neoplasia, were higher for 2-FIT than 1-FIT screening. However, after four 
consecutive rounds of FIT screening, the diagnostic yield among invitees was 
similar for both cohorts, with 4.4% for 1-FIT, and 4.7% for 2-FIT (p=0.46). Switching 
from a first round with 2-FIT to a second round with 1-FIT screening has been 
investigated after the second round.18 The additional value of a second test in the 
second round seemed limited, since more colonoscopies were required to detect 
additional advanced neoplasia. Modelling studies are necessary to evaluate cost-
effectiveness of 1-FIT versus 2-FIT screening. This can aid in defining the optimal 
FIT screening strategy by simulating different cut-offs and screening intervals for 
both strategies.
Potential limitations of our study include the relatively small sample size of the 
2-FIT cohort. In addition, persons were not randomized between 1-FIT and 2-FIT 
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screening. The fact that both study populations were randomly drawn from 
the same municipal registries in the same region, within the same time period 
indicates that both populations can be compared head to head.
Worldwide, different screening modalities and strategies exist, often tailored to 
available financial resources and colonoscopy capacity.6 Countries offering a 
FIT-based screening program vary in screening interval, cut-off concentrations 
and eligibility criteria in terms of age to start and stop screening.6 However, 
the optimal number of FITs to be used per screening round has not yet been 
investigated. We showed that after four rounds, 1-FIT versus 2-FIT screening 
yielded no difference in detection of advanced neoplasia and CRC. In this regard, 
the overall diagnostic yield of advanced neoplasia over time is a strong indicator 
to determine the impact of a screening program, especially to compare different 
screening tests or strategies. Notably, 2-FIT screening requires a substantial 
higher colonoscopy capacity due to a lower PPV. Given the limited colonoscopy 
capacity in most countries, the use of 1-FIT screening is recommended. 
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SUPPLEMENTARY FILES 
Supplementary file 4.1 The FITTER check-list for the reporting of studies using 
Fecal Immunochemical Tests for hemoglobin (FIT) 21 
Specimen Collection and Handling
In the first 3 rounds subjects received the OC-sensor (Eiken, Japan), and in the 
last round only 1-FIT cohort subjects received either the OC-sensor or the FOB-
Gold (Sentinel, Italy). Mean mass of feces collected by applicator stick:
OC-sensor: 10 mg feces, collected in 2 mL buffer.
FOB-Gold: 10 mg feces, collected in 1.7 mL buffer.
Participants were asked to sample feces according to instructions and post the 
feces sample within 24 hours after collection or keeping in the refrigerator until 
mailing. Participants signed an informed consent and were asked to write the 
date of sample collection on the device label before returning by post. They 
returned the FIT(s) and at ambient temperature by freepost to the laboratory of 
the Erasmus Medical Centre.
Analysis
The tests were stored at -20° until analysis, for at most 14 days. The OC sensor 
FITs were analyzed on the OC-sensor µ systems (Eiken, Japan), the FOB-gold 
FITs  were analyzed on a Sentinel Sentifit 270 system (Sentinel, Italy). All FIT tests 
were allowed to warm to room temperature before analysis and analyzed once. 
The analytical working range for the OC sensor µ was 1-200 µg Hb/g feces, and 
1-170 µg Hb/g feces for the Sentifit 270. Samples with fecal Hb concentrations 
above the upper analytical working limits were not diluted or re-analyzed.
Quality Management
Analytic runs were accepted only if the calibration and controls were in the margins.
The analyses were performed by 4 trained laboratory analysts. After the test was 
analyzed, the laboratory personnel entered the test result into the database. 
Result Handling
Units used, with conversion to µg Hb/g feces if ng Hb/mL was not used:
OC-sensor: 50 ng/mL Hb χ 10 µg Hb/g feces.
FOB-Gold: 59 ng/mL Hb χ 10 µg Hb/g feces.  
The test result was considered positive if the Hb concentration in the FIT sample 
was ≥ 10 µ g Hb / g feces in at least one FIT. 
153
One-sample and two-sample FIT screening
4
CHAPTER 5
Fecal haemoglobin 
concentrations predict future 
advanced colorectal neoplasia in 
long-term population-based 
FIT-screening
E.J. Grobbee
E.H. Schreuders
B.E. Hansen
M.J. Bruno
I. Lansdorp-Vogelaar
M.C.W. Spaander
E.J. Kuipers
 
Submitted
CHAPTER 5
Fecal haemoglobin 
concentrations predict future 
advanced colorectal neoplasia in 
long-term population-based 
FIT-screening
E.J. Grobbee
E.H. Schreuders
B.E. Hansen
M.J. Bruno
I. Lansdorp-Vogelaar
M.C.W. Spaander
E.J. Kuipers
 
Submitted
156
Fecal haemoglobin concentrations as a predictor in FIT screeningChapter 5
CHAPTER 1.1
General introduction
ABSTRACT 
Background and aims
Colorectal cancer (CRC) screening using quantitative fecal 
immunochemical tests (FITs) is rapidly gaining ground worldwide. FITs 
are invariably used in a dichotomous manner using pre-specified cut-
offs. To optimize FIT-based screening programs, we explored if fecal 
hemoglobin concentrations (fHb) of participants with a FIT below the 
cut-off (FITbco) could be used to predict future colorectal advanced 
neoplasia (AN) risk.
Methods 
Average-risk subjects aged 50-74 years, were offered four rounds 
of population-based FIT screening (cut-off 10 µg Hb/g feces). All 
subjects with a FITbco at first participation (baseline) were included. 
Hazard ratios (HRs) for AN were determined using Cox proportional 
hazard regression analyses. Logistic regression techniques were used 
to calculate risks of AN after consecutive FITbco results.
Results 
Out of 13,566 invitees, 9,561 (70%) participated at least once and 
7,663 (92%) had FITbco at baseline. Median follow up was 4.7 years (IQR 
2.0-6.1). After eight years of follow-up, a higher cumulative incidence 
of AN was found in screenees with baseline fHb between 8 to 10 µg 
Hb/g compared to those with fHb of 0 µg Hb/g (5 vs. 33%; p<0.001). 
The multivariate HRs increased from 1.2 to 8.2 for fHb concentrations 
between >0 and 2 µg Hb/g and ≥8 to 10 µg Hb/g (p<0.001). A 14-fold 
increased risk was found after two consecutive FITsbco with twice fHb of 
8 µg Hb/g versus twice 0 µg Hb/g (p<0.001). 
Conclusion 
Among screenees with a FITbco , baseline and consecutive fHb are 
independent predictors for incident AN. These findings provide tools 
for personalized strategies in population-based CRC screening. This 
may decrease unnecessary screenee burden and could optimize use 
of resources. 
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INTRODUCTION
Colorectal cancer (CRC) is among the most common causes of cancer-related mortality.1 Population-based CRC screening can significantly reduce 
disease burden. Fecal occult blood tests are widely accepted for this purpose.2 
3 A higher fecal hemoglobin (fHb) concentration is associated with a higher 
risk of advanced neoplasia (AN).4-7 Many screening programs worldwide use 
fecal immunochemical tests (FIT), that can be either qualitative (i.e. providing a 
positive or negative test result) or quantitative (i.e. quantifying fHb concentrations 
in feces).2 8 Although quantitative FITs provide exact fHb concentrations in µg 
Hb/g feces, current screening programs routinely use fHb in a dichotomized 
fashion. As such, they are invariably used as qualitative tests. A test is considered 
positive above a fixed threshold that is the same for all screenees in all rounds of 
screening. Those with a positive test are recommended to undergo colonoscopy. 
Individuals with a negative test are offered a renewed FIT after a predefined 
screening interval without taking into account previous fHb concentrations. Most 
FIT screening programs rely on annual or biennial screening, requiring participants 
to repeat the test multiple times over the course of years. 
To increase screening efficiency and impact of FIT screening programs, it is 
relevant to explore if screenees with a negative FIT, that is a fHb concentration 
below the pre-defined cut-off level (FIT below cut-off; FITbco), can be categorized 
according to their actual fHb concentration into different risk groups for later 
development of AN. Such tailored screening would allow for targeted variation 
of screening intervals, and decrease screening and colonoscopy demand 
or optimize its use. Currently, many countries with CRC screening programs 
struggle to match colonoscopy demands with limited resources.9-11 Over 
the course of multiple screening rounds, fHb concentration could then be of 
guidance in identifying those at low and high risk of AN, and thus form the basis 
of individualized screening strategies. Such information is of key importance for 
national population-based CRC screening policies. Previous studies have mainly 
focused on fHb concentrations of FIT-positive screenees, or have only assessed 
first round fHb concentrations.
5 12 13 At present, no literature is available on trends 
in individual fHb concentrations of FITbco screenees over consecutive screening 
rounds. Furthermore, it is not known whether these previous fHb concentration(s) 
can be used as a predictor for the future detection of AN. Therefore, we aimed to 
investigate trends in fHb of FITbco results at first participation, and in subsequent 
rounds as a predictor for future incidence of AN. 
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METHODS
Study design and participants
Details about this study cohort and the design have been described before.14 In 
short, individuals living in the southwest of the Netherlands were approached 
for four rounds of FIT-screening. Demographic data of all individuals between 
50 and 74 years living in this region were obtained from municipal population 
registers. Random samples were taken based on different postal codes. Exclusion 
criteria included a history of inflammatory bowel disease or CRC, a full colonic 
examination in the past two years, an estimated life expectancy of <5 years, and 
inability to give informed consent. In case of a positive FIT result, subjects were 
sent for colonoscopy and not re-invited for subsequent FIT rounds. Subjects 
were not invited when they had become older than 74 years, or when they had 
moved out of the region. The cohort was supplemented with new screening-naïve 
subjects in round 3 and 4 to best mimic a continuous, population-based screening 
cohort. Recruitment took place between November 2006 and December 2014. 
For this analysis all subjects participating in at least one screening round and 
with a negative FIT result, defined as a FIT result below the cut-off of 10 µg Hb/ g 
feces (FITbco) at their first participation (i.e. baseline), were included. 
FIT screening and colonoscopy 
Each screening round, eligible invitees received one FIT per mail. Invitees were 
instructed to collect one sample of one bowel movement. In the first 3 rounds 
subjects received the OC-sensor (Eiken, Japan), and in the last round subjects 
were randomized to receive either the OC-sensor or the FOB-Gold (Sentinel, 
Italy). The OC-Sensor and FOB-Gold perform equally over the relevant 
concentration range.15 Participants were asked to sample feces according to 
instructions and post the sample together with the consent form within 24 hours 
while storing it in the refrigerator until mailing. The OC sensor FITs were analyzed 
on the OC-sensor µ system (Eiken, Japan), the FOB-gold FITs were analyzed on 
a Sentifit 270 system (Sentinel, Italy). All FIT tests were analyzed once at room 
temperature. The analytical working ranges for the OC sensor µ and Sentifit 
270 were respectively 1-200 feces and 1-170 µg Hb/g feces. Samples with 
fHb concentrations above the upper analytical working limits were not diluted 
or re-analyzed. The test result of ≥10 µg Hb/g feces was considered positive. 
Subjects with a positive FIT were scheduled for colonoscopy within 4 weeks. 
In case colonoscopy was incomplete, a computed tomographic colonography 
was performed. Experienced board-certified gastroenterologists performed 
all endoscopies. The maximum reach of the endoscope, adequacy of bowel 
preparation, and characteristics and location of any polyps were recorded. All 
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polyps were removed and evaluated by dedicated gastrointestinal pathologists. 
Patients with a positive colonoscopy entered a surveillance program according 
to guidelines of the Dutch Society of Gastroenterology, whereas subjects with a 
negative colonoscopy were considered not to require FIT screening for 10 years. 
AN was defined as an adenoma of ≥ 10 mm, an adenoma with at least 25% villous 
histology and/or high-grade dysplasia, or CRC. 
Follow-up and interval carcinomas
Except for individuals who had moved out of the Netherlands, all recruited 
participants were followed for the development of CRC. Colorectal cancers 
diagnosed outside of the screening program (including CRCs in participants who 
did not return to screening, FIT interval cancers, post-colonoscopy CRCs, and 
CRCs detected at surveillance colonoscopy) were identified through linkage with 
the Dutch Comprehensive Cancer Centre (www.iknl.nl), which was up to date 
until March 2015. 
Statistical analysis 
Descriptive data were reported as proportions or means with standard deviation 
(±SD). For non-normally distributed data, the median and interquartile range 
(IQR) were given. To investigate the role of a negative baseline FIT value, fHb 
concentrations were divided into six categories; 0, >0-2, ≥2-4, ≥4-6, ≥6-8 and ≥8-
10. Per category the cumulative incidence of AN over four rounds was calculated 
using life tables and curves. Patients were censored at the end of follow up if the 
event (i.e. AN) had not occurred. 
A Cox proportional hazard regression analysis was performed to calculate hazard 
ratios (HRs), including 95% confidence intervals, to identify factors associated 
with the development of AN. These factors included age, gender, socioeconomic 
status (SES), and baseline fHb. The date of the baseline FITbco was defined as 
time 0. Only fHb concentrations below 10 µg Hb/g feces were used in these 
analyses. Factors with a p-value of < 0.10 in univariate analysis, were included 
in a multivariate model. Interaction terms were also evaluated in the multivariate 
model. A two-sided P value of < 0.05 was considered to be statistically significant. 
Analyses were performed using SPSS 21.0 statistics software (IBM Corp., 
Armonk, New York, USA). 
The prediction of an event (i.e. AN or CRC) given the outcome of fHb concentration 
of a FITbco at any round (i.e. visit) was analyzed applying a logistic regression 
technique allowing for multiple repeated measurements per subject using SAS 
PROC GENMOD with the REPEATED statement with an independent variance 
assumption.16 Each visit was hereby associated with the event. The analysis 
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included adjustment for age at first round (or age at time of FIT screening), sex, 
and time of round in relation to event or last follow-up. Interactions between gender 
and age as well as non-linearity of age and fHb concentration were tested using 
both pre-specified groups and polynomial regression. Factors with a P value < 
0.10 in univariate analysis, were included in the multivariate model. A two-sided P 
value < 0.05 was considered to be statistically significant. In addition, all analyses 
were adjusted for multiple testing. Using the results of logistic regression analyses 
heat plots were generated to depict the risk of AN after two FITbco. Analyses were 
performed using SAS 9.4 (SAS Institute Inc., Cary, North Carolina, USA). All authors 
had access to the study data and reviewed and approved the final manuscript. 
RESULTS
Baseline characteristics
Over four rounds of biennial FIT screening, a total 13,566 subjects were invited of 
whom 278 (2.0%) did not meet the inclusion criteria. Out of the 13,288 remaining 
subjects 9,557 (71.9%) participated at least once (Figure 5.1). Out of these 
participants, 8,744 (91.4%) had a FITbco at first participation and were included 
for analysis. Median age was 58 years (IQR 52-64 years) at baseline, with 47·1% 
of the screenees being male. Overall, 3,172 (36.3%) FITbco subjects participated 
in all four rounds, 1,235 (14.3%) in three rounds, 2,254 (25.8%) in two rounds, 
and 2·059 (23.6%) in one round. Median time between screening rounds was 23 
months (IQR 22 - 24 months). 
Role of baseline fHb in predicting risk of advanced neoplasia and 
colorectal caner
The majority of subjects (62.7%) participated for the first time in round one, 
the remaining subjects participated in round two (6.6%), round three (18.3%), 
and round four (12.3%). Because follow-up ended after the fourth round, only 
baseline fHb of subjects participating in one of the first three rounds (n=7,663) 
were included for survival analyses. Median follow up was 4.7 years (IQR 2.0-
6.1 years). Over the following rounds, 821 (10.7%) participants with a baseline 
FITbco had a positive FIT, of whom 91.8% underwent colonoscopy (n=754). 
During follow-up 221 (3.0%) cases were diagnosed with AN; 175 with advanced 
adenomas, 24 with screen-detected CRC, and 22 with CRC detected during 
follow-up, of which 8 were FIT interval cancers (Figure 5.1). 
Cumulative incidences of AN per category of fHb are shown in Figure 5.2. After 
5 years of follow-up, screenees with a baseline fHb concentration between 8 and 
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10 µg Hb/g had an 8-fold higher cumulative incidence of AN than screenees with 
a baseline fHb concentration of 0 µg Hb/g (p < 0·001). After 8 years of follow-
up the cumulative incidence increased with 28% compared to screenees with a 
baseline fHb concentration of 0 µg Hb/g feces (p<0.001). 
Cox proportional hazard regression analysis showed baseline fHb concentration 
was associated with the hazard of developing AN in multivariate analysis (Table 
5.1). Compared to screenees with a baseline fHb concentration of 0 µg Hb/g 
feces, HRs increased from 1.2 (95% CI 0.9-1.7) for fHb concentrations between 
>0 and 2 µg Hb/g, to 8.2 (95% CI 4.5-15.0) for fHb concentrations of ≥8 to 10 µg 
Hb/g (p<0.001).
Figure 5.1 Flowchart of study design and outcomes. 
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Table 5.1 Cox-regression analysis of baseline fHb concentration for hazard of the detection of 
advanced neoplasia during follow-up.
Advanced neoplasia
Univariate Multivariate
HR 95% CI HR 95%CI
Gender (male) 1·7* 1.3-2·3 1·6* 1·2-2·1
Age (years) 1·1* 1·0-1·1 1·1* 1·0-1·1
Baseline fHb concentration
    0 µg Hb/g Ref.* Ref.*
  >0-2 µg Hb/g 1·3 0·9-1·8 1·2 0·9-1·7
  ≥2-4 µg Hb/g 2·9 1·8-4·6 2·8 1·7-4·4
  ≥4-6 µg Hb/g 6·5 4·2-10·2 5·7 3·7-8·9
  ≥6-8 µg Hb/g 4·5 2·1-9·3 4·2 2·1-8·7
  ≥8-10 µg Hb/g 8·9 4·9-16·4 8·2 4·5-15·0
Socioeconomic status
   High Ref.
   Average 1·0 0·7-1·3
   Low 0·6 0·4-1·0
* p<0·001
fHb; fecal hemoglobin concentration, HR; hazard ratio, CI; confidence interval, conc; 
concentration, ref; reference category.
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Figure 5.2 Life table and curve for advanced neoplasia by fHb level per 2µg Hb/g. 
This figure shows that the effect on cumulative incidence of AN of baseline FIT is most prominent 
for fHb between 4 and 10 µg Hb/g.
1 2 3 4 5 6 7 8 Time (years)
f Hb  
(µg Hb/g)
0 4,927 4,185 3,639 2,852 2,410 2,090 1,485 726 Subjects at risk
>0-2 1,874 1,672 1,587 1,427 1,291 1,177 470 94 Subjects at risk
≥2-4 436 376 333 286 247 220 101 34 Subjects at risk
≥4-6 214 171 151 125 105 94 54 16 Subjects at risk
≥6-8 106 87 78 65 56 47 18 4 Subjects at risk
≥8-10 78 70 58 44 35 29 18 7 Subjects at risk
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Role of fHb concentrations of consecutive FITs in predicting risk of advanced 
neoplasia
To further explore the use of fHb of consecutive FITs, fHb concentrations of all 
screenees that had at least two consecutive FITsbco were analyzed. In multivariate 
logistic regression, including time between FITs and total follow-up time, several 
FITbco combinations were evaluated to determine relative risk of developing AN, 
these are shown in Table 5.2. ORs remained similar regardless of the sequence 
of fHb results.
Based on the logistic regression model risks were predicted for all possible 
combinations of fHb concentrations per 0.5 µg Hb/g feces. Using these risks, heat 
plots were generated for males and females starting screening from the age of 55 
years (Figure 5.3). These heat plots visualize the risk of AN after two consecutive 
FITbco at any round according to the combination of fHb concentrations. These 
heat plots highlight the increased risk of screenees with fHb concentrations up 
to 10 µg Hb/g and illustrate two-fold increased risk of AN for men compared to 
women.
Table 5.2 Multivariate logistic regression analysis evaluating various hypothetical combinations 
of fHb concentration of two previously negative FITs and odds ratio (OR) of developing 
advanced neoplasia during follow-up.
Advanced neoplasia
Multivariate
OR 95% CI p-value
Gender (female) 2·1 1·3-3·2 0·001
Age (years) 1·0 1·0-1·1 0·04
Combination of first and second fHb concen-
tration
    0 µg Hb/g and 0 µg Hb/g Ref. <0·001
    1 µg Hb/g and 1 µg Hb/g 1·7 1·5-1·9
    1 µg Hb/g and 5 µg Hb/g 4·4 3·1-6·3
    5 µg Hb/g and 1 µg Hb/g 4·5 3·1-6·6
    5 µg Hb/g and 5 µg Hb/g 7·8 4·6-13·3
    1 µg Hb/g and 8 µg Hb/g 9·0 5·2-15·6
    8 µg Hb/g and 8 µg Hb/g 14·3 4·8-42·3
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Figure 5.3 Heat plot of risk of advanced neoplasia (AN) during further follow up in screenees with 
two consecutive negative FITs for men (A) and women (B) starting screening at age 55 years.  
This plot illustrates the increased risk of AN according to fHb concentration. Notable is the 
two-fold increase for men compared to women. 
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DISCUSSION 
This study shows that, in a repeated-round FIT-based CRC screening program, 
fecal hemoglobin concentration below the cut-off is an independent predictor 
of incident AN. We demonstrated over 8 years of follow-up that screenees 
with a fHb concentration >0 µg Hb/g to 10 µg Hb/g have a significantly higher 
cumulative incidence of AN compared to those with a fHb concentration of 0 µg 
Hb/g. The risk of AN was 8-fold higher for screenees with a fHb concentration of 
more than 8 µg Hb/g compared to screenees with a fHb concentration of 0 µg 
Hb/g. We further show that this predictive capacity becomes even stronger with 
consecutive FITbco results obtained over repeated rounds. 
One other research group has studied the role of FIT concentrations below the 
cut-off.12 This Taiwanese study used a cut-off of 20 µg Hb/g feces (OC-Sensor 
100 ng Hb/ml buffer), and showed that HRs for AN during follow-up increased 
with fHb concentration up to 3.4 for subjects with an fHb level of 16-20 µg Hb/g 
feces. This HR is substantially lower than the HRs found in our study. This can 
be explained by the fact that the investigators used fHb concentrations between 
1-4 µg Hb/g feces as a reference and screenees with a fHb concentration of 0 
were not included in multivariate survival analysis. The results of this study were 
however hampered by the high rate of positive FIT screenees who did not undergo 
colonoscopy (42%) yet were included in the analyses. While there is no other 
literature on the use of quantitative FITbco results, a few studies did look at prior 
FITbco results of qualitative tests. An Australian study investigated the use of FIT 
in a colonoscopy surveillance program and found that subjects with a FITbco had 
the lowest risk of AN.17 A Chinese study compared the number of FITbco and found 
no differences in outcome between subjects with one FITbco versus subjects with 
three subsequent FITbco.
18 However, as the fHb concentrations were not reported, 
results could not be stratified according to fHb concentration, and comparison of 
these results to our findings is not possible. 
To the best of our knowledge, we are the first to explore the use of fHb 
concentrations of FITbco over consecutive rounds as a predictive variable for AN in 
population-based CRC screening. Exploring fHb concentrations over the course 
of years makes sense, as it has been hypothesized that during the development 
from adenoma to carcinoma, in the adenoma-carcinoma sequence, adenomas 
will increasingly bleed. This natural history of adenomas is supported by our 
findings. Our results are further strengthened by the finding that in screenees who 
participated in all four rounds fHb increased among those that were diagnosed 
with AN in the fourth round (Supplementary file 5.1). A similar trend was also 
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described by the Taiwanese study, demonstrating that median fHb increases over 
rounds among screenees that are diagnosed with AN in a later round.12 
Strengths of this study include the analysis over multiple rounds, stratifying for 
FITbco levels unto nil µg Hb/g feces. Also, only average risk individuals were 
included, and the program consisted of true population-based screening, with 
a consistent screening protocol. This makes these results applicable to all fecal 
occult blood screening programs worldwide.19 Our study also has its limitations, 
such as the limited number of subjects diagnosed with CRC after having 
participated in three or four rounds. One further issue of this study is that it is 
susceptible to verification bias, due to the fact that only FIT positive screenees 
are referred for colonoscopy. As such, the yield of AN could be equally high in 
screenees with low FIT-values, but these simply do not receive verification by 
colonoscopy. To partially assess the possibility of verification bias, we performed 
two additional analysis in which we compared yield of AN only in screenees with 
a positive FIT during follow-up or screenees with consistent FITbco (i.e. interval 
cancer rate; Supplementary File 5.2). Although numbers are small, both analyses 
consistently showed that the yield of AN was higher in those with higher levels of 
fHb, similar as our base case analysis. Next, data from our primary colonoscopy 
screening trail in the same region and time period also showed that FITbco predicts 
AN in a single round of FIT (Supplementary file 5.3).20These findings suggest that 
the impact of verification bias is small and corroborate our finding that FITbco is 
predictive for future AN. Despite the verification bias, the lack of colonoscopy 
in FIT negative screenees, is also a strength of our study. If all screenees 
would undergo colonoscopy, the opportunity to follow FITbco screenees for the 
development of AN would be lost.  
As more screening programs are being implemented worldwide and FIT is gaining 
popularity, the use of quantitative FIT should be further explored. Expressing 
FIT-results not solely as a positive or negative result, but incorporating fHb 
concentrations in risk prediction models to estimate risk of AN can improve 
screening efficiency. Our results justify evaluation of screening strategies in which 
fHb concentrations are used to establish screening intervals. In current practice, a 
screenee with a FITbco is re-invited in the next screening round to perform a ‘new’ 
FIT. This FIT result is used as a referral criterion for colonoscopy regardless of the 
fHb concentration measured in the previous round. By neglecting the previous FIT 
result, an opportunity is lost to use the quantitative information of two FITs for risk 
stratification. We demonstrate, as depicted by the heat plots, that previous FITs 
enable identification of those at low risk (e.g. screenees who twice had a result of 
0 µg Hb/g) and those at considerable risk. Such heat plots can be of use to visualize 
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risks of AN for screenees and health care professionals. Identifying those at high 
risk of AN would possibly decrease interval carcinoma rate. Next, combining fHb 
with known risk factors could facilitate establishing individual screening intervals. 
Such individualized screening intervals may increase adherence to screening, as 
the majority of participants (i.e. those with consecutive fHb concentrations of 0 
µg Hb/g feces and a low risk of AN) will then have to be screened less frequently. 
This in turn could increase screening efficiency. As a consequence, screening 
and subsequently colonoscopy demand would decrease. The latter is especially 
important, as many countries are struggling with limited colonoscopy capacity.8 21
The results of this prospective FIT-based CRC screening cohort show that fHb 
concentration of a FITbco in a first round of screening is an independent predictor 
for the risk of incident AN. Furthermore, consecutive FITbco could be used in 
determining personalized screening strategies. These findings pave the way for 
the use of fHb concentration in both public health programs as well as clinical 
decision-making. These results aid in informing patients about the risk of AN after 
multiple FITbco, and to alter screening intervals accordingly. 
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SUPPLEMENTARY FILES
Supplementary file 5.1 Median fecal Hb of subjects with FITbco of > 0µg Hb/g 
that participated in all 4 rounds. 
Results are presented by occurrence of advanced neoplasia (AN) detected in the 4th round. 
This figure shows an increase in median fHb concentration over consecutive rounds in subjects 
who had AN detected in the fourth round, indicating that those screenees that bleed for other 
reasons than AN, show less of an increase in fHb over rounds. 
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Supplementary file 5.2 Life table of FITbco per 5 µg Hb/g in those who had a 
positive FIT during follow-up (p<0.001; A) and those who never had a positive FIT 
in one of the four rounds (p=0.034;B). 
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Supplementary file 5.3 Predicted probability of advanced neoplasia (AN) of all 
subjects with fHb <10 µg Hb/g from previously published data.20
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CHAPTER 1.1
General introduction
ABSTRACT
Background & Aims
The efficacy of colorectal cancer (CRC) screening is dependent on 
participation and subsequent adherence to surveillance. The internet 
is increasingly used for health information and important to support 
decision-making. We evaluated the accuracy, quality, and readability of 
online information on CRC screening and surveillance.
Methods
A Website Accuracy Score and Polyp Score were developed, which 
award points for various aspects of CRC screening and surveillance. 
Websites were also evaluated using validated internet quality instruments 
(Global Quality Score, LIDA and DISCERN), and reading scores. 
Two raters independently assessed the top-30 websites appearing in 
Google.comTM. Portals, duplicates and news articles were excluded. 
Results
Twenty websites were included. The mean Website Accuracy Score 
was 26 out of 44 (range 9-41). Websites with the highest scores were 
www.cancer.org, www.bowelcanceraustralia.org and www.uptodate.
com. Median Polyp Score was three out of ten. The median Global 
Quality Score was three out of five (range 2-5). The median LIDA overall 
score was 74% and median DISCERN score was 45, both indicating 
moderate quality. The mean Flesch-Kincaid Grade Level was 11th 
grade rating the websites as difficult to read, 30% had a reading level 
acceptable for the general public (Flesch Reading Ease>60). There was 
no correlation between the Google rank and Website Accuracy Score 
(rs=-0.31; p=0.18). 
Conclusions
There is marked variation in quality and readability of websites on 
CRC screening. Most websites do not address polyp surveillance. The 
poor correlation between quality and Google ranking suggests that 
screenees will miss out on high-quality websites using standard search 
strategies. 
179
Quality of websites on CRC screening
6
INTRODUCTION
Screening is effective in reducing the burden of colorectal cancer (CRC) and many countries have implemented CRC screening programs.1 2 The success 
of CRC prevention is highly dependent on participation in the screening program. 
Initial participation and subsequent adherence to surveillance can be influenced 
by enhanced knowledge about CRC screening and colonoscopy outcome.3 4 
As more screening programs are implemented worldwide, providing adequate 
patient oriented information is increasingly important. Most organized screening 
programs approach individuals for screening on a voluntary basis without 
personal contact with a health professional.2 5 Accordingly these individuals may 
search for additional information on screening themselves. 
The internet is widely regarded as an important channel of health information.6 7 In 
Western countries, more than half of the population uses a smartphone allowing 
instant and rapid access to the worldwide web.8 However, few regulations control 
the information that individuals or organizations list on their web sites. A systematic 
review reported that 70% of studies identified quality issues with health- and 
disease-focused internet websites.9 Since the efficacy of a CRC screening 
program is dependent on informed participation, assessing the availability 
and quality of online information aimed at screenees is of crucial importance. 
Therefore, the aim of this study was to rate quality, accuracy and readability of 
web-based information on CRC screening from a screenee perspective. 
METHODS
Internet Search Strategy
Websites were identified by searching the World Wide Web with Google.comTM, 
the most frequently used Internet search engine.10 The search was performed 
with English settings, with location tracking and search activity history switched 
off so search results were not influenced by location or past searches. 
Searches were carried out in 2014, 2015 and 2016. The following search terms 
were used: “colorectal cancer screening” OR “bowel cancer screening” OR 
“colon cancer screening” (quotations included). The search terms used reflect 
the most searched terms listed in the statistics provided via Google Trends 
(Supplementary file 3.1). 
It is known that internet searchers do not typically view more than a few search 
hits and usually choose one of the first results displayed by the search engine.11 We 
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therefore decided to examine the first 30 hits, corresponding with the first three 
pages of Google searches.
Inclusion and exclusion criteria
English websites were included only if the main part of the site dealt with 
educational information about CRC-screening. Websites that merely contained 
portal links to other sites were excluded, as were duplicate websites, news 
articles and sites containing irrelevant information (e.g. advertising, retail sites, 
or patient fora).
Accuracy assessment
The variability and accuracy of the information provided by each website on key 
facts about CRC screening and surveillance was investigated. For this purpose 
a Website Accuracy Score specific for CRC screening was developed (Table 
6.1). In addition a separate Polyp Score for colorectal polyps was developed to 
assess information on important aspects of polyps, colonoscopy outcome and 
surveillance guidelines (Table 6.2). The Website Accuracy Score and Polyp Score 
consist of a list of key items deemed relevant for CRC screening and surveillance. 
They were generated through evaluation of the literature and discussions with key 
stakeholders. The Website Accuracy Score and Polyp Score went through five 
iterations and were pretested twice prior to its final use using a random selection 
of websites. The range of scores was 0 to 44 for the Website Accuracy Score 
and 0 to 10 for the Polyp Score. If a website did not discuss or name an item of 
the Website Accuracy Score or Polyp Score, zero points were awarded for that 
item. Items had to be clearly presented on the website; the search function of the 
website was not used to locate this information. 
Quality assessment 
In addition to Website Accuracy Score and the Polyp Score, a selection of validated 
scores was used to assess the website quality and reliability. The overall quality 
of each website was rated using the Global Quality Score. This is a previously 
validated five-point Likert scale to rate the overall quality of a website (Table 
6.3).12 13 It incorporates the accessibility of the information within the website, 
the quality of this information, the overall flow of information, and how useful the 
website reviewer thinks the particular website would be to a screenee. The Global 
Quality Score was assigned by the reviewer after evaluating the entire website. 
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The LIDA instrument is a validated question based instrument, assessing the 
overall score (0-96), accessibility (0-54), usability (0-12) and reliability (0-30) of 
healthcare websites. The scores are reported as percentages of the maximum 
score, overall scores >90% represent good results and <50% represent poor 
results. The online LIDA instrument was used for this study.14
The DISCERN tool is a validated 16-item questionnaire to rate the quality of 
written information on treatment choices for a health problem.15 16 The first 8 
questions address reliability, dependability and trustworthiness of a website, 
the next 7 questions focus on quality of information on treatment choices and 
the last question addresses the overall quality of the site. Each question is rated 
on a 5-point scale with a maximum score of 80. Questions were answered as if 
participation to CRC screening was the treatment choice. The total quality of 
each website was classified as high (≥65 points), moderate (33–64 points), or 
low (16–32 points). 
The amount of advertisements on each website was scored as none, little, 
average, or many and agreed through discussion by the two reviewers.
Readability assessment 
Readability, referring to the reading difficulty based on word and sentence length, 
was assessed by the use of two readability scores. The Flesch Reading Ease 
Score (FRE) assigns a value between 0 and 100 whereby a higher value represents 
a greater ease of reading. A section with a score of 90–100 is considered to be 
very easily understood, >60 is an acceptable level of difficulty for the general 
Table 6.3. Global Quality Score criteria used to score websites on CRC screening
Score Global Quality Score Description
 1 Poor quality, poor flow of the site, most information missing, not at all useful for 
patients.
 2 Generally poor quality and poor flow, some information listed but many important 
topics missing, of very limited use to patients.
 3 Moderate quality, suboptimal flow, some important information is adequately 
discussed but other information poorly discussed, somewhat useful for patients.
 4 Good quality and generally good flow, most of the relevant information is listed, 
but some topics not covered, useful for patients.
 5 Excellent quality and excellent flow, very useful for patients.
CRC; Colorectal cancer
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public and below 30 is considered very difficult to read.17 The Flesch-Kincaid 
Grade Level (FKG) uses the same input variables as the FRE score and outputs a 
US school grade indicating the average school grade able to read the text .17 The 
American Medical Association Foundation states that health-related materials 
for patients should be written at a level appropriate for those in the 6th grade 
or below.18 The FRE score and FKG score were calculated using the Microsoft 
Word 2007 program. A random 100 word sample of text was extracted from each 
website and pasted into the program by both reviewers independently.
Statistical analyses
The website assessment was performed by two independent raters (EHS, EJG). 
For Website Accuracy Score assessment, any difference in score between 
reviewers was resolved through discussion and by re-review of the website by 
both reviewers together to generate a single score for each website. Consensus 
in case of disagreement was achieved through discussion with a third reviewer 
(SvZ). For other quality parameters, the mean score of both website raters was 
used. Correlations between different quality parameters were analyzed using 
the Spearman rank-correlation coefficient because of non-normality of the data. 
Statistical tests were performed with the use of IBM SPSS software, version 21.0 
and Graphpad Prism 5. A two-sided p-value <0.05 was considered significant. 
All authors had access to the study data and reviewed and approved the final 
manuscript. 
RESULTS
The search
The Google search was carried out on April 9th, 2014 and resulted in over 2,000,000 
hits. The first 30 results were evaluated of which 20 websites were included. Two 
portal websites leading to another site, one duplicate site, one website with 
information on insurance reimbursement, three news articles, and three guidelines 
and medical articles clearly aimed at health professionals were excluded. All 
websites were accessed between April 2014 and June 2014. Additional Google 
searches were carried out on August 7th, 2015 and February 22nd, 2016 to evaluate 
possible changes in Google rank position. Most websites were published by a 
professional medical society (35%) or a governmental organization (30%) (Figure 
6.2). Almost half of the websites were from the United States (45%), others from 
the United Kingdom (25%), Canada (20%) and Australia (10%).
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Table 6.1. Colorectal cancer screening specific Website Accuracy Score components and 
percentage of websites that were awarded points for these items.
Website information components (maximum 44 points) Websites 
N (%)
CRC general information
Description of the colon/bowel/large intestine 15 (75)
Image of the anatomy of the intestines 15 (75)
Explanation of polyp as precursor of colorectal cancer 17 (85)
Development of a polyp into malignancy is a slow process (takes years) 8 (40)
Colorectal cancer can be prevented by removing precancerous polyps/ade-
nomas
15 (75)
Causes of CRC
Risk factors 
 Unknown 3 (15)
 Age (> 50) 13 (65)
 Gender (male) 0 (0)
 History of previous polyps 15 (75)
 Family history of colorectal cancer 17 (85)
 Hereditary / Familial adenomatous polyposis / Lynch  syndrome 14 (70)
Life style (2)
Unhealthy lifestyle (general)
Unhealthy diet (low fiber, high fat, red meat)
Smoking 
Alcohol
Obesity 
Mentions 1-2 life style factors: 1 point
Mentions 3 or more life style factors: 2 points
1 (5)
13 (65)
Symptoms of colonic polyps / CRC
Most polyps are asymptomatic 11 (55)
Mentions symptom(s) such as:
blood in stool/ rectal bleeding
change in bowel habit
unexplained weight loss
tenesmus (false urge)
13 (65)
Recommendation to contact medical doctor in case of symptoms 11 (55)
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Website information components (maximum 44 points) Websites 
N (%)
Screening for CRC
Mentions that there are different methods of screening 16 (80)
The detection and removal of polyps is main purpose of the screening pro-
gram for colorectal cancer
15 (75)
Mentions that not all tests have same accuracy 7 (35)
Mentions that not all tests have same patient burden 7 (35)
Colonoscopy is gold standard / most accurate for diagnosing polyps 7 (35)
Colonoscopy 20 (100)
 + explanation of procedure 17 (85)
 + explanation risks (bleeding and perforation are mentioned) 14 (70)
 + explanation polypectomy 13 (65)
 + explanation bowel preparation 13 (65)
Mentions flexible sigmoidoscopy 15 (75)
 + explanation procedure 13 (65)
 + explanation risks 8 (40)
Mentions FOBT (immunochemical or guaiac) 20 (100)
 + explanation procedure 16 (80)
 + has to be repeated every 1-2 years 13 (65)
 + stresses importance of repeated screening 7 (35)
 + explains possibility of false positive/negative results 11 (55)
Mentions barium enema 9 (45)
 + poor detection of (pre)cancer 3 (15)
Mentions CT colonography 11 (55)
 + explanation procedure 10 (50)
 + explanation risks 8 (40)
Mentions that all tests, when positive, need to be followed by colonoscopy 9 (45)
Mentions surveillance after colonoscopy in case of adenomas 3 (15)
Mentions that frequency of screening is different per test 7 (35)
Describes possibility of interval carcinomas (CRC after negative test) 4 (20)
Describes limitations of screening such as overdiagnosis and overtreatment 5 (25)
Maximum number of points is 1 per item, unless otherwise specified.
CRC; Colorectal cancer, CT; Computed Tomography, FOBT; Fecal Occult Blood Test. 
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Table 6.2 Polyp Score items and percentage of websites that were awarded points for these 
items
Website information components (maximum 10 points) Websites, 
n (%)
Description of what a polyp is; growth/mushroom/lump in the lining of the 
large bowel
15 (75)
Image of a polyp 9 (45)
Prevalence of people with polyps in population 6 (30)
Explains that there are different types of polyps 9 (45)
Explains that not all polyps have an equal risk of turning in to colon cancer 10 (50)
Explains differences between adenoma and hyperplastic polyp 4 (20)
Mentions that some polyp characteristics have a higher risk of malignant de-
generation; i.e. histological findings (villous aspect)
3 (15)
Polyp size as risk factor 3 (15)
Influence of degree of cleanliness of bowel on polyp detection 2 (10)
Explains surveillances intervals after polypectomy 2 (10)
Maximum number of points is 1 per item.
Accuracy and quality of website information
The mean Website Accuracy Score was 26 (range 9-41). Most websites contained 
general information on CRC screening, but description and risk of different screening 
modalities and limitations of screening were not always captured (Table 6.1). The 
median Global Quality Score was 3 (range 2-5). This score indicates that the quality 
of information of most websites was moderate. In many sites, some information was 
adequately discussed, while other parts of information were missing and the overall 
flow of information was suboptimal. There was a strong positive correlation between 
the Website Accuracy Score and the Global Quality Score with a Spearman’s rho (rs) 
of 0.81 (p<0.001) (Figure 6.1). The median Polyp Score was three (range 0-10, Table 
6.2). The Polyp Score correlated positively with the Global Quality Score (rs=0.81; 
p<0.001). The median LIDA overall score was 74% (Interquartile range, IQR 11). The 
median LIDA score for accessibility was 88% (IQR 8), for usability 63% (IQR 22), and 
for reliability 52% (IQR 26). The median DISCERN score was 45 (IQR 20) indicating 
moderate quality. Ten percent of websites (2/20) were classified by DISCERN as high 
quality, 80% (16/20) as moderate and 10% (2/20) as low quality. Both the validated 
LIDA and DISCERN had a moderate correlation with the Website Accuracy Score; 
rs=0.45 (p<0.05) and rs=0.66 (p<0.01) respectively. There was no correlation between 
the Google ranks and the Website Accuracy Score (rs=-0.31; p=0.18, rs=-0.47; p=0.08 
and rs=-0.31; p=0.25 for the 2014, 2015 and 2016 search respectively). 
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Table 6.4 lists the top five websites as rated by CRC screening specific Website 
Accuracy Score and other evaluations of website quality. The complete scores 
per website are published in a supplementary table (Supplementary file 3.2). 
Eight websites had initial inter-rater Website Accuracy Score differences of ≥8. 
Differences in scoring of Website Accuracy Score or Polyp Score between 
reviewers were due to oversight or differences in interpretation. 
Figure 6.1 Relationship of the Global Quality Score and the Website Accuracy Score used to 
evaluate colorectal cancer screening websites
rs; Spearman’s rho.
Table 6.4 Top 5 websites as ranked by the Website Accuracy Score with the corresponding 
Polyp Score, quality scores, reading scores and Google rank positions
Website Accuracy Quality Readability Google rank
WAS PS GQS DISCERN LIDA FRE FKG 2014 2015 2016
www.cancer.org 41 5 5 65 67% 62 9th 6 3 2
www.bowelcancer 
australia.org
38 2 3 35 58% 58 10th 5 X 29
www.uptodate.com 37 6 5 69 85% 28 14th 27 13 16
www.macmillan.
org.uk
35 5 4 49 69% 48 11th 19 X X
www.nlm.nih.gov/ 
medlineplus
34 6 4 57 81% 59 8th 4 4 4
FRE; Flesch Reading Ease score, FKG; Flesch-Kincaid Grade Level, GQS; Global Quality Score, 
PS; Polyp Score, WAS; Website Accuracy Score, X; Not in the first 30 Google results.
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Figure 6.2 Mean Website Accuracy Score, Global Quality Score and reading scores per 
website type.
FRE; Flesch Reading Ease score, FKG; Flesch-Kincaid Grade Level, GQS; Global Quality Score, 
WAS; Website Accuracy Score.
Readability of websites
The mean Flesch Reading Ease Score was 48 (range 27–76), 30% of the websites 
had a reading level acceptable for the general public defined by a Flesch Reading 
Ease Score of >60. The mean Flesch-Kincaid Gradel Level was 11 (SD ±2.2, range 
5–16), indicating that the text would be understandable to an average 11th grade 
US student. The reading level of healthcare and governmental websites was the 
easiest, whereas the reading level of open access information sites was the most 
difficult (Figure 6.2). 
Advertisements  
When assessing the amount of advertisement, 16 (80%) websites contained 
none, two (10%) contained a moderate amount of advertisement, and two (10%) 
websites contained many advertisements. The latter two were open access 
websites. Websites published by governmental organizations contained no 
advertisements. 
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DISCUSSION
This study shows that there is marked variation in accuracy, quality and readability 
of information on CRC screening websites and that most websites do not address 
polyp surveillance. The best five websites as ranked by the Website Accuracy 
Score are www.cancer.org; www.bowelcanceraustralia.org; www.uptodate.com; 
www.macmillan.org.uk; and www.nlm.nih.gov/medlineplus. Their corresponding 
Google rank positions varied over time and some of these websites will be missed 
by standard Google searches (Table 6.4). 
The poor correlation between website accuracy and Google ranking is especially 
concerning given the fact that Google is a prominent search engine.10 Internet 
users often do not go beyond the first page of a search, which can result in 
missing websites that provide high quality information. This problem has been 
identified before.12 13 19
Even though surveillance after colonoscopy, especially if adenomatous polyps 
were found, is important for CRC screening to reach its maximal efficacy, it 
was only mentioned in 15% of the websites. Surveillance intervals are based on 
findings during colonoscopy.20 However, clear and easy to understand information 
on how findings during a screening colonoscopy, i.e. adenomatous polyps, 
determine the follow-up surveillance recommendations was lacking in most sites. 
This is reflected in the low overall median Polyp Score (3 out of 10) and the fact 
that only two websites (10%) described the actual surveillance intervals. This 
is an important information gap since adherence to surveillance is influenced 
by enhanced knowledge.4 Previous studies have shown that patients may not 
be sufficiently aware of important endoscopic findings and the consequences 
this has for subsequent surveillance recommendations. 3 21 Understanding the 
need of surveillance likely will motivate participants to adhere to surveillance 
recommendations. 
The reading difficulty of most websites was far above the required standard. 
Only 5% of the websites met the recommended level by the American Medical 
Association Foundation of 6th grade or below.18 This suggests that most websites 
are too difficult for the average reader and this may result in misunderstanding 
of information. Other studies evaluating patient information websites also 
documented that the required reading levels were high and above the 
recommended 6th grade level.22-24 Our study showed that commercially funded 
websites were more difficult to read than governmental websites. This is in 
accordance with previous literature.22 
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When evaluating the Website Accuracy Scores, it became apparent that most 
websites only focused on the predominant screening test used in the country 
where the website originated, and did not provide information on other options 
for CRC screening. It is debatable whether it is necessary to inform screenees 
about all possible screening tests that are available.25 However, providing 
information that several different options exist may help individuals, who are 
interested in screening, to make an informed decision.25 26 Colonoscopy and 
guaiac or immunochemical Fecal Occult Blood Test (FOBT) were described in all 
websites in detail. However, not all websites stressed the importance of the need 
for repeated screening when FOBT is used. This in spite of strong evidence that 
repeating stool testing at regular intervals is of paramount importance for FOBT-
based screening to be effective in the long term.1 Only 20% of the websites 
mentioned the possibility of the occurrence of interval carcinomas. This may in 
part be explained by the fact that this aspect of CRC screening has only gained 
a lot of attention during the last few years. However, not mentioning potential 
limitations of screening may stand in the way of informed decision-making.27 
A strength of this study is that the Website Accuracy Score and Polyp Score 
are CRC screening specific evaluation tools. These content specific outcome 
measures showed moderate to strong correlation with the validated generic 
outcome measures of Global Quality Score, LIDA and DISCERN. This provides 
further evidence that the use of these CRC screening specific outcome measures 
provide meaningful and relevant information. The advantage of the Global Quality 
Score over LIDA and DISCERN is that it is short and easy to perform. We believe 
that the Global Quality Score is a good score for overall flow and ease of use of 
any website providing health information. 
This is to our knowledge the first review that systematically assessed the quality, 
accuracy and readability of patient-oriented websites on CRC screening as well 
as polyp surveillance. Previous studies have reported on the quality of web-
based information regarding CRC surgery or treatment but none were systematic 
reviews of existing websites.23 28 29 Two other publications evaluated CRC 
screening websites but these did not include detailed information on polyps and 
surveillance.30 31 An American study focused on the readability and suitability of 12 
CRC screening websites.31 However, these sites were self-chosen by the author. 
Another brief review examined five chosen websites and evaluated their content 
and usability.30 In both of these publications no apparent selection criteria for 
quality were used. Most of the listed websites did not appear in our original 2014 
search results, nor in the first three Google pages assessed in 2015 and 2016. 
Our study has some limitations. Both the Website Accuracy Score and Polyp 
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Score were not validated separately prior to use on the selected websites. 
However, the good correlation with other previously validated quality instruments 
suggests adequate content validity. We only searched using English search terms 
thus only English websites were retrieved. Another possible limitation is the fact 
that quotation based search terms were used which require words to appear 
together in retrieved websites. Omission of quotation marks when searches are 
done could lead to different results. 
The internet is increasingly used by consumers to find relevant health information. 
There is evidence that experience and knowledge of Internet use has a significant 
impact on the uptake of CRC screening.32 Furthermore, the credibility of cancer-
related information on the internet is associated with population compliance with 
CRC screening, indicating the relevance of this study.4 32 We believe health care 
providers interested in developing websites on CRC screening, for example for 
their own institutions, can use our approach to evaluate the quality and readability 
of provided information to develop the content of the site they are creating. 
Alternatively they can provide health care consumers to several of the high quality 
websites, listed in Table 6.4, that we identified.
Physicians should be aware of the limitation of Google searching for CRC 
screening. Our study may be helpful in that regard as it provides a list of those 
websites which provide the highest quality information on CRC screening. 
However, it is important to remember that the internet is “alive” and that quality 
of websites may change over time or that new high quality websites may be 
developed. 
In conclusion, our study showed that there is marked variation in overall quality of 
web-based patient information on CRC screening. Most websites lack important 
information regarding polyps and their importance for future follow up surveillance 
colonoscopies. Several high quality websites do exist but poor correlation with 
Google ranking suggests that these websites may be missed. High quality and 
readable websites are essential to provide patients with reliable information to 
make informed decisions on CRC screening and surveillance participation and 
to optimize efficacy.
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CHAPTER 1.1
General introduction
ABSTRACT
Background
Quality of colonoscopy has been reported to vary considerably between 
institutions and endoscopists. Use of quality indicators can address 
suboptimal clinical outcomes and may reduce variation in colonoscopy 
performance. Therefore the aim of this study was to assess if plenary 
feedback on quality indicators can improve quality indicators of routine 
colonoscopy and reduce inter-hospital variation.
Methods
All consecutive routine colonoscopies performed in two academic and 
five non-academic hospitals in the Netherlands from November 2012 to 
January 2013 and November 2013 to February 2014 were prospectively 
registered. Between these two registration periods, a meeting with all 
seven hospitals was organized in which quality indicators and inter-
hospital differences were discussed. Main quality indicators were 
adjusted cecal intubation rate (CIR) and adenoma detection rate (ADR). 
Quality indicators and variation in quality indicators were compared 
between hospitals in the first and second registration period.
Results
A total of 3129 patients were included in the first versus 5016 patients 
in the second registration period. The adjusted CIR was 97% in both 
registration periods. The overall ADR improved from 32% (95%CI: 
30–34%) to 36% (95%CI: 34–37%) (P<0.001). Two out of the three 
hospitals had an ADR below average during the first registration period 
and improved to better-than-average. Higher inter-hospital variation 
was found for ADR (range in quality 25 – 47%; coefficient of variation 
(CV) 13.7) compared to adjusted CIR (range in quality 93 – 99%; CV 
1.9). Variation in ADR reduced between the first and second registration 
period (CV 14.8 to 13.4).
Conclusions
In high-standard routine colonoscopy centers, plenary evaluation and 
discussion of inter-hospital differences reduced inter-hospital variation 
in quality of colonoscopy, although after correcting for confounders, 
overall ADR and adjusted CIR could not be improved. 
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BACKGROUND
Colonoscopy is the most common performed endoscopic procedure and considered the ‘gold standard’ investigation of the colon. The efficiency 
of colonoscopy in terms of reduction in post-colonoscopy colorectal cancer 
(CRC) incidence is mainly dependent on the quality of the procedure.1 2 Quality 
of colonoscopy can be evaluated by measuring performance parameters of an 
individual endoscopist or group of endoscopists with predetermined targets. 
These predetermined targets are called quality indicators, which are measurable 
outcomes for which there is evidence-based impact on outcome that support a 
minimum standard.3 
These quality indicators help to bring quality to higher standards and identifies 
suboptimal performance. Commonly used quality indicators are quality of the 
bowel preparation, cecal intubation rate, colonoscopy withdrawal time, and 
adenoma detection rate (ADR). The variation in ADR between endoscopists 
and the fact that ADRs is inversely correlated with the risk of post-colonoscopy 
colorectal cancers have become the rationale for the creation of targets for ADR 
in CRC screening. 
Adjusted cecal intubation rate (CIR) and adenoma detection rate (ADR) are 
recognized by experts as priority quality indicators for colonoscopy.3 For these 
indicators, there is a strong association between reaching the recommended 
target and important clinical outcomes.1-3 The performance target is ≥25% for 
ADR and ≥90% for CIR.3 
Variation in quality indicators between endoscopists plays an important role in 
colonoscopy outcome. Use of quality indicators and address suboptimal clinical 
outcomes, may reduce variations in colonoscopy performance, and will thereby 
close the gap between suboptimal and optimal performed colonoscopies. 
Therefore, reduction in variation of quality has emerged as an important priority for 
colonoscopy practice.3 Data on inter-hospital variation in quality of colonoscopy 
performance and initiatives to reduce this variation are limited.4-6 By measuring 
the quality indicators CIR and ADR differences in colonoscopy quality between 
hospitals can be depicted, as both indicators are affected by institutional and 
procedural factors.7 Therefore, we set up a multicenter initiative comparing 
quality of routine colonoscopy in seven hospitals to incite quality improvement 
by plenary feedback and discussion on inter-hospital differences. The aim of this 
study was to assess whether plenary feedback on quality indicators can stimulate 
improvement of colonoscopy and thereby reduce inter-hospital differences.
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METHODS
Study design and population
Design of the study and results of the baseline registration has been described 
elsewhere.7 In short, we performed a prospective baseline registration (i.e. 
registration period 1), including all consecutive colonoscopies performed in 
two academic and five non-academic hospitals in the Netherlands between 
November 1st 2012 and January 10th 2013. All endoscopists filled out data on the 
indication for colonoscopy, type and dose of sedation used, quality of bowel 
preparation, cecal intubation, detection and removal of polyps, pathology reports 
and complications. After the first registration period, all quality indicators per 
hospital were evaluated and inter-hospital differences were discussed during 
a plenary session. No directives were given regarding quality improvement. A 
second prospective colonoscopy registration was conducted between November 
1st, 2013 and February 24th, 2014. 
Patient and colonoscopy characteristics were obtained from electronic medical 
records. Cecal landmarks were noted in the colonoscopy report, and photographic 
documentation was routinely obtained. Sedation was provided using midazolam, 
propofol, and/or opioid analgesics. We excluded patients with inflammatory 
bowel disease, polyposis syndromes or hereditary colorectal cancer syndromes 
and total colectomy. This research used a de-identified dataset and the study 
was exempt from obtaining informed consent from patients, as determined by the 
Medical Ethical Committee in accordance with the Medical Research Involving 
Human Subjects Act.
Colonoscopy procedure
Indications for colonoscopy were grouped into four categories: (1) anemia, 
abdominal symptoms and overt or occult rectal blood loss; (2) screening 
colonoscopies in patients with a positive family history of CRC; (4) surveillance 
after CRC or colorectal adenoma(s); and (5) other. The ‘other’ indication category 
consisted mostly of patients with diverticular disease, liver metastases or other 
abnormalities found during imaging. Complications were subdivided into bleeding 
(only taken into account if it did not stop spontaneously or by an intervention 
during the colonoscopy), perforation, and post-polypectomy syndrome. 
Endoscopists were gastroenterologists, fellows in training for gastroenterology, 
or nurse endoscopists. All endoscopists performing colonoscopies during the 
registration periods were informed about the study and consented to participate.
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Definitions of quality indicators
Primary outcomes were the adjusted cecal intubation rate (CIR) and the adenoma 
detection rate (ADR). Secondary outcomes were adequate bowel preparation, 
mean number of adenomas per procedure (MAP) and mean number of adenomas 
per procedure in which at least one adenoma was detected (MAP+). The 
unadjusted CIR was defined as the proportion of colonoscopies in which the 
cecum was visualized, irrespective of reasons for not intubating the cecum. The 
adjusted CIR was calculated by excluding colonoscopies in which the endoscopist 
made the decision not to intubate the cecum because of severe colitis, colonic 
obstruction, or therapeutic targets not necessitating cecal intubation.3 For the 
adjusted CIR, if no cecum was present (i.e. because of right-sided hemicolectomy 
or ileocecal resection) but the complete colon was visualized, the procedure was 
considered complete. Colonoscopies with poor bowel preparation were included 
in the adjusted cecal intubation rate, as preparation is considered to be part of 
colonoscopy practice. The ADR was defined as the proportion of procedures 
in which one or more adenomas were found. Adequate bowel preparation was 
defined as a Boston Bowel Preparation Scale (BBPS) score ≥6.8 Split-dose bowel 
preparation was common practice in all seven hospitals.
Evaluation of variation
Variation in colonoscopy performance was evaluated between hospitals and 
between registration periods. Variations of performance parameters were 
analyzed quantitatively using coefficients of variation and visually in a funnel plot 
and colonoscopy quality indicator (CQI) plot. The funnel plots are a graphical 
representation of quality measures and provide additional insight in inter-hospital 
variation.9 10 In the funnel plot, 95% confidence interval to the mean illustrate how 
much common cause variation is expected for a given hospital volume. After the 
first registration, the CQI plot was constructed to evaluate inter-hospital variation 
in CQI’s and compare these with predetermined targets. The CIR and ADR per 
hospital and registration period were plotted in the CQI. For CIR, a minimum of 
90% was used, as recommended by guidelines.3 For ADR a line was drawn at the 
overall average of the first registration period (32%) to create a visual target for 
better-than-average performance. 
Statistical analysis
Categorical variables with two categories were compared using the chi-squared 
test and those with multiple categories with binary logistic regression analyses. 
Differences between groups for continuous variables were tested using the t test.
We performed multivariate binary logistic regression analyses to assess whether 
the registration period was independently associated with adjusted CIR and ADR. 
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These analyses were adjusted for patient characteristics (gender, age, American 
Society of Anesthesiologists Physical Status Classification System (ASA) score) 
and procedure-related factors (indication, type of endoscopist, hospital, bowel 
preparation). Registration period and variables of potential significance (P ≤ 0.10) 
were entered in the model. 
Variation in quality indicators was quantified using coefficients of variation. We 
used the coefficient of variation because it allows the dispersion of variables 
with different means to be compared. The coefficient of variation in colonoscopy 
quality was measured as SD/mean, multiplied by 100.11 
All p-values were two-sided and considered to be statistically significant if 
P<0.05. SPSS statistics software version 22.0 (IBM Corp., Armonk, New York, 
USA) was used for the calculations.
RESULTS
Baseline characteristics
A total of 3129 patients were included in the baseline registration (46% male, 
mean age 59 years) versus 5016 patients (49% male, mean age 60 years) in the 
second registration. Baseline characteristics are shown in Table 7.1.  Median 
number of colonoscopies per hospital in the first registration was 568 (range 
124- 793) and 670 (402 and 1375) in the second registration period. Most 
patients (70% and 65%) underwent colonoscopy because of anemia, abdominal 
symptoms or rectal (occult) blood loss. The majority of colonoscopies were 
performed by gastroenterologists with a median number of colonoscopies per 
endoscopist of 65 (IQR 41) in the first registration period and 103 (IQR 91) in the 
second registration period. Distribution of sex, age, ASA score and indication 
for colonoscopy differed significantly between the first and second registration 
period (Table 7.1). 
Colonoscopy performance before and after plenary feedback meeting
All hospitals performed above the recommended target for adjusted CIR. 
The unadjusted and adjusted CIR did not change after plenary feedback and 
remained 95% (P=0.81) and 97% (P=0.36), respectively. Reasons for not 
intubating the cecum were inadequate bowel preparation (27%), stenosis or 
obstruction due to tumor or diverticulosis (29%), technical difficulty (27%), 
therapeutic goal not requiring cecal intubation (4.3 %), pain (2.4 %), ileocecal 
resection or right hemicolectomy (5.2%) or other (5.1 %). The percentage of 
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patients with a BBPS ≥6 was 90% and increased to 91% (P=0.10). Percentage of 
polyp removal increased from 45% to 50% after plenary feedback (P<0.001) (Table 
7.2). Two out of the three hospitals that had an ADR below average during the first 
registration period improved to better-than-average. Overall ADR improved from 
32% to 36% (P<0.001). The MAP improved from 0.60±1.22 to 0.74±1.49 (P<0.001) 
and the MAP+ improved from 1.89 ± 1.48 to 2.09 ± 1.82 (P=0.005). 
Variation in quality of colonoscopyChapter 7
Table 7.1  Baseline characteristics 
Registration period 1 2 P-value
Number of colonoscopies 3129 5016
Age, mean ± SD (years) 59 ± 15 60 ± 15 0.006
Male gender 1423 (45.5) 2465 (49.2) 0.001
Indication (%)
   Symptomatic a / rectal (occult) blood loss
   Family history of CRC
   Surveillance after CRC / adenoma
   Other b
   Unknown
2198 (70.2)
263 (8.4)
626 (20.0)
42 (1.3)
3258 (65.0)
330 (6.6)
1071 (21.4)
258 (5.1)
96 (1.9)
P<0.001
P=0.002 
P=0.153
P<0.001
ASA-score (%)
   1
   2
   3
   4
   Unknown
1784 (57.0)
1061 (33.9)
160 (5.1)
6 (0.2)
118 (3.8)
2359 (47.0)
2174 (43.3)
338 (6.7)
17 (0.3)
128 (2.6)
P<0.001
P<0.001
P=0.003 
P=0.285
P=0.002
Conscious sedation (%)
   Yes
   No
   Not reported
2840 (90.8)
158 (5.0)
131 (4.2)
3783 (75.4)
110 (2.2)
1123 (22.4)
P<0.001
Endoscopist (%)
   Gastroenterologist
   Gastroenterology fellow
   Nurse endoscopist
   Unknown
1870 (59.8)
747 (23.9)
512 (16.4)
2804 (55.9)
949 (18.9)
1164 (23.2)
99 (2.0)
P<0.015
P<0.001
P<0.001
Organization (%)
   1
   2
   3
   4
   5
   6
   7
339 (10.8)
245 (7.8)
124 (4.0)
639 (20.4)
568 (18.2)
421 (13.5)
793 (25.3)
618 (12.3)
421 (8.4)
402 (8.0)
902 (18.0)
670 (13.4)
628 (12.5)
1375 (27.4)
a Includes anaemia, abdominal symptoms and changes in bowel habit
b Includes investigation for diverticular disease, abnormalities found with other imaging 
modalities and liver metastases.
American Society of Anesthesiologists Physical Status Classification System score (ASA 
score); Colorectal cancer (CRC); Standard deviation (SD)
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Table 7.3  Outcomes per hospital and type of endoscopist
Before and 
after plenary 
feedback
BBPS ≥6 CIR Adj. CIR ADR MAP Compli- 
cation
Hospital (n) % %  % % ± SD %
1 1  (339) 79.0 96.2 98.5 27.4 0.50 ±1.00 1.2
2  (618) 89.6 94.5 97.0 35.0 0.69 ±1.39 0.8
2 1  (245) 87.0 93.1 95.4 33.5 0.78 ±1.64 1.9
2  (421) 86.5 94.8 96.4 40.9 0.99 ±1.74 1.0
3 1  (124) 88.7 99.2 99.2 46.8 1.00 ±1.44 0.0
2  (402) 67.8 89.5 93.6 33.3 0.93 ±2.11 0.2
4 1  (639) 97.3 97.5 98.7 31.3 0.58 ±1.22 0.8
2  (902) 95.2 97.2 98.2 34.1 0.68 ±1.32 0.3
5 1  (568) 95.8 98.1 99.3 24.8 0.42 ±0.97 0.2
2  (670) 94.6 95.2 96.7 28.5 0.52 ±1.09 0.0
6 1  (421) 97.6 95.2 97.1 35.4 0.61 ±1.16 0.0
2  (628) 95.5 95.5 97.9 42.4 0.88 ±1.52 0.6
7 1  (793) 80.2 89.4 93.4 34.4 0.68 ±1.27 0.6
2  (1375) 92.4 92.6 95.9 36.7 0.74 ±1.46 0.4
Type of endoscopist
Gastro- 1  (1870) 90.1 94.8 96.8 29.8 0.55 ±1.15 0.5
enterologist 2  (2804) 91.3 94.4 96.5 34.7 0.74 ±1.50 0.5
Fellow 1  (747) 85.7 94.2 97.0 34.0 0.75 ±1.49 1.2
2  (949) 91.6 94.3 96.8 38.6 0.82 ±1.60 0.4
Nurse 1  (512) 93.9 95.7 97.8 36.1 0.57 ±0.96 0.2
endoscopist 2  (1164) 96.2 96.1 98.1 35.9 0.69 ±1.30 0.4
Before plenary feedback (1); After plenary feedback (2); Boston Bowel Preparation Scale (BBPS); 
CIR, cecal intubation rate; Adj. CIR, adjusted cecal intubation rate; ADR: adenoma detection rate.
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Predictors of colonoscopy quality outcome
Table 7.4 shows the results of the multivariate logistic regression analyses. There 
was variation between registration periods in the odds of adjusted CIR. Adequate 
bowel preparation was strongly associated with the adjusted cecal intubation 
rate with an odds ratio (OR) of 33.65, P<0.001 (Table 7.4). ASA classification was 
inversely correlated with cecal intubation rate, in patients with an ASA score >1 
the cecum was less often intubated. Hospital was an independent predictor for 
adjusted CIR (P<0.001) with OR’s ranging from 1.22 (95%CI 0.73 – 2.05) to 3.86 
(95%CI 2.15 – 6.93), with the hospital with largest volume as reference. 
After correcting for confounders, performing colonoscopy after plenary feedback 
was not statistically significantly associated with ADR (OR 1.05, 95%CI 0.94 χ 
1.17). In multivariate analysis, adenomas were more common in colonoscopies 
with an adequate bowel preparation (OR 1.73, 95%CI 1.38 – 2.17) and if cecal 
intubation was succeeded (OR 2.90, 95%CI 1.93 χ 4.35) (Table 7.4). Highest ADR 
was found in colonoscopies performed for surveillance of CRC or adenomas, 
followed by a positive family history. 
Figure 7.1  Variation of quality indicators among the 7 hospitals. 
For each quality indicator, the left bar represents the first registration period and the right bar 
the second.
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Table 7.4   Factors associated with adjusted cecum intubation rate and adenoma detection rate 
adjusted CIR ADR
Adjusted OR 
(95% C.I.)
P Adjusted OR 
(95% C.I.)
P
Registration period (first as 
reference)
0.70 (0.51 χ 0.96) 0.03 1.05 (0.94 χ 1.17) 0.39
Hospital
1
2
3
4
5
6
7
3.86 (2.15 χ 6.93)
1.22 (0.73 χ 2.05)
3.93 (1.76 χ 8.76)
1.79 (1.08 χ 2.95)
1.37 (0.81 χ 2.32)
1.35 (0.78 χ 2.32)
Reference
<0.001
1.00 (0.82 χ 1.21)
1.18 (0.96 χ 1.45)
1.19 (0.93 χ 1.53)
0.83 (0.72 χ 0.97)
0.60 (0.50 χ 0.73)
1.08 (0.90 χ 1.28)
Reference
<0.001
Type of endoscopist
Gastroenterologist
Fellow
Nurse endoscopist
Reference
1.26 (0.85 χ 1.86)
1.41 (0.89 χ 2.24)
0.25
Reference 
1.15 (0.99 χ 1.33)
1.15 (1.00 χ 1.33)
0.07
Male sex 1.63 (1.47 χ 1.81) <0.001
Age, per 10-year increase 0.94 (0.84 χ 1.05) 0.29 1.54 (1.48 χ 1.61) <0.001
ASA score
ASA 1
ASA 2
ASA 3
ASA 4
Reference
0.59 (0.41 χ 0.85)
0.63 (0.37 χ 1.06)
0.16 (0.03 χ 0.77)
0.008
Reference 
1.01 (0.90 χ 1.13)
0.96 (0.77 χ 1.20)
1.22 (0.42 χ 3.58)
0.95
Indication
Symptomatic / rectal (occult) 
blood loss
Family history of CRC
Surveillance after CRC / 
adenoma
Other
Reference
1.29 (0.59 χ 2.80)
1.61 (1.08 χ 2.42)
1.08 (0.51 χ 2.31)
0.14
Reference 
1.45 (1.19 χ 1.77)
1.78 (1.58 χ 2.01)
1.44 (1.10 χ 1.89)
<0.001
Adequate BBPS 33.65 (24.33 χ 46.54) <0.001 1.73 (1.38 χ 2.17) <0.001
Adjusted CIR - 2.90 (1.93 χ 4.35) <0.001
Odds ratio (OR); Confidence interval (CI); Cecal intubation rate (CIR); American Society 
of Anesthesiologists Physical Status Classification System score (ASA score); colorectal 
carcinoma (CRC); Boston Bowel Preparation Scale (BBPS).
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Variation of quality measures among hospitals
The magnitude and pattern of variation in quality varied widely across the 
different quality indicators. Variations in all quality indicators between hospitals 
are depicted Table 7.3. In unadjusted analyses, there was significant inter-hospital 
variation in adjusted CIR ranging from 93 % to 99% (P<0.001) before the plenary 
feedback and from 94% to 98% after the plenary feedback (P=0.001) (Table 7.3). 
Adequate bowel preparation varied between 79 % and 98% (P<0.001) before 
plenary feedback and from 68% to 96% after plenary feedback (P<0.001). Inter-
hospital ADRs varied between 25% and 47% (P<0.001) and between 29% and 
41% (P<0.001) before and after plenary feedback respectively. Quality indicators 
with the smallest variation coefficient were adequate bowel preparation and 
unadjusted and adjusted CIR (Table 7.2). Overall variation coefficients decreased 
for adequate bowel preparation, PDR and ADR (Table 7.2). 
Figure 7.1, showing the variation coefficients according to registration period and hos-
pital, demonstrates large variation in the adjusted CIR between hospitals. Intra-hos-
pital variation coefficients decreased for ADR in six out of the seven hospitals (Figure 
7.1). The quality indicators with the smallest overall variation coefficient were adequate 
BBPS, and unadjusted and adjusted CIR (Table 7.2). Figure 7.2 shows in a CQI plot, 
inter-hospital variation in ADR and adjusted CIR. In the funnel plots, the mean ADR 
is depicted for each endoscopist (Figure 7.3) and hospital (Figure 7.4) by registration 
period, showing large variation between individual endoscopists and hospitals. 
Figure 7.2  Colonoscopy quality indicator plot of ADR and adjusted CIR.
Each dot represents one hospital, bubble size is based on hospital-volume for that registration period
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Adverse events
Plenary feedback did not affect complication rate (P=0.98). There were no 
procedure related deaths. The overall perforation rate was 0.06%. 
Figure 7.3  Funnel plot showing each endoscopist’s ADR.
Each dot represents an endoscopist in the first registration period, each rhombus an 
endoscopist in the second registration period. Horizontal line is the overall mean ADR (35%) 
with 95% confidence interval.
Adenoma detection rate (ADR). 
Figure 7.4  Funnel plot showing each hospital’s ADR.
Horizontal line is the overall mean ADR (35%) with 95% confidence interval.
ADR; Adenoma detection rate.
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DISCUSSION
This multicenter initiative comparing quality of routine colonoscopy in seven 
hospitals revealed marked variation in quality indicators. We showed that a 
plenary feedback meeting to discuss inter-hospital differences, can reduce 
variation of quality between hospitals, although overall quality indicators could 
not be improved after correction for confounders. For hospitals with already good 
quality colonoscopies, plenary feedback helped to even improve colonoscopy 
performance. This underlines the importance of repeated quality assessment of 
colonoscopy in daily practice.
Implementation of CRC screening programs worldwide has largely increased 
colonoscopy demand.12 This increases the relevance of quality assurance in 
colonoscopy. Evaluating quality indicators allows detecting differences in 
colonoscopy performance between hospitals and reducing variation. Variation 
in quality has now been convincingly linked to important outcome measures. For 
example, interval cancers are more common in endoscopists with low ADR as 
compared to those with high ADR.1 2 In a large American study of 223,842 patients 
undergoing colonoscopy, a 3% reduction in CRC incidence and a 5% reduction 
in cancer mortality was found for each 1% increase in ADR.2 Mainly based on this 
study, ADR targets have now been set at 25%, although guidelines specifically 
state this applies to asymptomatic, average risk individuals.3 Age, gender, and 
indication of colonoscopy are known to affect the ADR, and adjustment for these 
factors is indicated when evaluating quality.13 14 To improve ADR interventions 
targeting endoscopist performance have generally been ineffective.4 Publically 
reporting physicians ADRs may improve ADR.15 Although this study was done 
in a single private practice and did not correct for possible confounders. In 
our study we found that a performance target of ADR ≥25% appeared to be 
applicable in routine colonoscopies and an increase in ADR for a single hospital 
can be achieved after having a plenary feedback. It is however important to 
realize that these targets should not be considered standard of care for routine 
colonoscopies. Rather, they should be used as performance targets in the quality 
improvement process.3 
Adjusted CIR was the strongest independent predictor of ADR in our study. 
This is also confirmed in previous studies showing that high CIR increases ADR, 
although contradictory conclusions have also been published.16-18 In the second 
registration period only 68% of the procedures performed in hospital 3 had 
an adequate BBPS, whereas overall this percentage was 91%. This finding is 
mostly likely explained by the difference in case mix. The proportion ASA 3 or 4 
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patients was 26% in hospital 3 versus 6 % for the other hospitals together (data 
not shown). Inadequate bowel preparation in ASA class ≥3 has been described 
previously.19 20 Also the strong decrease in performance in hospital 3 can be 
explained by case mix. The notable high ADR in the first registration period has 
been described previously.7 
As expected and consistent with reports from other institutions, there was a 
substantial variation in ADRs between hospitals as well as between individual 
endoscopists.7 14 After the plenary meeting, overall variation coefficients for ADR 
decreased and inter-hospital variation coefficients for ADR decreased in six out 
of the seven hospitals. 
Improvement in performance is important but it is even more important to 
understand the factors responsible for improved performance. By understanding 
the factors that could be attributable to random (common-cause) variation in 
colonoscopy performance rather than to systematic variation in colonoscopy 
performance (which is an indication of a change in the system), opportunities 
for targeted educational programs can be identified. Explanations that possible 
attributed to the improvement found in our study could be increased awareness 
and feedback. There is substantial evidence that feedback can effectively 
improve quality.21 22 However, it is known that feedback may be more effective 
when baseline performance is low, which does not apply for this study. Another 
reason for the improvement may be the start of the national Dutch colorectal 
cancer screening program in 2014, for which strict certification and continuous 
monitoring of quality measures of endoscopists and hospitals is required. 
To appreciate these findings, some limitations need to be discussed. Because 
endoscopists were aware of the quality registration, a Hawthorne effect may be 
contributing to the observed result.23 Another limitation of the study is that the 
sample size of colonoscopies from each endoscopist (median 65, IQR 41) may 
be insufficient to reliably assess individual ADR. We were unable to determine 
whether inter-hospital differences with regard to interventions attributed to 
improvement.
Different studies examined the effect of different interventions on the performance 
of colonoscopy quality.4-6 Our findings suggest that endoscopists’ knowledge 
that quality measures are being monitored represents a powerful tool that by 
itself can stimulate improvement of quality of colonoscopy. There the MAP and 
MAP+ reflect inspection of the entire length of the colon better than the ADR 
which rewards a “one-and-done” approach to colonoscopy, it is suggested in 
literature that it provides greater differentiation between endoscopists.24 This is 
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also in line with our results showing that both MAP and MAP+ had the highest 
variation coefficient and inter-hospital variance. Our findings encourage using 
MAP and MAP+ to assess quality variation in colonoscopy performance. Besides 
the use of MAP and MAP+ future studies should focus on qualitative evaluation of 
feedback pathways that have led to improvement. Understanding these pathways 
may allow the same or similar strategies to be applied in different settings. 
Furthermore, it is important to consider a longer-term view of performance and 
assess changes over a long time period. Strategies theretofore that account for 
regression-to-the-mean have been suggested.25 
In conclusion, there is considerable variation in quality indicators for colonoscopy. 
However, targets for CQI in CRC screening programs can also be achieved in 
routine colonoscopies. By plenary evaluation and discussion of inter-hospital 
differences in colonoscopy performance, variation between hospitals, especially 
ADR, can be improved. Further research is needed to identify factors responsible 
for the variation between hospitals, to achieve optimal effectiveness in 
colonoscopy performance. 
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CHAPTER 1.1
General introduction
ABSTRACT
Introduction
Adherence to surveillance colonoscopy guidelines is important to 
prevent colorectal cancer (CRC) and unnecessary workload. This 
study evaluated how well Canadian gastroenterologists adhere 
to colonoscopy surveillance guidelines after adenoma removal or 
treatment for colorectal cancer.
Methods
Patients with a history of adenomas or CRC who had surveillance 
performed between October 2008 and October 2010 were 
retrospectively included. Time-intervals between index colonoscopy 
and surveillance were compared to the guidelines of the American 
Gastroenterology Association (AGA) of 2008 and regarded as 
appropriate when the surveillance interval was ±6 months of the 
recommended time interval.
Results 
265 patients were included (52% male; mean age 58 years). Among 
patients with a normal index colonoscopy (n=110), 42% received 
surveillance on time, 38% too early (median difference=1.2 years 
too early), and 20% too late (median difference=1.0 years too late). 
Among patients with non-advanced adenomas at index (n=96), 25% 
received surveillance on time, 61% too early (median difference=1.85), 
and 14% too late (median difference=1.1). Among patients with 
advanced neoplasia at index (n=59), 29% received surveillance on 
time, 34% too early (median difference=1.86), and 37% later than 
recommended (median difference=1.61). No significant difference in 
adenoma detection rates was observed when too early surveillance vs. 
appropriate surveillance (34 vs. 33%, p=0.92) and too late surveillance 
vs. appropriate surveillance (21% vs. 33%, p=0.11) were compared.
Conclusion
A minority of surveillance colonoscopies are being performed according 
to guideline recommendations. Deviation from the guidelines did not 
improve the adenoma detection rate. Interventions aimed at improving 
adherence to surveillance guidelines are needed.
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INTRODUCTION
Colorectal cancer (CRC) is a leading cause of cancer-related mortality in the Western world.1 Screening for CRC decreases CRC-related mortality 
and CRC incidence.2 The adenoma-carcinoma sequence is accepted as the 
pathway of development of CRC and hence one of the main aims of screening 
colonoscopy is to detect and completely remove all adenomas.3 4 After neoplasia 
removal, patients remain at increased risk for adenoma recurrence. Therefore, 
surveillance after removal of adenomas or CRC is recommended. Some factors 
are associated with an increased risk of adenoma recurrence such as number of 
previous polyps and presence of villous features on histology.5 The surveillance 
interval is generally based on these findings at the index colonoscopy.6
The demand for colonoscopy procedures has risen considerably over the last 
years which led to increased wait times for gastroenterology care in many regions 
of the world, including Canada.7-9 The increase in demand for colonoscopy as 
a part of CRC screening is likely to lengthen wait times even further. Deviation 
from surveillance guidelines may further lead to unnecessary workload, and 
consequently a decrease in cost-effectiveness of CRC screening.10 Previous 
studies have shown that a significant proportion of gastroenterologists 
recommend follow-up intervals that deviate considerably from the published 
guidelines.11-13 
The objective of this study was to assess the appropriateness of recommended 
surveillance colonoscopy intervals in the Canadian endoscopy setting.6 
Furthermore, we aimed to determine whether the appropriateness of surveillance 
intervals influenced the detection of colorectal adenomas.
METHODS
This retrospective cohort study was conducted at the University of Alberta 
Hospital, Edmonton, Alberta, Canada. Ethical approval for this study was obtained 
by the Health Research Ethics Board (Pro00013953). Patients were identified and 
selected from a pilot study carried out as a first step in the creation of a CRC 
screening program (NCT00893503). This screening program, called SCOPE 
(Stop Colorectal Cancer through Prevention and Education), was launched in 
Edmonton to start a regional colon cancer screening program. The program was 
designed to test several steps in the referral process.  The average risk patient 
could be referred only if they had a positive fecal occult blood test. Patients were 
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also eligible to be referred to the program if they had a personal history of colon 
cancer or adenomatous polyps, or a family history of colon cancer or polyps. In the 
pilot study the program only accepted referrals coming from gastroenterologists. 
In all patients who had a personal history of cancer or adenomatous polyps, the 
baseline endoscopy report and histology of removed polyps was available. For all 
patients who had a prior index colonoscopy during which adenomatous polyps 
were removed, the program did accept the recommendation that was made by 
the colonoscopist who performed the index colonoscopy. Patients where only 
included in the current study if they had a personal history of adenomas or CRC 
and underwent colonoscopy in the SCOPE program for surveillance purposes. 
Patients with a history of inflammatory bowel disease, a known hereditary CRC 
syndrome or patients with colonoscopies that were performed for the evaluation 
of gastrointestinal symptoms were excluded. 
Patients with a personal history of adenomas or CRC who had a surveillance 
colonoscopy performed between October 2008 and October 2010 were included. 
The colonoscopy performed before the procedure done between October 2008 
and October 2010 was defined as the index colonoscopy. As all patients had 
an adenoma history this index colonoscopy might not have been their actual 
first-time colonoscopy done for adenoma or CRC surveillance. Consequently, 
even if our defined index colonoscopy was normal, these patients according 
to the American Gastroenterogical Association (AGA) guidelines of 2008 were 
supposed to undergo surveillance colonoscopy every 5 years because of 
their adenoma or CRC history.6 This aspect was not incorporated in the 2006 
AGA guideline but was already indebted in the 2006 American Society for 
Gastrointestinal Endoscopy (ASGE) guideline.14 The 2008 AGA guidelines were 
used in our analyses as this was a combination of the AGA and ASGE guidelines 
from 2006, both available at that time.
Data collection
The following data were collected from endoscopy reports: demographic data 
(age and gender), family history for CRC, index and surveillance colonoscopy 
characteristics such as date, cecal intubation rate, quality of bowel preparation 
(if not mentioned in the report it was assumed to be sufficient), and endoscopic 
findings including diagnosis, number, histology and site of polyps or cancer. 
Right sided adenomas were defined as adenomas found in the cecum, ascending 
colon, hepatic flexure or transverse colon.  Left sided was defined as splenic 
flexure, descending colon, sigmoid colon and rectum. Patients were categorized 
in different surveillance groups based on their most advanced lesion at index 
colonoscopy: normal, non-advanced adenoma, or advanced neoplasia. Advanced 
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neoplasia was defined as ≥3 adenomas or adenomas >10mm, with >25% villous 
histology or high-grade dysplasia, or CRC. For patients who were diagnosed with 
CRC during index colonoscopy, the date of their surgery was used in order to 
calculate the optimal surveillance interval.
The actual interval between the index and surveillance colonoscopy was compared 
to the recommended interval stated in the 2008 guidelines from the AGA.6 This 
guideline was used as the Canadian guideline, which has not been updated 
since 2004, does not state explicit recommendations for surveillance. A margin 
of six months around the recommended date was considered as an appropriate 
surveillance interval. Outcome measures were defined as the percentage of 
appropriate, too early, and too late procedures. Secondary outcomes were the 
adenoma detection rates (ADR) of the three categories, defined as the proportion 
of patients who had at least one adenoma at surveillance colonoscopy. For the 
ADR analyses and appropriateness categories, it was deemed to be appropriate 
to exclude the cases with poor bowel preparation on index procedure.
Statistical analysis
Descriptive statistics were used. Differences were assessed for significance by 
means of the Student’s t-test for continuous data and the Chi-square test for 
categorical data. The level of statistical significance was defined as a two-sided 
p-value <0.05. All analyses were performed using statistical software package 
SPSS PASW 17.0, Chicago, IL, USA.
RESULTS
After excluding 11 cases in whom no information was available about the 
index findings, 265 patients were included for analyses (52% male; mean age 
on index: 58 yrs, SD=11). Table 8.1 summarizes the patients’ characteristics 
stratified for the findings at index colonoscopy. The median number of previous 
colonoscopies was 1 (range: 0-6). Index colonoscopy was normal in 42% of the 
patients (n=110/265), non-advanced adenomas were found in 36% (n=96/265), 
and advanced neoplasia was detected in 22% of the cases (n=59/265). Three 
patients (1%) had CRC.
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Surveillance colonoscopy
Of all 265 surveillance colonoscopies, 33% (n=87/265) were classified as 
procedures performed on time according to the AGA guidelines. In 46% of the 
patients (n=121/265) the surveillance interval was shorter than recommended, and 
the remaining 21% (n=57/265) underwent surveillance later than recommended 
compared to the surveillance guidelines. 
Figure 8.1 shows the actual observed mean time interval between index and 
surveillance colonoscopy compared with the recommended time interval stratified 
for the index finding. The median difference between the recommended time 
interval and the observed interval was -1.8 years (inter quartile range (IQR)=1.12) 
for surveillance colonoscopies which were performed too early, and +1.1 years 
(IQR=1.34) for those which were performed too late. 
Table 8.2 shows the findings at index colonoscopy per appropriateness cate-
gory. In 17% of the patients who received surveillance colonoscopy too early, a 
poor bowel prep quality was mentioned at index procedure compared to 5% at 
surveillance procedures performed on time (p<0.01). No significant differences 
for a positive family history and cecal intubation rates were observed between 
the three appropriateness categories (all p-values > 0.1). After exclusion of 
patients with poor bowel preparation on index, the proportion of patients with a 
surveillance colonoscopy performed on time was 35%. 
Nonadvanced adenomas (n=96)
CRC (n=3)
Piecemeal removal (n=5)
Table 8.1 Patient characteristics at index colonoscopy
Total 
 
(n=265)
Normal 
findings  
(n=110)
Nonadvanced 
adenoma
(n=96)
Advanced 
neoplasia 
(n=59)
Age, years, mean ± SD 58±10.5 59±10.8 57±10.0 59±11.0
Male sex, n (%) 138 (52) 61 (56) 46 (48) 31 (53)
Cecal intubation rate, n (%) 230 (95) 98 (94) 84 (97) 48 (94)
Adequate bowel preparation, n (%) 238 (90) 97 (88) 89 (90) 55 (93)
Family history of CRC*, n (%) 61 (23) 22 (19) 27 (28) 13 (22)
Interval until surveillance  
colonoscopy (years, ±SD)
3.8±1.7 4.3±1.5 3.8±1.5 2.8±2.0
* first degree relatives with CRC extracted from endoscopy report if available
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Surveillance colonoscopy
Of all 265 surveillance colonoscopies, 33% (n=87/265) were classified as 
procedures performed on time according to the AGA guidelines. In 46% of the 
patients (n=121/265) the surveillance interval was shorter than recommended, and 
the remaining 21% (n=57/265) underwent surveillance later than recommended 
compared to the surveillance guidelines. 
Figure 8.1 shows the actual observed mean time interval between index and 
surveillance colonoscopy compared with the recommended time interval stratified 
for the index finding. The median difference between the recommended time 
interval and the observed interval was -1.8 years (inter quartile range (IQR)=1.12) 
for surveillance colonoscopies which were performed too early, and +1.1 years 
(IQR=1.34) for those which were performed too late. 
Table 8.2 shows the findings at index colonoscopy per appropriateness cate-
gory. In 17% of the patients who received surveillance colonoscopy too early, a 
poor bowel prep quality was mentioned at index procedure compared to 5% at 
surveillance procedures performed on time (p<0.01). No significant differences 
for a positive family history and cecal intubation rates were observed between 
the three appropriateness categories (all p-values > 0.1). After exclusion of 
patients with poor bowel preparation on index, the proportion of patients with a 
surveillance colonoscopy performed on time was 35%. 
Nonadvanced adenomas (n=96)
CRC (n=3)
Piecemeal removal (n=5)
Figure 8.1 Mean time interval between index and surveillance colonoscopy compared to time 
interval recommended by the AGA guideline of 2008.
Table 8.2 Findings at index stratified for appropriateness according to the guidelines
Surveillance colonoscopy, n (%)
On time
(n=87)
Too early*
(n=121)
Too late*
(n=57)
Positive family history of CRC 17 (20) 29 (24) 15 (26)
Cecal intubation rate at index # 78 (93) 111 (96) 42 (98)
Adequate bowel prep at index 83 (95) 100 (83) ** 55 (97)
Median difference, years (IQR)*** 0.07 (0.40) -1.8 (1.12) 1.1 (1.34)
Findings at index
Normal index 46 (53) 42 (35) ** 22 (39)
Non advanced adenoma at index 24 (27) 59 (49) ** 13 (22)
Advanced neoplasia∞ at index 17 (20) 20 (17) 22 (39) **
 *= earlier respectively later than recommended in the 2008 AGA guideline; **= statistically 
significant compared with surveillance colonoscopy on time; ***=mean difference between 
the recommended time interval and the observed interval between index and surveillance 
colonoscopy; #= total numbers differ due to missing data; ∞= ≥3 adenomas or >10mm, with 
(tubulo-)villous histology or high-grade dysplasia or colorectal cancer. IQR inter quartile range; 
prep Preparation
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Normal index colonoscopy
Among patients with a normal index colonoscopy (n=110), 42% of patients 
(n=46/110) received surveillance colonoscopy on time, 38% (n=42/110) too early 
(median difference= -1.23 years too early; IQR=1.54), and 20% (n=22/110) too 
late (median difference=0.98 too early; IQR=0.86). 
Non advanced adenoma at index colonoscopy
Among patients with non-advanced adenomas at index colonoscopy (n=96), 25% 
(n=24/96) received surveillance colonoscopy on time, 61% of cases (n=59/96) 
too early (median difference= -1.85 years too early; IQR=1.24), and 14% 
(n=22/96) of patients received their surveillance colonoscopy too late (median 
difference=1.05 years too late; IQR=1.74). Among patients with normal or non-
advanced findings on index colonoscopy (n=206), the percentage of patients 
undergoing surveillance earlier than recommended was significantly higher (49%; 
n=101/206) than in patients with advanced neoplasia (34%; n=20/59) (p=0.040). 
Advanced neoplasia at index colonoscopy
Among patients with advanced neoplasia, 29% (n=17/59) received surveillance 
colonoscopy on time, 34% (n=20/59) too early (median difference= -1.86 
years too early; IQR=0.92), and 37% (n=22/59) later than recommended 
(median difference=1.61 years too late; IQR=2.08). All patients that had CRC 
detected at index colonoscopy (n=3) did receive surveillance on time. Of the 
five patients who had a piecemeal removal of their advanced adenoma at index 
colonoscopy, four returned too late and two of these patients had advanced 
neoplasia at surveillance colonoscopy. Among patients with advanced neoplasia 
on index (n=59), the percentage of patients undergoing surveillance later than 
recommended was significantly higher (37%; n=22/59) than in patients with non-
advanced or normal findings (17%; n=35/206) (p=0.001). 
Adenoma location distribution on index procedure and surveillance practice 
patterns
In Table 8.3, the distribution in location of most advanced index findings is 
presented, stratified for the different appropriateness categories. Overall, in 53% 
the adenoma location was only right-sided. Among patients who were diagnosed 
with both left and right-sided adenomas at index, earlier surveillance interval than 
recommended by guidelines was more often seen, compared to surveillance on 
time according to the guidelines (8% vs. 2% p=0.08).
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Adenoma detection rate at surveillance colonoscopy 
Adenomas were found on surveillance in 32% of cases (n=83/265), 8% of patients 
(n=20/265) had advanced adenomas. No CRC was identified at surveillance 
colonoscopy.The ADR for appropriate versus non-appropriate surveillance 
colonoscopy (stratified for index findings) are summarized in Table 8.4. Patients 
were excluded from this analysis, if they underwent surveillance procedure 
too early and had a poor bowel preparation during the index colonoscopy. 
The ADR at surveillance colonoscopy was significantly higher in patients with 
advanced neoplasia at index (n=26/59, 44%) vs. normal index colonoscopy 
(n=26/100, 26%), p=0.01. No significant difference in the ADR on surveillance 
was observed for procedures that were performed on time according to the 
guidelines compared to too early performed procedures (33% (n=29/87) vs. 
34% (n=34/100 respectively), p=0.923). The ADR was also not significantly 
different between appropriate versus too late procedures (33% (n=29/87) vs. 
21% (n=12/57) respectively, p=0.11). The detection of advanced adenomas at 
surveillance colonoscopy was not significantly different between appropriate vs. 
too early performed procedures (5% (n=4/87) vs. 10% (n=10/100), p=0.161) nor 
for appropriate vs. too late performed surveillance according to the guidelines 
(5% (n=4/87) vs. 9% (n=5/57), p=0.312). 
Table 8.3 Adenoma findings and sites on index and surveillance colonoscopy stratified for 
appropriateness according to the guidelines
Surveillance colonoscopy, n (%)
On time
(n=87)
Too early*
(n=121)
Too late*
(n=57)
Right sided adenomas index 24 (28) 38 (31) 19 (33)
Left sided adenomas index 17 (20) 29 (24) 14 (25)
Adenomas on both sides index 2 (2) 10 (8) 1 (2)
Right sided adenomas SC 22 (25) 22 (18) 9 (16)
Left sided adenomas SC 5 (6) 13 (11) 5 (9)
Adenomas on both sides SC 3 (3) 10 (8) 9 (0)
SC= surveillance colonoscopy; *= earlier respectively later than recommended in the 2008 
AGA guideline; 
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DISCUSSION
Recent reports have shown that there are significant problems with wait times for 
colonoscopy procedures in many centers in Canada.7 It is expected that, in the 
context of CRC screening and its associated need for surveillance procedures, 
the demand on endoscopy units will increase. This study aimed to assess how 
well endoscopists in the Canadian endoscopy setting adhere to the guidelines 
for surveillance colonoscopies and whether improvements are achievable which 
would help to decrease wait times.
Our study showed that in a significant proportion of patients surveillance 
colonoscopy was not performed at the recommended time interval. Only 
33% of the patients underwent a surveillance colonoscopy according to 
the AGA guideline. The largest group consisted of patients that underwent 
procedures earlier than recommended (46%). Underuse was also reported, 
as 21% of the patients received their colonoscopy too late. Shortening or 
lengthening the surveillance intervals did not significantly affect the ADR. 
Table 8.4 Adenoma detection rate at SC stratified for appropriateness according to the 
guidelines
Surveillance colonoscopy, n (%)
On time
(n=87)
Too early*
(n=121)
Too late*
(n=57)
ADR at SC
Adenoma at SC 29 (33) 24 (34) 12 (21)
Nonadvanced adenoma at SC 25 (29) 24 (24) 7 (12)
Advanced neoplasia∞ at SC 4 (5) 10 (10) 5 (9)
ADR at SC per index
   Normal index 14 (16) 8 (8) 4 (7)
   Non-advanced adenoma index 8 (9) 14 (14) 4 (7)
Advanced neoplasia at index 7 (8) 12 (12) 4 (7)
*= earlier respectively later than recommended in the 2008 AGA guideline; ∞= ≥3 adenomas or 
>10mm, with (tubulo-)villous histology or high-grade dysplasia or colorectal cancer; #= poor 
bowel preparation on index excluded
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Several surveys have documented suboptimal usage of surveillance colonoscopy, 
with physicians often recommending surveillance intervals that are too short.12 15 
A Dutch study reported that 52% of the respondents used shorter surveillance 
intervals than stated by the national recommendations.11 Suboptimal usage 
of adherence in daily practice has also been shown in several studies.13 16-18 A 
study from the USA observed a considerable disparity between guidelines 
and endoscopists’ recommendations in colonoscopy reports, with more 
surveillance colonoscopies occurring too soon; in only 37% of the cases were 
the recommendations consistent with the guidelines.13 Another study from the 
Netherlands reported low follow-up rates for surveillance colonoscopy after the 
removal of adenomas or CRC; more than one-third of patients (35%) tended not 
to undergo surveillance colonoscopies although overuse was also observed.17
As the risk for finding adenomas during surveillance colonoscopy differs based 
on baseline findings, guideline recommendations for surveillance colonoscopy 
are stratified based on the index findings.5 6 There is evidence that surveillance 
colonoscopy is over-utilized in low-risk subjects and underutilized in high-risk 
subjects.16 A US community practice assessment of utilization of surveillance 
colonoscopy showed under-usage of surveillance practice in terms of longer 
follow up intervals if high risk lesions at index colonoscopy existed (31%).13 In our 
study a similar trend was observed in adherence patterns for surveillance practice 
between advanced and non-advanced lesions on index procedures.18 Patients 
with non-advanced adenomas (49%) often received surveillance too early while 
patients with advanced neoplasia often underwent surveillance colonoscopy too 
late according to the guidelines (37%). 
Of all patients with index procedures that revealed advanced adenoma, 39% 
also had adenomas at surveillance colonoscopy (n=23/59). This underlines that 
advanced adenoma at index colonoscopy is an important risk factor for adenoma 
recurrence and thereby supports the guidelines for more vigilant surveillance.16 
However, in our study the detection rate of recurrent adenomas was also high in 
25% of patients with normal index colonoscopies. It emphasizes that our current 
findings must be taken with caution for surveillance colonoscopy in general. The 
fact that 25% of the patients with a normal index still had adenomas at surveillance 
colonoscopy indicates that these patients remain at high risk for developing 
metachronous adenomas, despite normal findings at a previous surveillance 
colonoscopy. The yield of surveillance colonoscopy did not significantly differ 
between colonoscopies carried out at appropriate or inappropriate times, 
suggesting that deviating from the guidelines does not necessarily affect the 
yield of surveillance colonoscopy. However, our sample size may have been too 
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small to detect significant differences in ADR. In addition, similar detection rates 
in advanced adenomas between on time (8%) vs. too late procedures (7%) were 
observed. It is well established that the detection of adenomas is dependent 
on the quality of bowel preparation.19 Clinical decisions about the surveillance 
interval derived from colon cleanliness assessment can vary considerably among 
endoscopists and there is little agreement on what constitutes an insufficient 
bowel preparation.20 However, in our analyses it was shown the surveillance 
procedures performed too early still yielded high detection rates appreciably if 
patients with a poor bowel preparation were excluded.
Apart from suboptimal bowel preparation on index procedure, several other 
explanations have been suggested for the high detection rate and non-adherence 
to surveillance recommendations such as an incomplete examination, possibly 
incomplete removal of lesions and the presence of a family history of CRC.15 
Although in the too early surveillance cohort relatively more patients had a 
family history of CRC (24%) compared to the surveillance on time population 
(20%), the difference was not significant. It must be acknowledged that we do 
not know how reliable the reporting is for family history in colorectal cancer in 
this retrospective analysis. Additionally, there were no significant differences 
between cecal intubation rates in the three appropriateness categories. Quality 
issues may have been involved but these could not be adequately assessed in a 
prospective manner. In the cohort of patients that received earlier surveillance, 
8% of patients had left- and right-sided adenomas versus 2% in the cohort 
that received surveillance on time (p=0.08). Retrospective reports have argued 
that the effectiveness of colonoscopy for left-sided and right-sided colorectal 
neoplasia seems to differ. A Canadian study showed that the protective effect 
of a complete colonoscopy was strong for mortality from distal lesions, but not 
associated with mortality from proximal lesions.21 This might be an explanation 
why physicians recommended a shorter surveillance time interval if patients had 
lesions in the proximal part of their colon or to detect synchronous lesions in the 
proximal and distal colon. However, our data did not show that recommendations 
for only proximal-sided lesions were shorter compared to surveillance if only 
distal lesions on index colonoscopy existed. 
Additionally, insufficient awareness of guidelines may be an important factor for 
non-adherence by physicians. Several studies have shown that appropriate use of 
surveillance after the detection of adenomas or CRC depends to a great extent 
on the knowledge physicians have of surveillance guidelines.12 15 A recent study 
using hypothetical cases evaluating the knowledge of Canadian endoscopists 
about guidelines for follow-up colonoscopies showed that many gave the wrong 
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recommendation.22 Another study showed that priming endoscopists by means of 
distributing guideline pocket pamphlets for use in endoscopy units, did increase 
the compliance to guidelines.23 
Another possible explanation why endoscopists may recommend follow up 
colonoscopies that are too soon is that they base the recommendation on the 
number of polyps that they removed during the procedure before the pathology 
is back. An example of this would be a patient with four small polyps but the 
pathology only showed adenomas in two. Other explanations for less effective 
surveillance programs besides nod-adherence by physicians can be found in 
patient related factors such as non-attendance to surveillance colonoscopy. Most 
studies in this area focus on clinician adherence to published guidelines rather 
than patient adherence to clinician recommendations.  Because our study design 
was limited to only patients who had returned for their surveillance colonoscopy, 
it is not known how many patients, who underwent an index colonoscopy that 
warranted follow-up, did not return for surveillance colonoscopy.
As previously indicated, patients who had a prior history of colon cancer or 
removal of adenomatous polyps could be referred to the SCOPE Program. This 
pilot program did not change any of the recommendations that were made by 
colonoscopists at index colonoscopy as it was designed to test several steps 
in the referral process. In general terms it is often difficult for physicians to 
change follow-up recommendations made by other physicians, in particular if this 
would mean that follow-up colonoscopy is postponed to a later date. One of 
the obvious advantages of having an organized CRC screening program is that 
follow-up recommendations will be standardized, which will lead to more optimal 
use of resources.  
One of the limitations of our study was the small sample size. Furthermore, the 
results of our study were collected from a large city in Canada and may not 
be generalizable to other regions. We also did not analyze the characteristics 
and practice profiles of the endoscopists in our region, such as number of 
colonoscopies performed per year. Additionally, since the guidelines have been 
revised in 2008, differences in practice by clinicians over time may be attributable 
to adaptation and incorporation of new guidelines and or heightened awareness 
as CRC screening is becoming more widespread.  Our results should be 
interpreted also knowing there is a lack of an explicit guideline from the Canadian 
Association of Gastroenterology (CAG). The CAG surveillance guidelines, 
compared to the AGA guideline, are less explicit and recommendation implies 
that endoscopists should decide about the appropriate surveillance interval to a 
greater extent based on clinical judgment. The CAG guideline of 2004 however, 
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also recommends a 5 year interval for 1 or 2 adenomas and a 3 year interval for 3 
or more adenomas similar to the 2008 AGA guideline. Although they do not give 
specific recommendations for advanced adenomas, they do specify the term and 
refer to the AGA guideline. 
Lastly, the 6-month margin around the optimal follow-up date for colonoscopy 
was arbitrarily chosen. There are no data in the literature to indicate what an 
optimal choice is for a time interval around appropriateness. However, we believe 
the 6-month- interval was a reasonable choice in the context of the current wait 
times problems for endoscopy in Canada. 
In conclusion, a minority of the surveillance colonoscopies are being 
performed according to the recommendations for surveillance colonoscopy 
after polypectomy or CRC removal. Where a large proportion of patients who 
receive surveillance colonoscopies after the detection of adenomas or CRC are 
seen too often, another group of patients referred for surveillance or screening 
colonoscopy face a long wait time for gastrointestinal care. The results suggest 
that efforts should be made to raise awareness among endoscopists about 
proper surveillance intervals. Our results indicate that quality improvement 
programs in this area have the potential to result in important clinical benefits 
for the endoscopy department, especially in the context of wait times and costs.
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SUMMARY
Colorectal cancer (CRC) screening is a rapidly moving field. In this 
thesis we explored strategies and insights that may help to optimize 
CRC screening programs.
The main topics of the thesis were introduced in Part I. An overview 
was given of the burden of CRC worldwide and the initiatives to reduce 
this burden. All modalities eligible for screening were discussed with 
special focus on fecal tests. These chapters were followed by the aims 
and outline of the thesis. 
In Part II we expanded our knowledge on various strategies in fecal occult 
blood test-based CRC screening. We compared the diagnostic test 
accuracy of guaiac fecal occult blood tests and fecal immunochemical 
tests (FITs) for advanced neoplasia and CRC in average risk individuals 
and found higher sensitivities for FIT on both outcomes. We demonstrated 
that detection of advanced neoplasia by FIT increases significantly with 
age and fecal Hb cut-off concentration. We gave insight in how increasing 
the cut-off concentration or screening age, reduces colonoscopy 
demand and affects diagnostic yield of advanced neoplasia and missed 
lesions. We explored the best screening strategy in terms of number of FIT 
samples and recommend the use of 1-sample FIT compared to 2-sample 
FIT screening, because of equal detection of advanced neoplasia after 
four rounds. We found that, among 1-sample FIT screenees with a fecal 
hemoglobin (Hb) concentration lower than the applied cut-off, baseline 
fecal Hb and consecutive fecal Hb concentrations were independent 
predictors for incident advanced neoplasia risk. 
In Part III we showed that quality and readability of online information 
on CRC screening can be improved. We found that quality standards 
used in CRC screening programs can also be achieved in routine 
colonoscopies. Plenary feedback on inter-hospital differences in 
quality indicators of colonoscopy reduced variation, although overall 
quality indicators could not be improved. We determined adherence 
to recommended colonoscopy surveillance following removal of 
adenomas, and found suboptimal compliance.
This final part discusses the main findings and insights obtained 
from our research projects and gives directions for future research.  
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Colorectal cancer (CRC) ranks third among the most commonly diagnosed cancers worldwide, with wide geographical variation in incidence and 
mortality across the world.1 
CRC screening tests can be used to identify asymptomatic individuals with 
advanced adenoma and (early) cancer, together named advanced neoplasia. 
Removal of these lesions reduces CRC incidence and prevents CRC related 
mortality.2-4 There are various screening modalities available for CRC screening, 
each with advantages and disadvantages.5 Fecal occult blood tests (FOBT) are 
widely accepted for this purpose in large-scale population-based screening 
programs.6 7 FOBTs can select screenees at higher risk of advanced neoplasia 
from the large target population and thereby enable the most efficient use of 
limited colonoscopy resources.
FECAL OCCULT BLOOD TEST BASED COLORECTAL 
CANCER SCREENING (PART II)
The aim of Part II was to explore various aspects of and strategies on FOBT-
based screening.
Guaiac fecal occult blood test versus fecal immunochemical test
FOBT screening is based on the principle that a large proportion of colorectal 
neoplasia bleed microscopically before any clinical signs or symptoms become 
noticeable for the screenee. Bleeding tends to be intermittent, and blood is 
distributed unevenly in the stool.8 The concept of detecting CRC by testing for 
blood in the stool is based on the observation that cancers bleed because of 
disruption of the normal mucosa. The amount of blood increases with the size of 
the polyp and/or the stage of the cancer.9-12 The guaiac FOBT (gFOBT) was one 
of the first FOBTs used in CRC screening. Large trials have shown a significant 
reduction in CRC-related mortality after screening with gFOBT.2 More recently, 
the fecal immunochemical test (FIT) has been introduced as an alternative to 
gFOBT. FIT has several advantages compared to gFOBT screening. These 
include that FIT detects human blood specifically, in contrast to the gFOBT which 
can falsely detect other blood substances from digested food. Second, FITs are 
more specific for lower gastrointestinal tract bleeding since globin is degraded by 
digestive enzymes in the upper gastrointestinal tract. Third, the sample collection 
for most FIT variants is less demanding than for gFOBT-sampling, both in terms 
of number of samples required and handling of stools (smear cards for gFOBTs 
vs brush/spatula for FIT testing). Fourth, FIT screening does not require dietary 
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restrictions. Our Cochrane systematic review and meta-analysis showed that 
FIT had a higher discriminative ability than gFOBT for both advanced neoplasia 
and CRC as estimated by the HSROC model summary curves (Chapter 2). 
Our findings were strengthened by the fact that most studies were of high 
methodological quality. Summary sensitivity of FIT for advanced neoplasia and 
CRC in average-risk individuals was superior to gFOBT. However, the specificity 
of both tests was similar. Although the majority of clinical trials that demonstrated 
reduction in CRC mortality used gFOBT, it is successfully argued that using a 
more accurate FOBT (i.e. FIT) will only improve the mortality benefit from FOBT 
screening. 
These results from Chapter 2 strongly support current guideline recommendations 
for implementing FIT-based CRC screening programs or switch from gFOBT to 
FIT in case of existing programs.13
Population-based CRC screening programs that have been implemented over 
the last years indeed use FIT.5 For example, The Netherlands implemented a 
FIT-based national screening program in 2014 with gradual roll-out until 2020.14 
France switched from gFOBT to FIT in 2015.5 From January 2016, the national 
screening committee in the UK has recommended a change from gFOBT to FIT 
after positive results of a FIT pilot study.15
Searching for the best FIT screening strategy – age and cut-off
Thus, FIT-screening seems the way to go because of its superior adherence, 
usability and accuracy. However, within FIT screening different strategies can be 
applied such as cut-off concentration used and age of the population screened. 
Both vary between countries, often tailored to available financial resources and 
colonoscopy capacity.16 17 A high cut-off and narrow screening age range result 
in a low positivity rate and consequently low colonoscopy demand.18 Within the 
first round of our CRC screening cohort, we estimated the effect of increasing 
the cut-off concentration and screening age on the colonoscopy demand and 
advanced neoplasia detection and miss rate (Chapter 3). 
We found that FIT positivity rates, detection rates and the positive predictive 
value (PPV) all significantly increased with age. Both increasing the screening 
starting age and increasing the cut-off concentration resulted in a substantial 
reduction in colonoscopy demand. However, at the expense of missing advanced 
neoplasia, albeit in a similar ratio for both strategies. The lower sensitivity of higher 
cutoff concentrations may be compensated by repeating the test in subsequent 
rounds. Yet, an optimal cut-off concentration or screening age range could not 
be established in this study in a single screening round. Literature states that in a 
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Western population the optimal cut-off concentration is low (10 µg Hb/g feces) 
and screening age range is wide (45-80 years).19 Since younger persons have 
more life-years to gain, lower detection rates compared to elder individuals are 
generally acceptable. 
Positivity rate is a surrogate marker for fecal hemoglobin (Hb).20 Any factor 
affecting positivity, including age, sex, socio-economic status, previous screening 
participation or FIT brand will be reflected in the fecal Hb concentration.21 22 In the 
Netherlands asymptomatic persons aged 55-75 years are invited biennially for 
one FIT. At the start of the national screening program, a considerably higher 
than expected positivity rate was found.16 23 This was, among other reasons, 
because the individuals screened were substantially older than in our previous 
CRC screening trial. To meet the higher than anticipated colonoscopy demand, 
the cut-off concentration for colonoscopy referral was elevated.14 16 
Optimizing CRC screening is a continuous process. Screening policymakers 
should be aware of factors influencing positivity rate and closely monitor 
outcomes of a screening program to make adjustments if necessary. As the 
screening program evolves, regular assessment of positivity rates at different 
fecal Hb cut-offs with distributions by age and sex is recommended.
Searching for the best FIT screening strategy – number of FIT samples
Besides screening age-range and cut-off concentration, different strategies 
exist with regard to the number of FITs used per screening round. We previously 
demonstrated that two-sample FIT (2-FIT) screening, using at least one positive 
test as referral criteria, provides a higher detection rate for advanced neoplasia 
than 1-sample FIT (1-FIT) screening.24 However, this was at the expense of higher 
positivity rates and thus the need for more colonoscopies. Data on participation 
and diagnostic yield of successive rounds were needed to provide more insight 
in the long-term effectiveness of 1-FIT versus 2-FIT screening. 
We hypothesized that 2-FIT screening might require less screening rounds 
to be as equally effective as 1-FIT screening in terms of cumulative yield and 
sensitivity of multiple screening rounds and number of interval cancers. In 
Chapter 4 we therefore evaluated the results of 1-FIT versus 2-FIT screening 
after four screening rounds. Participation is an important early indicator for an 
effective population-based screening program. In both screening cohorts, a high 
cumulative participation over four consecutive rounds was seen. Repeated 1-FIT 
and 2-FIT screening resulted in a similar cumulative yield of advanced neoplasia. 
The PPV was however lower for 2-FIT than 1-FIT screening, which resulted in a 
higher (unnecessary) colonoscopy demand. 
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Interval cancers, i.e. cancers occurring after a negative screening test and 
before the next screening test is due, are worldwide considered an important 
indicator of the quality and effectiveness of CRC screening.25 Although large 
number of FIT screening studies were performed over the last two decades, few 
studies reported on interval CRC rates over multiple screening rounds.26-28 We 
identified interval CRCs through record linkage with the Dutch Comprehensive 
Cancer Centre for all participants. The FIT interval CRC rate among screenees 
participating at least once was 0.11% for 1-FIT and 0.09% for 2-FIT screening, 
although numbers were too small to reach statistical significance.
Our above described results on 1-FIT and 2-FIT screening at a cut-off 
concentration of 10 µg Hb/ g feces point towards the use of 1-FIT screening. 
However, other strategies within 2-FIT screening are possible, such as a 
higher cut-off concentration, referral criteria of both positive tests (alone or in 
combination with a higher cut-off), longer screening intervals or combination with 
other screening tests such as DNA-methylation tests. In our study, screenees 
with at least one positive FIT at a cut-off concentration of 10 µg Hb/ g feces were 
referred for colonoscopy and not re-invited. Therefore our study did not allow 
for simulation of such strategies apart from the first round.24 Modelling studies 
are necessary to evaluate (cost-)effectiveness of 1-FIT versus 2-FIT screening by 
simulating different cut-offs and screening intervals for both strategies. This can 
further aid in defining the optimal FIT screening strategy.
The ultimate purpose of CRC screening is decreasing mortality, so future studies 
should report long-term follow up data on mortality and interval cancer rates of 
FIT-based CRC screening programs. We encourage authors to report a clear 
definition of interval carcinomas, using standardized nomenclature as developed 
by the Expert Working Group on interval CRC of the Colorectal Cancer Screening 
Committee of the World Endoscopy Organization.25 
Searching for the best FIT screening strategy – use of individual fecal Hb 
concentrations
FIT has the advantage that fecal Hb concentrations can be measured yielding a 
quantitative test result. Nonetheless, at present FIT is mostly used like the gFOBT 
with a pre-determined cut-off for referral to colonoscopy. This strategy does not 
fully profit from the knowledge that higher fecal Hb concentrations are associated 
with a higher risk of advanced neoplasia.18 29-31 Currently, many countries with 
FIT-based CRC screening programs struggle to match colonoscopy demands 
with limited resources.16 17 32 To increase screening efficiency and impact of 
FIT screening programs, it is relevant to explore if screenees with a negative 
FIT, ( i.e. a fecal Hb concentration below the pre-defined cut-off), can be 
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categorized according to their actual fecal Hb concentration into different risk 
groups for development of advanced neoplasia. Such tailored screening would 
allow for targeted variation of screening intervals, and decrease screening and 
colonoscopy demand or optimize its use. 
Therefore, in Chapter 5 we aimed to investigate trends in actual fecal Hb 
concentrations of negative FIT results at first participation and in subsequent 
rounds as a predictor for future incidence of advanced neoplasia. We showed 
that fecal Hb concentrations of negative FIT results can be used to predict 
incident advanced neoplasia and CRC. Furthermore, in this study we were the 
first to show the added value of fecal Hb concentrations of consecutive negative 
FIT results over multiple screening rounds in predicting who is at risk of advanced 
neoplasia. We provided practical heat plots to visualize the risk for screenees 
after two negative FIT results. 
This study supports the use of fecal Hb concentrations in CRC screening 
optimization. Our findings provide a tool for personalized screening strategies 
to identify subgroups that are at higher risk of neoplasia within the average-risk 
target population. This could be similar to coronary heart disease risk management 
for which cholesterol is a predictor.33 Changes in cholesterol are monitored over 
time and combined with other risk factors such as age, gender, body mass index 
and blood pressure to provide a risk-based score.33 Future studies should focus 
on combining fecal Hb concentrations with known CRC risk factors to establish 
individual tailored screening intervals to maximize screening benefit and efficacy. 
QUALITY IN SCREENING AND COLONOSCOPY (PART 
III)
The aim of PART III of this thesis was to provide more insight in factors that are 
associated with quality in CRC screening, surveillance and colonoscopy.
Optimizing online CRC screening information
The efficacy of CRC screening is dependent on participation and subsequent 
adherence to surveillance but screening has potential side-effects, including 
potential harm associated with (follow-up) colonoscopy. The importance of 
disclosing appropriate information to enable target groups to make informed 
decisions about screening participation has been emphasized.34 The internet 
is increasingly used for health information and therefore the assessment of the 
availability and quality of online information for screenees is essential. 
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We evaluated the accuracy, quality, and readability of online information on 
CRC screening and surveillance in Chapter 6. We showed marked variation 
in accuracy, quality and readability of information on CRC screening websites 
and that most websites do not address polyp surveillance. Several high quality 
websites do exist but we learned that it cannot be assumed that screenees will 
find these websites because of poor correlation between accuracy and Google 
ranking. Most websites lacked important information regarding polyps and their 
importance for future surveillance colonoscopies. 
Adenomas are found in up to 50% of patients aged 50 years and older who 
undergo colonoscopy.35 36 Therefore, also knowledge about post-polypectomy 
surveillance and post-polypectomy compliance to follow-up screening is 
important.37 38 Previous studies have shown that most adenoma patients are 
unaware of their surveillance recommendations.39 40 Physicians should explain the 
need of surveillance, this will likely motivate patients to adhere to surveillance 
recommendations.
Health care providers interested in developing websites on CRC screening can 
use our approach to evaluate the quality and readability of provided information 
to develop the content of the site they are creating. Alternatively they can provide 
screenees to several of the high quality websites, as identified in Chapter 6.
Optimizing colonoscopy
Colonoscopy is the most commonly performed gastrointestinal endoscopic 
procedure and considered the ‘gold standard’ investigation of the colon. Aside 
from primary colonoscopy screening, all CRC screening tests are followed by 
colonoscopy in case of a positive test result. Measuring and optimizing quality 
of colonoscopy contributes to an optimal preventive effect of CRC screening 
and surveillance. The ideal outcome measure for screening is reduction in CRC 
incidence and mortality. However, this outcome necessitates many subjects 
and years of follow-up, and therefore surrogate quality measures are used. For 
this purpose, performance parameters i.e. quality indicators of an individual 
endoscopist or group of endoscopists are compared with predetermined 
targets. Despite some limitations, adenoma detection rate (ADR), defined as 
the proportion of colonoscopies that detect one or more adenomas, is currently 
considered the best surrogate outcome measure and has emerged by experts as 
priority quality indicator of colonoscopy.41 A second priority indicator is adjusted 
cecum intubation rate (CIR), reflecting the proportion of procedures in which the 
complete colon is visualized.41 Low CIR and poor bowel preparation may explain 
the relative failure of colonoscopy to protect against proximal cancers.42 43 
247
General discussion and future perspectives
9
Reduction in variation of quality has also emerged as an important priority for 
colonoscopy practice. We therefore assessed in Chapter 7 whether plenary 
feedback on these priority quality indicators can stimulate improvement of routine 
colonoscopy and thereby reduce inter-hospital differences. We found that quality 
indicators used in CRC screening programs can also be achieved in routine 
colonoscopies. In high-standard routine colonoscopy centers, plenary evaluation 
and discussion of inter-hospital differences reduced variation of quality indicators, 
although overall quality of colonoscopy was not improved. Higher inter-hospital 
variation was found for ADR compared to adjusted CIR. 
Health care programs should routinely register colonoscopy quality indicators. 
In this regard, benchmarking variation in quality may highlight additional 
opportunities to improve care. The use of quality indicators and addressing 
suboptimal clinical outcomes may reduce variations in colonoscopy performance, 
and will close the gap between suboptimal and optimal performed colonoscopies. 
In the Netherlands, colonoscopy quality indicators are incorporated in an 
accreditation and auditing process, which started in 2014 for endoscopists 
who participate in the national CRC screening program.44 45 The Dutch Society 
for Gastroenterologists is currently working on an registration program for all 
endoscopists in the Netherlands. This allows endoscopists to measure and 
benchmark their performance. Endoscopists’ knowledge that quality measures 
are being monitored may in this regard represent a powerful tool that by itself can 
stimulate improvement of quality of colonoscopy.
Optimizing surveillance
A considerable proportion of all colonoscopies is performed for surveillance 
purposes. This proportion will further increase with the implementation of CRC 
screening programs. Adherence to surveillance colonoscopy guidelines is 
therefore important to prevent unnecessary workload. In Chapter 8 we evaluated 
how well Canadian gastroenterologists adhered to colonoscopy surveillance 
guidelines after adenoma removal or treatment for CRC. Our study showed 
that in only a third of patients, surveillance colonoscopy was performed at 
the recommended time interval. Of all surveillance colonoscopies, 46% were 
performed earlier than recommended. Underuse was also reported, as 21% of 
the patients received their colonoscopy too late. Deviation from the guidelines 
did not improve the ADR. 
Interventions to improve adherence to surveillance guidelines are needed 
because inappropriate surveillance colonoscopies seriously hamper the 
effectiveness and efficiency of surveillance. While a large proportion of patients 
who receive surveillance colonoscopies after the detection of adenomas or 
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CRC are seen too often, another group of patients referred for colonoscopy 
face a long wait time for gastrointestinal care.46 47 This is concerning because 
delayed surveillance is associated with an increased rate of advanced adenoma 
and especially CRC.48 Also a more recently Italian study reported a high rate of 
inappropriate recommendations for patients with low risk or no adenomas found 
at colonoscopy after a positive FIT.46 
In the light of the recently implemented FIT screening programs for which many 
countries struggle with colonoscopy capacity, quality improvement initiatives 
should strive for optimizing the use of surveillance colonoscopy. Efforts should 
be made to raise awareness among endoscopists about proper surveillance 
intervals. 
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Summary in Dutch
SUMMARY IN DUTCH
Dikke darmkanker, dat is kanker die ontstaat in de dikke darm of endeldarm, is een belangrijk gezondheidsprobleem. Het staat op de derde plaats van meest 
voorkomende kankersoorten. Het duurt lang voordat darmkanker  zich ontwikkelt 
en de ziekte geeft pas in een laat stadium klachten. Als darmkanker in een vroeg 
stadium wordt ontdekt, is de kans op genezing groter en de behandeling minder 
zwaar. De ziekte begint meestal als een poliep, adenoom genoemd. Adenomen 
komen regelmatig voor bij mensen ouder dan 50 jaar. Voortgeschreden adenomen 
hebben een verhoogde kans om uit te groeien tot darmkanker. Als adenomen 
volledig worden verwijderd kunnen ze niet meer uitgroeien tot darmkanker. Met 
screening (een bevolkingsonderzoek) kan darmkanker worden voorkomen of in 
een vroegtijdig stadium worden ontdekt en behandeld. Door invoering van een 
bevolkingsonderzoek zullen uiteindelijk minder mensen sterven aan deze ziekte. 
Om deze redenen hebben veel landen een bevolkingsonderzoek naar darmkanker, 
of wordt deze op dit moment ingevoerd. Er zijn verschillende testen waarmee 
darmkanker screening uitgevoerd kan worden en voor veel testen zijn meerdere 
strategieën mogelijk. Dit proefschrift richt zich op strategieën om de kwaliteit van 
darmkanker screening te optimaliseren.
In het eerste deel (Deel I) wordt een uitgebreid overzicht gegeven van wat er 
tot nu toe bekend is over darmkanker screening, worden de verschillende testen 
toegelicht en worden de doelstellingen van het proefschrift beschreven. De testen 
die op dit moment beschikbaar zijn voor darmkanker screening kunnen grofweg 
worden ingedeeld in ontlasting testen en testen die de binnenkant van de darm 
afbeelden. De ontlasting test wordt thuis uitgevoerd en vervolgens opgestuurd 
naar een laboratorium. Daar wordt gekeken of er bloed in de ontlasting zit. Deze 
hoeveelheid bloed is vaak te weinig om met het blote oog te kunnen zien. Bloed 
kan wijzen op darmkanker of darmpoliepen die kunnen bloeden als de ontlasting 
er langs schraapt. Het bloed kan ook komen van bijvoorbeeld aambeien, een 
scheurtje bij de anus, of een darmontsteking. Om hier uitsluitsel over te geven is 
een inwendig kijkonderzoek van de darm nodig, een zogenaamde colonoscopie. 
Hierbij wordt een flexibele slang, waaraan een lampje en een camera zit, via de 
anus in de dikke darm gebracht.
In het tweede deel (Deel II) wordt dieper ingegaan op de ontlastingstest als 
methode voor darmkanker screening. De twee meest gebruikte ontlastingstesten 
zijn de guaiac fecaal occult bloed test (gFOBT) en de fecaal immunochemische 
test (FIT). In Hoofdstuk 2 hebben we een zogenaamde meta-analyse uitgevoerd, 
waarbij we alle studies bij elkaar hebben opgeteld die één van deze testen heeft 
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bestudeerd in de algemene populatie. We vonden dat de FIT darmkanker en 
voortgeschreden adenomen beter detecteert dan de gFOBT. De FIT lijkt dan ook 
de meeste geschikte test te zijn om te gebruiken voor darmkanker screening. 
Onderzoek is nodig hoe het gebruik ervan kan worden geoptimaliseerd. Er zijn 
namelijk vele strategieën mogelijk om FIT te gebruiken. Zo kan bij sommige 
FITs de hoeveelheid bloed (fecaal hemoglobine (Hb)) die wordt gemeten in 
de ontlasting uitgedrukt worden in een getal, een zogenoemde kwantitatieve 
bepaling. Vervolgens kan bepaald worden boven welke Hb concentratie wordt 
doorgestuurd voor colonoscopie, de afkapwaarde voor een positieve test. Veel 
landen worstelen met een tekort aan colonoscopie capaciteit waardoor de 
screening strategie en afkapwaarde zo gekozen moet worden dat deze aansluit 
op de beschikbare capaciteit. 
In Hoofdstuk 3 gaven we inzicht in de manier waarop het verhogen van de 
afkapwaarde of het screenen van een kleinere leeftijdsrange, invloed heeft 
op de colonoscopie vraag en diagnostische opbrengst van voortgeschreden 
neoplasie en gemiste laesies. Een hoge afkapwaarde en kleine screening 
leeftijdsrange leiden tot een laag positiviteitspercentage en dientengevolge een 
lage colonoscopie vraag. Uit deze analyse bleek verder dat het verhogen van de 
afkapwaarde of het screenen van een kleinere leeftijdsrange beiden evenredig de 
colonoscopie vraag en diagnostische opbrengst van voortgeschreden neoplasie 
en gemiste laesies beïnvloedden. 
In Hoofdstuk 4 verkenden we de beste screening strategie met betrekking tot 
het aantal FIT testen per screeningsronde. We vergeleken het screenen met 1 
FIT per screeningsronde met 2 FITs per ronde. Beide strategieën detecteren na 4 
screeningsronden evenveel voortgeschreden neoplasie, terwijl daar voor de 2 FIT 
strategie meer colonoscopiëen voor nodig zijn. We raden daarom het gebruik van 
1 FIT per screeningsronde aan in plaats van 2 FITs per keer. 
Na het definiëren van het aantal FITs per ronde, hebben we gekeken naar de 
mogelijkheden met betrekking tot de fecaal Hb concentratie (hoeveelheid 
bloed) die wordt gemeten bij het analyseren van de FIT. Op dit moment wordt 
alleen gekeken of de fecaal Hb concentratie boven of onder de afkapwaarde 
is waarop doorgestuurd wordt voor colonoscopie. De daadwerkelijke fecaal 
Hb concentratie wordt buiten beschouwing gelaten. Dit is een gemiste kans 
omdat in de literatuur al bekend is dat de hoogte van de fecaal Hb concentratie 
gecorreleerd is met de kans op voortgeschreden adenomen of darmkanker. 
Daarom hebben we in Hoofdstuk 5 gekeken of de fecaal Hb concentratie onder 
de afkapwaarde (dus negatieve FIT) bij de eerste keer deelnemen aan screening 
voorspellend is op de kans om in de daaropvolgende jaren gediagnosticeerd 
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te worden met voortgeschreden neoplasie of darmkanker. We toonden aan dat 
fecale Hb concentraties van negatieve FIT resultaten kunnen worden gebruikt 
om toekomstige geavanceerd neoplasie en darmkanker te voorspellen. Verder 
hebben we in deze studie de toegevoegde waarde laten zien van het gebruiken 
van fecale Hb concentraties van opeenvolgende negatieve FITs om de kans op 
geavanceerde neoplasie te voorspellen. Dit onderzoek onderschrijft het gebruik 
van fecale Hb concentraties om darmkanker screening te optimaliseren. 
Na uitgebreid te hebben stilgestaan bij de ontlastingstest, belicht Deel III van dit 
proefschrift de kwaliteit van darmkanker screening en colonoscopie. 
Colonoscopie is het meest uitgevoerde inwendige onderzoek van het 
maagdarmkanaal en wordt beschouwd als de ‘gouden standaard’ voor het 
onderzoeken van de dikke darm. Het onderzoek wordt niet alleen uitgevoerd na 
een positieve ontlastingstest, maar bijvoorbeeld ook als personen darmklachten 
hebben. Indien poliepen worden gevonden en verwijderd worden patiënten vaak 
opgevolgd (surveillance). In het kader van deze surveillance wordt de colonscopie 
vaak na enkele jaren herhaald, zodat eventuele nieuw ontstane poliepen ook 
kunnen worden verwijderd. Het meten en optimaliseren van de kwaliteit van de 
colonoscopie draagt bij aan een optimale preventieve werking van darmkanker 
screening en surveillance. In Hoofdstuk 6 hebben we gedemonstreerd dat de 
kwaliteit en leesbaarheid van online gegevens over darmkanker screening en 
surveillance kan worden verbeterd. We evalueerden in Hoofdstuk 7 de invloed 
van plenaire terugkoppeling van kwaliteitsparameters van colonoscopie aan 
zeven Nederlands ziekenhuizen. We vonden dat de kwaliteitsnormen gebruikt 
voor darmkanker screening colonoscopiëen ook kunnen worden gebruikt voor 
normale colonoscopiëen. Na plenaire terugkoppeling van de kwaliteitsparameters 
van colonoscopie nam de variatie tussen ziekenhuizen af. In een groot deel van 
de ziekenhuizen verbeterde de kwaliteitsparameters van colonoscopie, hoewel 
de kwaliteitsparameters algeheel niet konden worden verbeterd. In Hoofdstuk 8 
hebben we gekeken naar de naleving van surveillance richtlijnen na verwijdering 
van adenomen of darmkanker. Het bleek dat de richtlijnen niet goed werden 
nageleefd, waarbij zowel colonoscopiëen te vroeg werden herhaald, als te laat. 
Het niet naleven van de richtlijn leidde niet tot een hogere detectie van adenomen.
In het laatste deel (Deel IV) worden de belangrijkste bevindingen en inzichten 
verkregen uit de onderzoeksprojecten samengevat, en geven we op basis 
daarvan suggesties voor toekomstig onderzoek (Hoofdstuk 9).
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ABBREVIATIONS
AA  advanced adenoma
ADR  adenoma detection rate
AN  advanced neoplasia
ASA  American society of anesthesiologists
ASRi age-standardized incidence rate
ASRm age-standardized mortality rate
BBPS Boston bowel preparation score
BCO  Below the cut-off
BMI  body mass index
CCE colon capsule endoscopy
CI  confidence interval
CIR  cecal intubation rate
CQI  colonoscopy quality indicator
CRC  colorectal cancer
CTC  computed tomography colonography
DTA  diagnostic test accuracy
FIT  fecal immunochemical test for hemoglobin
fHb  fecal hemoglobin
FKG  Flesch-Kincaid Grade Level
FN  false negatives
FP  false positives
FOBT  fecal occult blood test
FRE  Flesch Reading Ease score
FS  flexible sigmoidoscopy
g gram
gFOBT  guaiac fecal occult blood test
GQS Global Quality Score
Hb hemoglobin
HGD  high grade dysplasia
HP  hyperplastic polyp
HR  hazard ratio
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IQR  inter quartile range
MAP  mean adenomas per procedure
MAP+  mean adenomas per positive procedure
ml milliliter
ng nanogram
OC optical colonoscopy
OR  odds ratio
PDR polyp detection rate 
PR  positivity rate
PPV positive predictive value
RCT randomized controlled trial
SD  standard deviation
TN  true negatives
TP  true postives
TVA  (tubulo) villous adenoma
TA  tubular adenoma
µg microgram
WAS  website accuracy score
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Icelandic Cancer Society, Reykjavík, IJsland
2015 24 hours
Screening, wie, hoe en waar? - Renesse Symposium ‘Colorectale 
kankerzorg regisseren?’, Renesse, The Netherlands
2016 12 hours
Outcome of one- versus two-sample FIT screening after four 
rounds - World Endoscopy Organization (WEO) Colorectal Cancer 
Screening Meeting, Vienna, Austria
2016 24 hours
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Poster presentations
Year Workload
Third round of two-sample immunochemical fecal occult blood test 
screening in the Netherlands - United European Gastroenterology 
week, Vienna, Austria
2014 12 hours
Systematic Assessment of Quality of Patient Information on 
colorectal cancer screening on the internet - Digestive Disease 
Week, Washington D.C., United States of America
2015 12 hours
Third round of two-sample immunochemical fecal occult blood 
test screening in the Netherlands - Digestive Disease Week, 
Washington D.C., United States of America
2015 12 hours
Plenary feedback on interhospital differences in quality indicators 
for colonoscopy stimulates quality- Digestive Disease Week, 
Washington D.C., United States of America
2015 12 hours
Systematic Review of Quality of Patient Information on 
Colorectal Cancer Screening on the Internet – United European 
Gastroenterology Week, Barcelona, Spain
2015 12 hours
Four Rounds of Two-Sample Fecal Immunochemical Occult Blood 
Test Screening. Digestive Disease Week, San Diego, CA, United 
States of America. Abstract rated top 10% of all abstracts
2016 12 hours
Meta-Analysis on Guaiac-Based Fecal Occult Blood Tests versus 
Fecal Immunochemical Tests for Colorectal Cancer Screening in 
Average-Risk Individuals. Digestive Disease Week, San Diego, CA, 
United States of America.
2016 12 hours
Four Rounds of Two-Sample Fecal Immunochemical Occult Blood 
Test Screening. United European Gastroenterology week, Vienna, 
Austria
2016 12 hours
Attended (inter)national conferences
Year Workload
Najaarscongres, Nederlandse Vereniging voor Gastro-enterologie, 
Velhoven, The Netherlands
2013 12 hours
Najaarscongres, Nederlandse Vereniging voor Gastro-enterologie, 
Velhoven, The Netherlands
2014 12 hours
United European Gastroenterology Week, Vienna, Austria 2014 28 hours
Digestive Disease Week, Washington D.C., United States of 
America
2015 28 hours
United European Gastroenterology Week, Barcelona, Spain 2015 28 hours
Voorjaarscongres, Nederlandse Vereniging voor Gastro-
enterologie, Velhoven, The Netherlands
2015 12 hours
Digestive Disease Week, San Diego, United States of America 2016 28 hours
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Attended seminars 
Year Workload
3e Nationaal congres bevolkingsonderzoek darmkanker, Utrecht, 
the Netherlands
2013 6 hours
28th Erasmus Liver day. Rotterdam, The Netherlands 2013 6 hours
Wetenschapsmiddag Arts-assistenten vereniging (AAV), Erasmus 
MC, Rotterdam
2014 6 hours
10th year symposium Gastroenterology, Rotterdam 2015 6 hours
World Endoscopy Organization (WEO) Colorectal Cancer 
Screening Meeting, Vienna, Austria
2014 8 hours
World Endoscopy Organization (WEO) Colorectal Cancer 
Screening Meeting, Washington D.C., United States of America
2015 8 hours
World Endoscopy Organization (WEO) Colorectal Cancer 
Screening Meeting, Barcelona, Spain
2015 8 hours
World Endoscopy Organization (WEO) Colorectal Cancer 
Screening Meeting, San Diego, United States of America
2016 8 hours
World Endoscopy Organization (WEO) Colorectal Cancer 
Screening Meeting, Vienna, Austria
2016 8 hours
 
 
Memberships
Netherlands Association of Gastroenterology (NVGE) 2013 – current
Landelijke vereniging van Artsen in Dienstverband (LAD) 2014 – current
American Gastroenterological Assocation (AGA) 2013 – 2015
Vrouwen binnen Erasmus MC Netwerk voor Academici (VENA) 2013 – 2014
Koninklijke Nederlandsche Maatschappij tot bevordering der 
Geneeskunst (KNMG) 
2005 – current
Peer review acitivities 
Clinical Gastroenterology and Hepatology
Scottish Government Health Directorates, Translational Clinical Studies Research; grant 
proposal  
Gut
Endoscopy
World Journal of Gastroenterology
Medical Decision Making
Digestive and Liver Disease
International Journal of Cancer
Alimentary Pharmacology & Therapeutics.
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Educational activities and lecturing
Year Workload
Tutoring first year students curriculum Medicine, Erasmus University 
Rotterdam, Rotterdam, The Netherlands
2014-
2015
40 hours
Supervising graduation project Stella Nieuwenburg, medicine 
student Erasmus University Rotterdam, Rotterdam, The Netherlands
2014 40 hours
Tutoring first year students curriculum Medicine, Erasmus University 
Rotterdam, Rotterdam, The Netherlands
2015-
2016
40 hours
Gastro-intestinale bloedingen, curriculum spoedeisende hulp en 
intensvive care verpleegkundigen i.o., Erasmus Zorgacademie
2013-
2015
40 hours
Coach professional development (“Professionele ontwikkeling”) 
Bachelor medicine students, Erasmus University Rotterdam, 
Rotterdam, The Netherlands
2015-
2016
24 hours
AcknowledgementsPHD portfolio
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Fanny, ik heb het volste vertrouwen in jou als opvolger; heel veel succes!
Lieve mede-promovendi (de dak-duiven en lab-ratten), zonder zo’n fantastische en 
diverse groep collega’s was promoveren niet half zo leuk geweest! Ik denk met een 
grote glimlach op m’n gezicht terug aan de gezellige koffie-momentjes en borrels, het 
lief en leed delen met mijn roomies van Ca-419, de bruggenlopen, en de legendarische 
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